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SUMMARY
Yellow fever virus (YFV) is a mosquito-transmitted, enveloped, positive stranded
RNA virus belonging to the genus flavivirus, which causes hemorrhagic fever in
humans in Africa and South America. The YFV is responsible for 200 000 clinical
infections per year including 40 000 deaths. Despite the presence of a highly
effective YF vaccine called 17D vaccine, this disease is now strongly re-emerging
and has to be considered as a public health problem. The present live attenuated
17D vaccine has two major drawbacks: 1) the ancient production method by
inoculating viable embryonated eggs which limits the vaccine production capacity
and, therefore, impairs attempts to control the disease and may contribute to
vaccine supply shortage. 2) this vaccine is a non clonal vaccine which is constituted
of heterogenous virion sub-populations. Furthermore, recent reports of several
cases of viscerotropic and neurotropic disease associated with 17D vaccination have
raised the obvious question of vaccine safety. Taken together, these data show that
it appears essential to design a new clonal vaccine which could be based on
infectious cDNA clone and produced in animal cell culture. For this purpose, the
knowledge of YFV neutralizing epitopes is essential. Because YFV immunity is
mainly antibody-mediated, we wanted to isolate human neutralizing antibodies
specific for YFV and use them as a tool to characterize the neutralizing epitopes of
YFV. The phage display technology provides one of the most convenient systems to
isolate such neutralizing recombinant antibody fragments. We generated YF
patient-derived antibody phage libraries which were screened against purified
virions of the YFV-204-WHO vaccine strain. This step led to the isolation of several
single-chain antibody fragments (scFv) which recognized conformational and pH
sensitive epitopes in the envelope E protein. Three genetically closely-related and
competing scFvs were found to be able to neutralize in vitro the 17D vaccine strain
and five wild-type African strains of YFV. To map their epitopes, neutralization
escape variants of the YFV-17D-204-WHO were generated using one high-affinity
scFv (scFv-7A). Amino acids (aa) E-153, E-154 and E-155 in domain I and aa E-71
in domain II of the E protein were shown to be the critical components of one
complex neutralizing epitope. These aa do not form a contiguous epitope on the
monomeric E protein, but are in close vicinity in the dimeric form the E protein is
predicted to adopt, based on the crystal structures of related flaviviruses. The
neutralizing epitope is thus predicted to be formed by contribution of aa from
domain I and II of opposing E monomers. The nature of this epitope was supported
by the analysis of one wild-type YFV strain (Senegal 90) which is naturally resistant
to neutralization by scFv-7A. Microneutralization assays using sera from YFV-
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infected patients and 17D-immunized travelers confirm the importance of E-71 in
YFV neutralization but also showed that those escape variants, originally present in
the vaccine lot, do not carry a risk of neutralization escape in persons who are
immunized with the 17D vaccine. The potential neutralization mechanism by which
these scFvs act, particularly by preventing the fusion process, and their potential
use as a therapeutical tool are discussed. The structural complexity of the epitope
identified in this work has implications for understanding the mechanism of
antibody-mediated neutralization of YFV and these data may be useful for the
design of a new recombinant yellow fever vaccine based on a cDNA-derived
infectious clone.
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I-INTRODUCTION
I-1 . Yellow fever (YF).
I-1-1. Disease.
Yellow fever disease is a viral hemorrhagic fever mainly characterized by severe
liver, myocardial and renal injury. The progression of this disease usually follows
three stages: a first stage called “period of infection” which occurs three to six days
post infection during which infected people suffer from high fever, headache,
myalgia and nausea. After three to four days, patients enter into a second phase
called “period of remission” at which time all symptoms disappear. At this stage,
people either recover without any sequels or they enter into a last stage called
“period of intoxication”. This stage occurs generally three to six days after onset of
symptoms and is characterized by high fever, intense jaundice, multiorgan failure,
a generalized hemorrhagic state (“black vomit”), hypotension, coma and, most of
the time, death. The case fatality rate of yellow fever disease is around 20 to 40%
(Monath and Barrett, 2003) No specific treatment for yellow fever is available so far
and only intensive supportive cares may improve the outcome of infected patients.
Yellow fever can be prevented using a safe and highly effective vaccine called 17D.
I-1-2. Epidemiology.
Fig 1: Distribution of Yellow fever disease in South America and Africa. In grey are indicated the
yellow fever endemic zones. Red stars represent reported YF outbreaks between 1985 and 2003.
Yellow fever disease is endemic in South America and in sub-Saharan Africa (Fig 1).
Although an effective and safe live-attenuated 17D strain vaccine exists, YF
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remains a serious health problem in African and South American tropical areas with
an estimated number of 200 000 clinically apparent infections and 40 000 deaths in
the endemic regions annually (Monath, 1999), (Robertson et al., 1996).
I-1-3. Resurgence of yellow fever as a major public health problem.
The resurgence of the disease (Fig.2B) is mainly explained by relaxation of
immunization programs resulting in a lower YF vaccination coverage in developing
countries, particularly in Africa. As shown in Fig.2A, despite the successful
eradication in the 70’s of mosquitos Aedes aegypti which are the urban vector of
yellow fever, a reinfestation with this vector is now observed in South America
suggesting future changes in yellow fever epidemiology. Changes in human
demography (shift from rural to urban residence) and economical development
(travelling) are also factors which are responsible for the increase of yellow fever
activity (Monath, 1999).
Fig 2. Resurgence of yellow fever as a major public health problem. A) re-invasion of South
America by the urban vector of yellow fever, Aedes aegypti, during the period 1930-1999 (Monath,
2004). B) number of reported cases of yellow fever per decade from 1950 to 1999.
I-1-4. Transmission cycles.
The yellow fever virus (YFV) which is the causative agent of the yellow fever
disease is transmitted to vertebrates (human and non-human primates) by diurnal
mosquitos during feeding. Thus, primates are considered as vertebrate host and
mosquitos as arthropod host. Since they can be infected for life, mosquitos are
considered as the YFV reservoir.
In South America, two cycles are observed: an endemic “sylvatic cycle” in which
YFV is transmitted to monkeys by infected mosquitoes (Heamagogus species). Non-
human primates infected during the sylvatic cycle with YFV either die from infection
30s 1970 1999
1950-59 1960-69 1970-79 1980-89 1990-99
A) B)
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or develop immunity and serve as amplifying hosts. Humans are accidentally
infected when entering into the jungle, via contacts with infected mosquitos.
Infected humans can then spread YFV through urban mosquitos (Aedes aegypti)
leading to the establishment of the “urban cycle” and a YF urban outbreak. In
Africa, YF transmission is identical except that a third cycle called “savannah cycle”
has been identified due to the concomitant presence of humans and monkeys in the
moist Savannah at the border between the jungle and the city (Barrett and Monath,
2003)
I-2. Yellow fever virus (YFV).
I-2-1. Taxonomy of flaviviruses.
The genus Flavivirus forms together with the two other genera Pestivirus and
Hepacivirus the family Flaviviridae It includes 73 viruses divided into non-vector
transmitted, tick-borne and mosquito-borne flaviviruses. Flaviviruses are present on
all continents. Many members of this genus that includes yellow fever virus (YFV),
dengue virus (DV), Japanese encephalitis virus (JEV), Tick-borne encephalitis virus
(TBEV) and West Nile virus (WNV) are human pathogens causing a significant
morbidity and mortality worldwide (Calisher and Gould, 2003).
I-2-2. Classification of the yellow fever virus.
The YFV is the prototypic member of the genus flavivirus. Recent phylogenetic
studies have shown that YFV is closely related to nine other flaviviruses (Banzi,
Bouboui, Edge Hill, Jugra, Saboya, Potiskum, Sepik, Uganda S and Wesselsbron),
Sepik virus being the most closely related one (Calisher and Gould, 2003).
To date, seven YFV genotypes have been defined based on a phylogenetic analysis
from the nucleotide sequences of prM/M and E genes (Fig.3). Two were identified in
South America (South America I and South America II) and five in Africa (Angola,
East Africa (EA), East and Central Africa (EA/CA), West Africa I (WAI) and West
Africa II (WAII)) (Mutebi et al., 2004) (Mutebi et al., 2001).
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Fig 3: Phylogenetic relationships among genotypes of YFV from Africa and South America,
using Dengue virus type 1 as an outgroup. From (Mutebi et al., 2001).
I-2-3. Structure of the virion.
Flaviviruses are spherical enveloped viruses with a diameter of around 50-60 nm.
The genome of the YFV consists of a non-segmented 11 kb positive single-stranded
RNA (Fig.4A). The genome of the wild-type YFV Asibi strain is composed of 10 862
nucleotides (Rice et al., 1985). It is composed of a single open reading frame (ORF)
flanked by two short noncoding regions at the 5´and the 3´termini (5´NCR and
3´NCR). These NCR are not well conserved among flaviviruses but have been
shown to form cyclic and secondary structures and may play a major role in virus
replication and viral proteins translation (Hahn et al., 1987). In infected cells, the
ORF is translated as a single polyprotein which is further processed to yield viral
structural and non structural proteins. The N-terminal part of this polypeptide
encodes three structural proteins which form the mature virion: the capsid protein
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C, the precursor of the membrane protein prM, and the envelope protein E. The
rest of the polyprotein encodes for 7 non-structural proteins which are responsible
for viral replication and protein processing: NS1, NS2A, NS2B, NS3, NS4A, NS4B
and NS5 (Lindenbach and Rice, 2003).
Fig 4: The flavivirus particle. A) Schematic representation of the positive single stranded RNA
genome of YFV. B) Schema of infectious YFV particle. C) Electron micrograph of Dengue Virus. D) Model
of crystallized mature Dengue virus; E homodimers are depicted. Domain I, II and III of each E
monomer are coloured in red, yellow and blue, respectively. Adapted from (Lindenbach and Rice, 2003;
Mukhopadhyay et al., 2005).
I-2-3-1. The Capsid protein C.
This protein of 11 kDa is a highly basic protein which forms the nucleocapsid of
flaviviruses. Charged residues at its N and C termini are probably responsible for
the interaction with the viral RNA genome whereas its internal hydrophobic domain
mediates membrane association.
I-2-3-2. The Membrane protein M.
The protein M is the minor glycoprotein of flaviviruses which is initially produced in
infected cells as its precursor prM (MW approx. 26 kDa). Upon expression, this
precursor prM is rapidly folded to form heterodimers with the major envelope
3´NS2BC prM E NS1 NS2A NS 3 NS 4A NS4B NS 5
Structural Proteins Non Structural Proteins
5´
NCR NCR
A)
B)
C)
E protein
M protein
Nucleocapsid
Positive -stranded RNA genome
Lipid bilayer
Positive-single stranded RNA genome
A)
D)
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protein E. Studies have shown that this protein may act as a chaperone-like protein
ensuring the correct folding of the E protein. The prM protein is further cleaved into
its mature form M by a furin-like enzyme in the secretory pathway just before the
release of flavivirus particles.
I-2-3-3. The Envelope protein E.
The major envelope protein of flaviviruses, the E protein, is a 55 kDa type I
membrane protein. This protein has been crystallized for TBEV (Rey et al., 1995)
and for DV type 2 (Modis et al., 2004).This surface protein is divided into 3 domains
and forms homodimers on the viral surface (Fig 4B and 4D). The E protein has been
shown to govern virus attachment and to mediate virus entry. The E protein will be
extensively described in the section I-3.
I-2-3-4. The Non Structural (NS) proteins.
The NS proteins are less extensively described than the structural proteins. The
NS1 protein is found within infected cells, on the cell surface and as a secreted
protein. The role of this glycoprotein remains unclear but may play a role in RNA
replication. Interestingly, a strong humoral response following infection is
developed against this protein and antibodies directed against the cell surface form
of NS1 mediate complement-mediated cytotoxicity. The NS2A protein is a small
hydrophobic protein which seems to be involved in RNA packaging and RNA
replication  The NS2B protein is a small membrane-associated protein which forms
a complex with the NS3 protein. The NS2B-NS3 complex is involved in polyprotein
processing and RNA replication The function of the NS4A and NS4B proteins is still
unknown. NS5 is a large protein which plays a major role in RNA replication. This
protein has been presumably identified as the polymerase of flaviviruses (for review
see Lindenbach and Rice, 2001).
I-2-4. Pathogenesis.
Wild type YFV induces two different patterns of infection and injury in animal
models: neurotropism and viscerotropism. In rodents (mice, hamsters and guinea
pigs), the YFV is neurotropic (infection of the brain leading to encephalitis). In non-
human primates, the virus is viscerotropic (infection of the liver, spleen, heart and
kidneys) and leads to a disease which resembles the human disease (Monath and
Barrett, 2003).
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I-2-5. The Flavivirus life cycle.
Flaviviruses enter into the cell via the endocytosis-mediated pathway through the
interaction of the E protein with its cellular receptor (Heinz et al., 2004). This
cellular receptor has not been with certainty identified so far (see I-2-6). It has
been shown that this interaction is driven by the IgG-like domain III of the E
protein. Bound particles are then internalised via clathrin-coated vesicles. The
release of the nucleocapsid and the genome is mediated through a fusion process
with occurs in the endosomal compartment. This fusion process is an acid-
dependent process, by which the low pH shift induces irreversible conformational
changes of the E protein, leading to the exposure of the fusion peptide (cd loop), its
anchoring into the cellular membrane and finally the fusion of both viral and cellular
membranes. The capsid is then released into the cellular cytoplasm where viral
replication takes place. The decapsidation process allows the release of the positive
single-stranded RNA genome which is used as a template for the translation of viral
proteins and for the transcription of negative single-stranded RNA molecules. Those
molecules are then used as a template for the production of positive single-
stranded RNA genomes, which are further encapsidated into new viral particles.
Assembly of the virion progeny seems to take place in the ER lumen. The particles
have a lipid envelope decorated with E proteins monomers bound to the M protein
precursor prM and represent immature virions. These particles are then exported
out of the cell via the Golgi network through the exocytosis pathway. Shortly before
release, the prM protein is cleaved to M protein, leading to its dissociation with E
monomer. The E monomers then dimerize yielding the infectious particle. The
association prM-E has been shown to prevent irreversible conformational changes in
the E protein induced by pH-shift which may occur during the transport of particles
out of the cell. (For review see Heinz et Allison., 2003).
I-2-6. Cellular receptor(s) for Flaviviruses.
The domain III of the E protein is thought to mediate attachment of virions to their
target cell through the binding to a cellular receptor. However, this cellular receptor
has not been clearly identified yet. Several studies have shown that the dendritic-
cell-specific ICAM-grabbing non-integrin protein (DC-SIGN), the glucose-regulating
protein 78 (GRP78/BiP), CD14-associated molecules and more recently, the heat
shock proteins HSP90 and HSP70 may act as cellular receptors for DV (Navarro-
Sanchez et al., 2003), (Jindadamrongwech et al., 2004) (Chen et al., 1999)
(Reyes-Del-Valle et al., 2005). Heparan sulfates and other glycosaminglycans have
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also been proposed to be attachment receptors for flaviviruses (Chen et al., 1997;
Hung et al., 1999; Kroschewski et al., 2003; Lin et al., 2002). Moreover, it has
been shown for DV that the entry process differs between mammalian cells and
mosquito cells (Hung et al., 2004). As flaviviruses are able to infect a high number
of different cell lines, it seems that various receptors would be needed for flavivirus
infection and that different flaviviruses could use different receptors. The presence
of an additional coreceptor has been postulated to explain the restricted tropism of
flaviviruses (Martinez-Barragan and del-Angel, 2001). However, the molecular
mechanism by which flaviviruses enter into the cell is still obscure. For YFV and
mosquito-borne viruses, a solvent-exposed loop (the Fg loop) in domain III of the E
protein and especially the Arg-Gly-Asp (RGD) motif has been proposed to be a
recognition motif for integrin-binding (Kuhn and Rossmann, 1995). Nevertheless,
mutagenesis of this motif in YFV-17D did not alter the virus-cell binding, suggesting
that integrins do not function as a major YFV 17D receptors via the RGD motif
(van-der-Most et al., 1999). Recently, heparan sulfate has been proposed as a
putative cellular receptor for YFV (Germi et al., 2002).
I-2-7. Flavivirus fusion with host cell membranes.
I-2-7-1. The fusion peptide.
The fusion peptide responsible for the fusion of viral and cell membranes during the
flavivirus life cycle is located at the tip of domain II of the E protein. This fusion
peptide is formed by a highly conserved hydrophobic loop previously called cd loop
This peptide spans aa 98 to 110 of the E protein. Mutations in this region have been
shown to affect fusion and virulence of TBEV (Allison et al., 2001).
I-2-7-2. The fusion mechanism.
The fusion mechanism by which flaviviruses enter into the cell has been recently
identified as a new fusion process called the class II fusion process (Heinz et al.,
2004; Modis et al., 2004). After endocytosis of flavivirus virions, the release of the
genome into the cytoplasm of the infected cell is mediated through low pH shift in
the endosomal compartment. Acidification of the endosomal compartment promotes
irreversible rearrangements and conformational changes of the E protein on the
virion surface, leading to the dissociation of the E homodimers into E monomers
and then to E trimerization. These data have been obtained by crystallizing the pre-
and post-fusion states of the E protein of TBEV and DV (Allison et al., 1995; Stiasny
et al., 1996; Stiasny et al., 2001; Modis et al., 2004, Stiasny et al., 2004; Stiasny
et al., 2005). A detailed mechanism for the membrane fusion process of flaviviruses
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has been recently proposed (Fig.5) (Modis et al., 2004). Following pH shift in the
endosomal compartment, E homodimers dissociate into monomers, resulting in the
swing of the domain II towards the host cell membrane, the exposure of the buried
fusion peptide located at the tip of the domain II, its anchoring into the host cell
membrane and finally the formation of E homotrimers. Rearrangement of the
domain III brings the viral membrane and the host cell membrane in close contact
leading to fusion of both membranes.
Fig. 5. Proposed fusion mechanism for flaviviruses. From (Modis et al., 2004).
I-3. The YFV envelope protein (the E protein).
The E protein is the major envelope glycoprotein of flaviviruses. It has been shown
to mediate three crucial functions: attachment of the virus to the host cell through
receptor binding, virus-cell membrane fusion upon pH shift and antibody-mediated
neutralization.
Fig 6: Schematic representation of  E protein on the viral surface. The ectodomain, the stem
region and the transmembrane domain of the E protein are depicted. Domains I, II and III of the
ectodomain are coloured in lilac, yellow and blue, respectively. The red dot at the tip of the domainII
represents the putative fusion peptide (cd loop). From (Mukhopadhyay et al., 2005).
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I-3-1. Molecular Structure.
The molecular weight of the E protein is around 55 kDa and this protein is
composed of 495 amino acids. Treatment of TBE or DV virions with trypsin
promotes the release of a soluble fragment of the E protein, the ectodomain, which
is composed of residues 1-395 of the E protein. The crystal structure of the
ectodomain has been resolved at 2 Å resolution for TBEV and for DV type 2 (Rey et
al., 1995) (Modis et al., 2004). This fragment is anchored into the viral membrane
via a transmembrane domain (residues 451-495 for DV) which is composed of 2
transmembrane helices (Fig.6, E-T1 and E-T2). A stem region (residues 396-450
for DV) links both domains together. This stem region is presumably formed by two
amphiphatic helices (Fig 6, E-H1 and E-H2) (Zhang et al., 2003). The E protein
forms homodimers with an anti-parallel head-to-tail conformation on the surface of
infectious flavivirus particles. The overall dimensions of the E dimer are approx. 150
Å x 55 Å x 30 Å. This dimer is oriented parallelly to the viral membrane and gently
curved. Infectious virions contain 90 E dimers (180 E protein monomers) covering
the entire viral surface and forming a smooth shell (Kuhn et al., 2002) (Fig.4D).
The E protein is very conserved among all flaviviruses and shares a common
architecture. Conservation of cysteine residues and similar hydrophobicity profiles
suggest a common folded structure of the E protein for all flaviviruses. The E
ectodomain is divided into 3 domains: a central domain (domain I), a dimerization
domain (domain II) and an IgG-like domain (domain III). Domain I contains the N-
terminal part of the E protein and is formed by a β-barrel. Domain II forms an
elongated structure which promotes dimerization of two E monomers. At the tip of
domain II is located a hydrophobic and glycin-rich sequence called cd loop, which
has been proposed as the internal fusion peptide for flaviviruses (Allison et al.,
2001). The domain III contains the C-terminal part of the E protein ectodomain and
forms a typical IgG-like domain with an axis which is located perpendicularly to the
axis of the virion surface. The domain III has been shown to govern virus
attachment through its interaction with a cellular receptor (Bhardwaj et al., 2001;
Chen et al., 1997; Crill and Roehrig, 2001; Hurrelbrink and McMinn, 2001; Mandl et
al., 2000).
I-3-2. Antigenic structure.
Because of its preponderant role in virus attachment and cell fusion, the E protein is
the major inductor of neutralizing antibodies.
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I-3-2-1. Flavivirus E-specific neutralizing antibodies and neutralizing epitopes.
The E protein elicits neutralizing antibodies as well as non-neutralizing antibodies
suggesting that neutralizing epitopes are restricted to some E protein areas.
Moreover, E-specific flavivirus neutralizing antibodies can be either virus-specific of
virus cross-reactive; the virus-specific ones having the highest neutralizing activity
in vivo (Mandl et al., 1989; Roehrig, 2003). Several studies identified neutralizing
epitopes for several flaviviruses by generating variants resistant to neutralization
for a defined antibody. The Table 1 lists amino acid residues found to form
neutralizing epitopes for DV, WNV, YFV, JEV and TBEV. The molecular location of
these residues on the crystal structure of the DV E protein shows that flaviviruses
neutralizing epitopes are distributed over the entire surface of the E protein, in the
three domains. Moreover, most of neutralizing epitopes are located on the upper
surface of the E protein and, thus, accessible to antibodies as expected (Fig 7). To
date, epitope mapping of neutralizing flavivirus epitopes has been performed using
mouse monoclonal antibodies with the exception of a recent paper using
monoclonal antibodies generated from chimpanzees infected with DV (Goncalvez et
al., 2004).
Virus Antibody Aa substitution Domain Reference
DV-2 mAb(10F2) 69, 71, 112 &
124
402
II
III
(Lok et al., 2001)
DV-2 mAb(6B2) 311 III (Lok et al., 2001)
DV-1 mAb(M-10) 279 I-II junction (Beasley and Aaskov,
2001)
DV-1 mAb(M-17) 293 I-III junction (Beasley and Aaskov,
2001)
DV-2 mAb(4G2) 169 & 275 I-II junction (Serafin and Aaskov,
2001)
DV-3 mAb(1H9) 386 III (Serafin and Aaskov,
2001)
DV-2 mAb(G8D11) 307 III (Lin et al., 1994)
DV-2 mAb(6B2) 311 III (Lok et al., 2001)
DV1-2 Fab 1A5
(monkey)
106 & 317 II & III (Goncalvez et al., 2004)
DV-2 mAb(3H5) 383, 384 & 385 III (Hiramatsu et al., 1996)
WNV mAbs 306, 307, 330 &
332
III (Sanchez et al., 2005)
WNV mAb(5C5) 307 III (Beasley and Barrett,
2002)
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WNV mab(5H10) 330 III (Beasley and Barrett,
2002)
WNV mAb(5H10) 332 III (Beasley and Barrett,
2002)
WNV mAb (E16) 306, 307, 330&
332
III (Oliphant et al., 2005)
WNV mAb 332 III (Li et al., 2005)
YFV(17D) mAb(2C9) 71 II (Lobigs et al., 1987)
YFV(17D) mAb(2E10) 71 & 72 II (Lobigs et al., 1987)
YFV(17D) mAb(B39) 155 & 158 I (Ryman et al., 1997)
YFV(17D) mAb(864) 305 & 325 III (Ryman et al., 1997)
JEV mAb (E3.3) 331 & 332 III (Lin and Wu, 2003)
mAb 52 I-II junction (Morita et al., 2001)
mAb 126 I-II junction (Morita et al., 2001)
mAb 136 I-II junction (Morita et al., 2001)
mAb 275 I-II junction (Morita et al., 2001)
mAb 270 II (Cecilia and Gould, 1991)
mAb 333 III (Cecilia and Gould, 1991)
TBEV mAb(IC3) 181 I (Holzmann et al., 1989)
mAb(IE3) 123 II (Holzmann et al., 1989)
mAb(IO3) 368 III (Holzmann et al., 1989)
mAb(A3) 71 II (Mandl et al., 1989)
mAb(A3) 67 II (Mandl et al., 1989)
mAb(A4) 233 II (Mandl et al., 1989)
mAb(A5) 207 II (Mandl et al., 1989)
mAb(i2) 171 I (Mandl et al., 1989)
mAb(B1) 389 III (Mandl et al., 1989)
mAb(B4) 384 III (Mandl et al., 1989)
Table 1: Location of neutralizing epitopes identified on the E protein for several flaviviruses.
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Fig 7: Molecular location of neutralizing epitopes for several flaviviruses on the crystal
structure of the homodimer envelope glycoprotein E of DV. A) Top view. B) Side view. Domain I,
II and III of one E monomer are coloured in red, yellow and blue, respectively. Neutralizing regions
identified for DV, WNV, YFV, JEV and TBEV are colored in green, white, magenta, orange and black,
respectively.
I-3-2-2. E protein cross-reactive epitopes for flaviviruses.
Human infection by flaviviruses elicits humoral immune response and the
generation of virus-specific antibodies but also flavivirus cross-reactive antibodies.
Analysis of these flavivirus cross-reactive antibodies using bioinformatical studies
and mutagenesis allowed the identification of some residues (E-104, E106, E-107,
E-126, E-226 and E-231) defining three distinct cross-reactive flavivirus epitopes.
Three aa residues (E-104, E106, E-107), which define two of these three epitopes,
were found to be located within the fusion peptide (Crill and Chang, 2004).
I-3-2-3. Neutralizing determinants on the E protein identified for YFV.
Six aa residues associated with mAb-neutralization escape variants have been
identified in the E protein of the YFV 17D-204 vaccine strain. The first study was
conducted by Lobigs et al. in 1987 (Lobigs et al., 1987). They identified aa E-71
and E-72 as critical residues for the neutralizing activity of the two cross-competing
mAbs 2C9 and 2E10 and these aa were identified as components of the first
discrete epitope characterized for YFV 17D-204. E-71 and E-72 are both located in
domain II of the E protein (Fig.8, in cyan). A second neutralizing epitope was
identified by Ryman et al. in the E protein of the YFV 17D-204 strain, formed by E-
155 and E-158 and recognized by the mAb B39 (Ryman et al., 1997). These aa are
located in domain I of the E protein (Fig 8, in green). A third neutralizing epitope
has been identified also by Ryman et al. In this study, aa E-305 and E-325 were
A) B)
Inner surface 
Outer surface 
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found to be part of the neutralizing epitope which is recognized by the mAb 864
(Ryman et al., 1997). This epitope is located in domain III of the E protein (Fig 8,
in orange).
Fig 8: Neutralizing epitopes identified for the YFV and their projection to the E protein crystal
structure of DV type 2. The sequence of the YFV was modeled onto the published crystal structure of
the Dengue type 2 virus E protein. E-71 and E-72 (in cyan) were identified by Lobigs et al, 1987; E-155
and E-158 (in green) were identified by Ryman et al, 1997; E-305 and E-325 (in orange) were identified
by Ryman et al, 1997. A) Top view. B) Side view.
I-4 The Yellow Fever vaccine.
The concomitant isolation of wild-type YF viruses in 1927 by the Pasteur Institute in
Dakar, Senegal (the French viscerotropic strain) and by American researchers from
the Rockefeller foundation in Ghana (Asibi strain) promoted the development of
efforts to generate a live-attenuated YF vaccine by passaging the wild-type strain in
a substrate that was restrictive for growth. In the absence of the invention of cell
culture, the viruses were initially passaged in Asian non-human primates which are
highly susceptible to visceral YFV infection.
I-4-1. The French Neurotropic Vaccine (FNV).
The French Viscerotropic Virus (FVV) was passaged in mouse brains leading to the
isolation of an adapted virus without any viscerotropism for monkeys: the French
Neurotropic virus (FNV) which could be used as a vaccine. Despite some studies
Inner surface 
Outer surface 
E305; E325 E155; E158
E71; E72
E305; E325
E155; E158
E71; E72 
A) B)
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showing that this FNV vaccine could cause in some instances lethal encephalitis in
monkeys, it was widely used for immunizations in French Equatorial Africa starting
in 1932. By 1947, around 14 millions, and by 1953, 56 million people were
vaccinated with the FNV vaccine. The incidence of FNV-associated encephalitis was
estimated around 1:3000 to 1:10 000, which was shown later to be a gross
underestimation. During the 60’s, studies on adverse effects associated with FNV
underlined that the safety of this strain had not been evaluated carefully and led to
a restricted use of this vaccine (to persons over 14 years of age). The production of
the FNV vaccine was finally stopped in 1982 (for review see Monath, 2004).
I-4-2. The 17D vaccine.
Empiric passages of the wild-type Asibi strain in 1933 started the history of the 17D
vaccine, which is still manufactured and commercialized around the world. Theiler
and Smith from the Rockefeller Institute, New York, serially passaged the wild-type
Asibi strain in mouse brain and later in embryonic chicken tissue to generate a YFV
variant exhibiting loss of viscerotropism and neurotropism for humans. After 18
passages in mice embryos tissues, the new-adapted virus was cultured 74 times in
chicken embryos without brain and nervous tissues to avoid a neuroadaptation to
take place as observed for the FNV. At passage 176, the obtained YFV variant was
tested in monkeys and was found to provide protective immunity without any
viscerotropism or neurovirulence. This attenuated strain was called 17D strain. In
1936, the first human trials using this virus were conducted on volunteers. From
passage 195, the initial lineage of the 17D vaccine split into 2 different ones. The
virus was sent to Brazil, further passaged in chicken embryo tissue and
embryonated eggs leading to the generation of the YFV 17DD strain. This strain
strain is manufactured and commercialized in Brazil as the 17DD vaccine strain.
One 17DD seed was also transferred to Senegal where 17DD vaccines are also still
manufactured. The 17D virus was passaged independently at the Rockefeller
Institute in parallel subcultures until passage 204. At this time, studies underlined
the importance of controlling passage level and virus substrain and led to the
establishment of a seed lot system. Primary and secondary seed lots were prepared
from the substrain 17D-204. The latter was used to produce multiple vaccine
batches by propagating the virus in embryonated eggs. All current 17D-204
vaccines derive from the original 17D–204 strain. With 400 millions doses
distributed worldwide, the 17D vaccine is one of the safest and robust live
attenuated vaccine (for review see Monath, 2004).
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I-4-2-1. Molecular determinants of the YFV-17D vaccine strain attenuation.
To define more precisely mutations which are responsible for the attenuated
phenotype of the 17D vaccine, the vaccine strains (17DD and 17D-204-ATCC) and
the wild-type Asibi strain were sequenced and compared (Hahn et al., 1987). These
analysis revealed 20 amino acid changes out of 3411 (0,59%) and 4 nucleotide
differences in the 3´NCR. These changes are not distributed homogeneously all
over the genome. Many of these substitutions (8/20) are found in the E protein
suggesting a preponderant role of these changes in the YFV attenuation process.
Nevertheless, it is clear that attenuation and virulence are multigenic involving
structural and non structural proteins and, thus, cannot be linked to a specific
mutation.
I-4-2-2. Quasispecies nature of the 17D vaccine strain.
Due to uncontrolled repeated passages of the wild-type strain by different
manufactures, the nature of the 17D vaccines which are now produced around the
world has been shown to be heterogeneous. It is now well established that all 17D
vaccine substrains are genetically different and even each 17D-204 batch consists
of an heterogeneous mixture of virion sub-populations which defines the
quasispecies nature of the 17D vaccine strain. Such variants were found to differ in
plaque morphology, mouse virulence, oligonucleotide fingerprinting patterns and
antigenicity (Barrett, 1997; Barrett and Gould, 1986; Ledger et al., 1992; Liprandi,
1981). The quasispecies nature of the 17D vaccine strain has been illustrated with
the ARILVAX vaccine (Pugachev et al., 2002). This vaccine was derived from the
17D-204 strain and is produced and commercialized in the United Kingdom by
Evans Vaccines. Analysis of one ARILVAX vaccine vial revealed a heterogeneity of
12 nucleotides within viruses from the same vial. Two nucleotides changes leading
to amino acid substitutions at position E-240 and NS3-195 were observed.
Interestingly, E-240 has already been shown to play a role in YFV neurovirulence in
mice (Ryman et al., 1998). This aa residue has also been shown to be located
within a T-helper cell epitope for Murray Valley encephalitis virus (Mathews et al.,
1991). The NS3-195 has been described as a critical residue for ATPase activity of
the NS3 protein for DV (Li et al., 1999). These observations available for the
ARILVAX vaccine are probably true for all 17D strain-derived commercialized
vaccines. Such a result definitely raises the question whether some variants with
higher pathogenicity could, in some instances, be selected and may have an role in
vaccine effectiveness and safety.
I-INTRODUCTION
20
I-4-2-3. YFV 17D vaccine production.
Currently, the 17D vaccine (17DD and 17D-204) is produced by ten manufacturers
in the USA, Brazil, France, United Kingdom, France, India, Colombia, Russia,
Senegal and Switzerland (previously Germany). Approx. 55 millions doses are
manufactured annually (Monath, 2004). This vaccine is still produced by inoculation
into viable embryonated eggs from specific pathogen free (SPF) chickens. This old
manufacturing method is a critical factor which strongly impairs the attempts to
control the disease by limiting the vaccine production capacity. In 1997, only 4
millions doses were distributed in Africa, whereas 24 millions doses would be
required to protect 80% of African children and 240 million doses to start
preventive mass campaigns (Monath, 2004). This restricted vaccine production is
also a major drawback in case of high demand especially when YF outbreaks occur.
Vaccine shortage has been already experienced in Guinea during a YF outbreak in
2000 (Nathan et al., 2001). Thus, a novel vaccine production method is strongly
needed. Using an infectious clone from a YFV 17D-204 strain-derived cDNA,
Marchevsky et al. reported that the progeny virus exhibited comparable features to
viruses from the vaccine strain but showed a slightly higher neurovirulence activity
in monkeys (Marchevsky et al., 1995). Nevertheless, the cell culture-based vaccine
production made from a YFV infectious clone may provide an efficient alternative to
the present embryonated eggs-based method. Therefore, the knowledge of
neutralizing epitopes is important for the standardization of a cDNA-based vaccine.
I-5 Immune Response to YFV.
The human antibody response following YFV-infection has to date not been
characterized on the molecular level.
I-5-1. Innate immune response.
Studies on 17D vaccinees have described the activation of natural killer cells (NK
cells) and the development of a type I interferon response shortly after virus
inoculation during the early phase of viral replication (Bonnevie-Nielsen et al.,
1995; Fagraeus et al., 1982) (Wheelock and Sibley, 1965). In addition, levels of
several cytokines and T-cell activation markers were shown to increase after 17D
vaccination (Reinhardt et al., 1998). Because one in seven wild-type YFV-infected
persons develop illness, it is clear that the innate immune response may fail to
protect the host. Nevertheless, innate immune responses are believed to be
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important for viral haemorragic fevers by delaying the viral replication until the
development of the adaptive immune response (Sabin, 1952). On other hand, a
study on cytokine/chemokine responses in YF patients has recently shown that a
strong activation of these molecules is associated with poor outcome of the patients
(ter-Meulen et al., 2004).
I-5-2. Adaptive immune response.
YFV wild-type and 17D vaccine infections are followed by a rapid and specific
immune response. The humoral immune response has been well described,
whereas few studies have performed on the cellular immune response. The E
protein has been shown to be the major determinant in terms of neutralizing
antibodies induction and cytotoxic T-cell response, and thus, plays a major role in
protective immunity.
I-5-2-1. Humoral immune response.
Neutralizing antibodies appear 7-8 days after YFV infection or 17D vaccination
(Monath and Barrett, 2003; Reinhardt et al., 1998). The appearance of IgM
neutralizing antibodies following wild-type YFV infection has been shown to occur
during the first week of illness and to decline 30 to 60 days after onset (Lhuillier
and Sarthou, 1983; Lhuillier et al., 1986). IgG antibodies mainly against the E
protein appear 10 days post infection The neutralizing antibody peak is observed
around 30 to 40 days after infection and slowly declines after 6 months (Monath
and Barrett, 2003; Reinhardt et al., 1998). Nevertheless, neutralizing antibodies
have been shown to persist for many years and have been documented as long as
78 years post illness (Monath, 2001). They provide a complete protection against
disease on re-exposure to the virus. Most of the neutralizing antibody specificities
which are produced following YFV infection and provide protection have been shown
to be directed against the YFV-E protein (Brandriss et al., 1986; Gould et al., 1986;
Pincus et al., 1992). However, several studies have shown that non structural
proteins, especially NS1, may play a role in YFV humoral immune responses.
Passive transfer of anti-NS1 antibodies confered protection after challenge in mice
(Gould et al., 1986; Schlesinger et al., 1986). Mice and monkeys immunized with
NS1 were also protected following challenge by developing complement-mediated
cytolytic antibodies (Gould et al., 1986; Putnak and Schlesinger, 1990; Schlesinger
et al., 1986). However, the in vivo relevance of those anti-NS1 antibodies in
recovery or protection remains uncertain.
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I-5-2-2. Cellular immune response.
There are no data on human cellular response following wild-type YFV infection. A
few studies have shown, in 17D vaccinees, an increase of CD8+ T cells in the early
period of vaccination and lasting up to 13 days post vaccination (Reinhardt et al.,
1998). For 17D vaccinees, CD8+ T-cell epitopes were found in E, NS1, NS2B and
NS3 proteins (Co et al., 2002). In mice, studies have shown that CD4+ cells are
critical mediators to protect against YF-encephalitis (Liu and Chambers, 2001). It is
clear that helper and cytotoxic T lymphocytes play an important role in viral
clearance during primary infection but further studies have to be performed to
define the cellular immune response following YFV infection in humans.
I-6. Adverse effects following YF 17D vaccination.
Although the YFV-17D vaccine is known to be one of the safest vaccine with more
than 400 millions doses given to humans around the world, several published data
showed that this vaccine is responsible for a non-negligible number of side effects
leading in some instances to the death of the vaccinated patient. The mechanism of
these events are not completely understood but could be due to the quasispecies
nature of the 17D vaccine lots and to currently unknown host factors. It has been
also shown that advanced age of vaccinated travelers (more than 60 years old) is a
risk factor to develop such serious adverse effects (Khromava et al., 2005).
Adverse effects following vaccination with the 17D yellow fever vaccine are
nowadays considered as an important problem associated with immunization
coverage, especially of travelers, and has been repeatedly described since 1996.
The risk of fatal side effects after 17DD-YFV vaccination has been calculated as
0.043 to 2.131 fatalities per million doses administered (Struchiner et al., 2004).
These side effects are generally categorized as two groups related to the dual
tropism of the YFV: the yellow fever-associated neurotropic disease (YEL-AND) and
the yellow fever-associated viscerotropic disease (YEL-AVD). The increasing
recognition of YF vaccination-related side effects, since the introduction of improved
surveillance in the late 90´s, strongly suggests that the number of cases associated
with adverse affects has been probably underestimated and thus, an increase of the
number of such cases might be observed in the next years.
I-6-1. The YELlow fever-Associated Neurotropic Disease (YEL-AND).
The total number of reported YEL-AND cases has been evaluated to be 25, of which
15 occurred during the 50´s when the vaccine was used without any age restriction
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(Monath, 2004). Of those 25 reported cases, 1 was fatal for a 3 year-old boy in
1965. The study of this case in 1994 showed that the variant found in cerebral fluid
of the boy differed from the parental 17D-204 virus by two amino acid residues at
position 155 and 303 in the E protein (Jennings et al., 1994). Nevertheless, it has
not been formally evaluated whether such a variant could be the result of a
selection process or if mutations occurred de novo.
I-6-2. The YELlow fever-Associated Viscerotropic Disease (YEL-AVD).
14 YEL-AVD have been reported worldwide (10 in the last decade), out of which 8
were fatal. The first report described YEL-AVD which occurred in four elderly
travelers in USA in 1998, of which three died. Viruses isolated from fluids of two
patients did not differ from the parental YFV 17D-204 strain. From one case,
sequencing analysis revealed nucleotide differences leading to amino acid
substitutions at position M-6 and E-326, when compared to the parental YF 17D-
204 virus used for vaccination (Martin et al., 2001). The second study reported the
death of two persons following 17DD vaccination in Brazil. Both patients died from
viscerotropic disease within 1 week. 17DD virus was isolated from fluids and
sequencing analysis showed that both viruses, 17DD from patients and 17DD from
the vaccine lot, were identical and did not induce disease in monkeys, pointing to a
possible role of host factors (Vasconcelos et al., 2001). The third study reported the
death of a man after YFV 17D-204 vaccination in Australia. Partial sequencing
analysis of the virus showed that both viruses (from fluids and from the vaccine lot)
were identical. However, the E gene has not been sequenced so far (Chan et al.,
2001). Thus, it cannot be excluded that a selected variant was responsible for the
reported adverse effects. Recently, a fatal YEL-AVD event has been reported in
2004 in Spain following 17D-204 vaccination (Eurosurveillance, 2004). Sequencing
analysis does not reveal any mutation in the virus isolated from fluids (M.Niedrig,
personal communication). The last reported fatal case occurred in USA but no
further informations about the nature of the virus are available yet (Gerasimon and
Lowry, 2005).
I-7. Antibodies.
Antibodies or immunoglobulins (Ig) are soluble glycoproteins whose function is the
elimination of foreign antigens like infectious microbes. They represent one of the
main effectors of the humoral immunity. Their function is based on a specific and
physical interaction with the antigen. The diversity of antigenic determinants which
can be recognized by the human antibody repertoire is estimated to be 107 to 109.
I-INTRODUCTION
24
I-7-1. Structure of antibodies.
Antibodies are either produced in a membrane-bound form by B-lymphocytes or as
secreted molecules by antigen-stimulated B cells (Plasma cells). The membrane-
bound form (mainly IgM) mediates the activation of B cells through the interaction
with the antigen. The secreted form (IgM, IgG, IgA and IgE) bind the antigen and
trigger several effector mechanisms leading to its elimination.
A secreted IgG antibody molecule has a symmetric core structure composed of two
identical heavy chains and two identical light chains (Fig.9). The structure is stably
maintained by disulfide bridges and non-covalent links. Light chains can be of two
different isotypes: the κ isotype or the λ isotype. However, an antibody molecule is
always composed of 2 light chains from the same isotype. Each chain is divided into
constant domains and variable domains, according to their amino acid sequence
variability. The heavy chain is divided into three constant domains (CH1, CH2 and
CH3) and one variable domain (VH). The light chain is divided into one constant
domain (CL) and one variable domain (VL). The VH and VL domains, named
Fragment variable (Fv), form the antigen-binding site and, thus, participate in the
antigen recognition function of antibodies. The CH domains (CH2 and CH3) form the
Fc receptor of antibodies which mediates effector functions. Due to this symmetric
structure, two antigen-binding sites (VH-VL) are present for each IgG molecule and,
thus, can bind two antigens. Such a flexibility is conferred by a hinge region located
between domains CH1 and CH2. The VH and VL domains can be divided into seven
regions: four relatively conserved regions named Framework Regions (FR1, FR2,
FR3 and FR4) and three hypervariable regions named Complementary Determining
Regions (CDR1, CDR2 and CDR3). Antigen recognition and binding by antibodies is
mainly mediated by these hypervariable CDR regions. As shown in Fig.10, CDR
loops from both chains (VH ad VL) form a pocket to which the antigen docks. This
physical property of the CDR regions explains why they are found to be the most
important part of antibodies in terms of antigen specificity. In addition, it has been
shown that the VH domains play a more important role in specificity than the VL
domains and that the VH-CDR3 is one of the major determinant in terms of antigen
specificity (Kabat and Wu, 1991).
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Fig 9: Schematic drawing of an IgG immunoglobulin. From (Kontermann and Duebel, 2001).
Fig 10. Antigen-binding site and CDR regions. VH, VL and are indicated. CDR1, CDR2 and CDR3 of
the VL fragment are indicated in red, light green and orange, respectively. CDR1, CDR2 and CDR3 of the
VH fragment are indicated in cyan, dark green and blue, respectively. From (Kontermann and Duebel,
2001).
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I-7-2. Germline organization of the genetic loci of antibodies.
The Ig heavy chains, the Ig lambda light chains and the Ig kappa light chains are
encoded by three different loci which are located on different chromosomes (in
humans, chromosome 14, chromosome 22 and chromosome 2, respectively). The
genetic locus encoding for the heavy chain is composed of four genes: V, D and J
segments which encode for the VH domain and the C segment which encodes for
the CH1, CH2 and CH3 domains of the heavy chain. The genetic locus encoding for
the light chain is composed of only two segments V and J, forming the VL domain
and the C segment, forming the CL domain. All these segments are not present in
one copy but in a cluster of different segments (Vn, Dn, Jn, Cn in Fig.11).
I-7-3. Somatic recombination, affinity maturation and isotype switching in
antibody diversity.
The germline organization of antibody loci described previously is present in all cell
types. However, membrane-bound or secreted antibodies are produced only in B-
cells, through DNA rearrangements which occur in developing B-cells. This process
is called somatic recombination. The huge diversity of the antibody repertoire is
mainly driven by the somatic recombination process via two distinct mechanisms:
the combinatorial diversity and the junctional diversity. The somatic recombination
promotes the selection and the physical assembly of one V segment, one D
segment (for heavy chain) and one J gene from all DNA segments in each
developing lymphocyte to form a VDJ gene (for the heavy chain) or VJ gene (for the
light chain). This mechanism is mediated through enzymes called V(D)J
recombinases (mainly RAG-1 and RAG-2 complex) which introduce double-stranded
breaks in the DNA and rearrangements, resulting in the juxtaposition of V(D)J
segments, (“V-J, D-J and V-D-J rearrangements” in Fig.11). The transcriptional
processing leads to the production of transcripts containing a V(D)J sequence
encoding for the variable domain of the chain and a C domain encoding for the
constant domain of the chain. The random combination of germline V, D, J
segments among the multiple copies present in Ig loci defines the combinatorial
diversity.
The junctional diversity enhances the size of the antibody repertoire by promoting
modifications within one germline combination. At the time of V-J, D-J and V-D-J
joinings, nucleotides are added (TdT-mediated process) or removed (nuclease-
mediated process) at the junction sites. The sites of V(D)J junctions exhibit the
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greatest variability and form the CDR3 regions which, as mentioned above, are the
critical determinants for antigen specificity.
Fig 11: Schematic representation of the somatic DNA recombination process. Adapted from
(Abbas AK, 2003)
The third mechanism which governs antibody diversity is called affinity maturation.
Whereas combinatorial and junctional diversity mechanism take place during the
lymphocyte maturation, the affinity maturation occurs following the development of
T-dependent humoral responses. The capacity of antibodies to neutralize foreign
elements depends on high affinity and high avidity interactions. The affinity
maturation process promotes the production of high-affinity antibodies against one
particular antigen. This process is dependent upon the activation of helper T cells
and occurs in the germinal center of B cells. The V genes of the activated B-cells
undergo point mutations at a high rate, probably after repeated stimulations by
helper T cells. The precise molecular mechanism of this process is still unknown.
Those V gene mutations will allow the generation of different B cell clones able to
produce antibodies with higher affinity for the antigen. Since the mutations occur
randomly within the V genes, this mechanism may generate antibodies with a
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decreased affinity or even with a loss of affinity for the antigen. Nevertheless, only
B-cells which produce high-affinity antibodies will be selected for survival.
Another mechanism, which is dependent upon helper T cells activation and which
contributes to antibody diversity, is called heavy chain isotype switching or class
switching. In response to signals from helper T cells, activated B-cells undergo a
process of heavy chain isotype switching, resulting in the production of antibodies
with heavy chains of different classes. Its molecular mechanism is a process called
switch recombination, in which CH genes encoding for the constant domain of
antibodies are rearranged in a similar way to VDJ rearrangements. In the absence
of helper T cells signal, plasma cells produce IgM. The encounter of helper T cells
stimuli by activated B-cells promotes switching to other isotypes (IgG, IgA or IgE).
The switch to different classes of antibodies which distinct effector functions allows
the development of adapted responses against different types of infectious agents.
I-7-4. Antiviral antibodies and their mechanism of action.
The major role of antibodies is to bind foreign elements leading to their elimination
from the organism. Antibodies promote their role via several effector functions. The
recognition and the binding of infectious microbes like viruses by the variable
regions of antibodies promote the physical neutralization of the infectious agent.
This process is called neutralization, resulting in the inability for the virus to infect
its target cell. The most effective neutralizing antibodies belong to the IgG isotype.
Such virus-antibody complexes can be recognized by phagocytes through the
interaction between the Fc portion of IgG antibodies and the Fc receptors present
on the surface of phagocytes. This process of coating particles for phagocytosis is
called Fc-receptor-dependent phagocytosis or opsonization and leads to the
phagocytosis and the destruction of the virus. Antibody–coated infected cells are
recognized via the Fc part of antibodies by NK cells, which in turn destroy the
infected cell. This process is called antibody-dependent cell-mediated cytotoxicity
(ADCC). The antigen-antibody complexes are also recognized by soluble molecules
of the complement system, promoting phagocytosis.
I-7-5. Monoclonal antibodies and biological applications.
Monoclonal antibodies are molecules which are specific for a particular antigenic
determinant. They play a profound role in molecular diagnosis, therapeutical
applications and in fundamental research. In the last forty years, efforts have been
developed to produce monoclonal antibodies, which could be used for such
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purposes. In 1975, Koehler and Milstein revolutionized the field by developing the
hybridoma technology, which allows the production of monoclonal antibodies
(mAbs) in virtually unlimited quantities. They immortalized antibody-secreting B
cells from immunized mice by fusing them with a myeloma cell line, resulting a cell
line called hybridoma. Such cell lines retain the immortality of the myeloma cell line
and the specific antibody production of the B cell. The major drawback of this
method is that such monoclonal antibodies are not human and could generate
difficulties when use as therapeutical tools in humans. Attempts to produce human
mAbs were performed but were never really successful due to the lack of a suitable
human myeloma cell line, to the instability of the hybridoma when fused to a
murine myeloma cell line or to low quantity when immortalized following Epstein
Barr virus transformation. An alternative is the “chimerization” of those murine
mAbs by replacing the murine constant regions by human ones. Those chimeric
antibodies display the same specificity for the antigen through the murine V
domains but possess human effector functions of the Fc regions which are not
recognized as foreign in humans. Another approach is the “humanization” of mouse
mAbs by grafting the murine CDRs domains of the mAb to a whole human antibody.
All these methods have been successfully used to produce mAbs in large quantity
which can be used in therapeutical approaches in human clinical cases.
Nevertheless, these methods can be laborious, expensive and the screening of such
hybridomas can be limited. Genetic-engineering of antibodies were developed in the
last decade and provides an alternative approach to the hybridoma technique. One
of the most effective system is the phage display technology.
I-8. Phage Display technology.
Phage display is a very powerful technique to obtain libraries containing millions or
even billions of different peptides or proteins. This technology has been successfully
used to study protein-ligand interactions, to improve affinity of proteins for their
binding partners or to isolate antibodies specific for antigens (Azzazy and
Highsmith, 2002).
I-8-1. Principle.
The history of the phage display technology started in 1985 when G. Smith showed
for the first time that it was possible to express and display foreign proteins on the
surface of filamentous bacteriophages (M13 or fd) (Smith, 1985). This could be
done just by fusing, within the phage genome, the nucleotide sequence of the
protein of interest to the gene encoding a phage coat protein (typically pIII). Upon
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expression, the fusion protein (foreign protein-phage coat protein) is incorporated
and displayed on the surface of the recombinant phage particles. Such phage
display libraries can then be easily screened against one given antigen to isolate
proteins with specific functions. The two major advantages of this rather simple but
powerful method based on protein-protein interactions are that specific ligands can
be selected from a vast number of different sequences by a simple enrichment
method. Moreover, the structural and functional information of the protein of
interest displayed on the phage surface is physically linked to its genetic
information which is contained in the phage genome.
I-8-2. Filamentous phages.
Bacteriophages (or also called phages) are viruses which infect a variety of gram-
negative bacteria using F pili as receptors. Filamentous phages (M13, fd or f1
strains) are a group of bacteriophages with a tube-like shape. Those phages are
about 1 µm long and 6 nm in diameter. These particles are mainly composed of the
major phage coat proteins pVIII which are helically-arranged. Around 2700 copies
of pVIII form a wild-type filamentous phage virion. Three to five copies of another
phage coat protein, the pIII protein are found at one tip of the particle. This protein
is responsible for the attachment of the phage to the bacterial pili and, thus,
mediates the infection of the bacteria. The filamentous phage genome is composed
of a 6.4 kb single-stranded DNA consisting of 11 genes. The process of infection is
initiated by the attachment of the phage coat protein pIII to the bacterial F pili. This
promotes the dissociation of the phage coat proteins on the bacterial surface
allowing the ssDNA phage genome to enter into the cytoplasm of the bacteria. A
complementary DNA strand is then synthesized by the host DNA replication
machinery, resulting a double-stranded replicative form (RF). This RF serves as a
template for the generation of new single-stranded DNA genomes as well as for the
production of phage proteins. The particles are then assembled in the cell
membrane and phages are released into the extracellular compartment through an
extrusion process. Filamentous phages are non-lytic bacteriophages; phages are
secreted continuously without killing the host (for review see Russel, 1991).
I-8-3. Phage display system.
First attempts to generate recombinant phages displaying foreign proteins on their
surface were done by cloning the DNA sequence of the foreign protein in frame with
the gene encoding the pIII or pVIII protein directly into the phage genome (mainly
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by using the pIII gene, because only very small peptides can be fused to the pVIII
protein without altering the phage properties). Nevertheless, such a system was
found not to be very effective due to instability during assembly and the low
transformation efficiency. To circumvent these problems, a new generation of
vectors called phagemids was designed and a system of phage rescue was
established (Mead and Kemper, 1988).
I-8-3-1. Phagemids.
Phagemids are double-stranded DNA hybrid molecules from the phage genome and
a plasmid vector. The phagemid pHEN3 we used in this work is depicted in Fig.15.
It is composed of a plasmid backbone bearing a colE1 ori enabling the phagemid to
replicate in the E.coli host cell, a M13 ori allowing the phagemid to be packaged
into recombinant phage particles, an ampicillin resistance gene for selection of
phagemid-containing colonies, a peptide leader pelB promoting the secretion of the
fusion protein in the periplasm of the host cells, the LacZ promoter which allows the
inducible expression of the fusion protein “protein of interest-pIII coat protein” (its
expression is inhibited by glucose and promoted by IPTG) and the gene encoding
for the pIII protein of the M13 phage. Restriction sites are also found for cloning of
the protein of interest into the phagemid. Two tags (His-tag and Myc-tag) are found
on the C-terminal part of the pIII protein for detection of the fusion protein.
However, the phagemid lacks all other structural and non structural proteins which
are required for a complete phage particle.
I-8-3-2. Helper phages.
Those structural and non structural proteins can be supplied in trans by infecting
phagemid-transformed bacteria with helper phages. This process is called “phage
rescue”. Helper phages (such as M13KO7 or VCSM13) are almost identical to wild-
type phages except that their genome contains a mutated origin of replication. As a
result, this ori is slightly defective for replication, resulting in a lower encapsidation
capacity. Thus, phagemids are preferentially packaged into the virion progeny.
Since helper phages provide all proteins including wild-type pIII protein, a
competition takes place between the phagemid fusion protein pIII and the helper
phage wild-type pIII for incorporation into recombinant phages. The resulting
phage population consists of recombinant phages displaying on their surface
between none and five copies of the fusion protein encoded by the phagemid.
Studies have shown that the ratio of pIII-fusion protein vs wild-type pIII in a
rescue phage population varies between 1:9 to 1:1000, but typically the majority of
recombinant phages bear only a single copy of the fusion protein (Azzazy and
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Highsmith, 2002). To circumvent such a limitation, recent studies are in progress to
limit the expression of the wild-type pIII. Nevertheless, many articles have shown
that this system is extremely powerful and suitable to isolate diverse ligands. One
of the most important applications of the phage display technology is the isolation
of recombinant antibody fragments against a specific antigen.
I-8-4. Phage-displayed scFv libraries.
The phage display technology provides an easy and efficient tool to access the
antibody repertoire by generating phages displaying on their surface recombinant
antibodies. (Hoogenboom, 2002), (Azzazy and Highsmith, 2002)
I-8-4-1. scFV antibody fragment.
Due to the structural complexity of an antibody molecule, it is not possible to
generate recombinant phages displaying entire antibodies. However, as mentioned
above, Fv fragments, which are composed of variable domains of light chains (VL)
and heavy chains (VH) of antibodies, are responsible for antigen binding and, thus,
determine the antigen specificity of antibodies. For this reason and due to the small
size of such fragments, recombinant phages expressing and displaying a
recombinant version of Fv fragments called scFv were generated. scFv (single-chain
Fragment variable) are synthetic molecules corresponding to the Fv fragments in
which VL an VH domains are joined together with a flexible peptide linker. This
linker which is composed of a stretch of Glycine and Serine (Gly4Ser)3) stabilizes
the structure and ensures the formation of the VH and VL antigen-binding site.
Fig 12: Schematic drawing of a scFv molecule.Vh: variable domain of heavy chains of antibodies,
Vl: variable domain of the light chains of antibodies. From (Kontermann and Duebel, 2001).
I-8-4-2. Construction of phage display scFv libraries.
VH and VL genes from the whole antibody repertoire are PCR-amplified by using a
set of primers specially designed to amplify all rearranged human V-genes (Marks
et al., 1991; Marks et al., 1991; Orlandi et al., 1989). These primers are specific for
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regions which are well-conserved among all V-genes families named framework
regions (see I-7-1). The first set of primers is specific for the region encoding the N
terminal part of VH and VL domains which is found at the beginning of the FR1
region. The second set of primers is specific for the region coding for the junction
between the J segment of the V domain and the first C domain. This region is
located downstream of the CDR3 in the FR4 region. (see Fig. 11). Furthermore, sets
of degenerated primers are used to optimize the amplification of all rearranged V
domains. All PCR-amplified regions are then cloned as scFvs molecules in the
phagemid, used to transform bacteria resulting in the construction of bacterial scFv
libraries. Generation of recombinant phages displaying scFvs on their surface is
achieved by infecting these phagemid-transformed bacterial cells with helper
phages. Theoretically, those recombinant phages mirror the antibody repertoire
initially present in patients whose lymphocytes were taken. The diversity of libraries
can even be greater since the cloning method allows the free combination of VH
and VL domains which may be not have been originally present in the donor. The
construction of libraries is extensively described in Methods and in Fig. 16a; 16b.
Fig 13: Representation of a recombinant phage expressing and displaying on its surface scFv-
pIII fusion proteins. From (Azzazy and Highsmith, 2002).
I-8-4-3. Source of RNAs
Because plasm cells are responsible for the production of antibodies, they represent
the biological material which is used to construct phage antibody libraries. Such
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cells can be isolated from peripheral blood lymphocytes (PBL), bone marrow or
spleen. However, due to technical problems, especially encountered when libraries
are constructing from humans, PBL cells harvested from blood are preferentially
used.
I-8-4-4. Types of Phage antibody libraries.
 Antibody phage librariees are classified according to the nature of the donor and its
antibody specificities. Three types of libraries can be constructed.
Naïve libraries.
Such libraries are constructed using B-cells from naïve or non immunized donors.
Because, any immune response can biased towards one specific antigen, a single
naïve library can be used to isolate antibody fragments against various antigens.
This type of libraries can be used to isolate antibodies against self antigens,
haptens or small antigens and therefore this potentially limited diversity can
reduced the quality content of such libraries.
Immune libraries.
Phage libraries can also be constructed using material from immune or immunized
donors. These libraries contain a high content for diverse antibodies against one
specific antigen. Furthermore, many of these antibodies have undergone the affinity
maturation process during immunization and, therefore, exhibit a high affinity for
the antigen.
Synthetic libraries.
A third class of libraries called synthetic libraries can also be designed. In this
strategy, residues from the CDRs of the whole antibody repertoire can be randomly
PCR-mutated resulting in a large number of specificities, many of which are not
present in the natural repertoire..
I-8-5. Selection of antibody libraries: “Biopanning”.
In order to isolate recombinant phages displaying scFvs with a specific affinity for
one given antigen from billions different phages from the constructed libraries, a
biopanning or selection step is required. This method is based on the interaction
between the antibody fragment (scFv) displayed on the phage surface and the
antigen of interest. Phages are panned against the antigen of interest which can be
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immobilized on a plastic surface, in solution or expressed on cell surfaces (Azzazy
and Highsmith, 2002). Multiple and successive selection steps are usually
performed to allow an enrichment with antigen-specific phages. Finally, monoclonal
phages displaying a specific affinity for the antigen can be isolated and further
characterized. (Fig. 14).
Practically, recombinant phages are incubated with the antigen of interest which is
usually immobilized onto a plastic surface (Fig.14 [1]). In this case, the antigen is
captured onto plastic phase by chemical coupling or non-covalent adsorption to a
hydrophobic plastic surface. After the incubation step, unbound phages are
eliminated by washes (Fig.14 [2]) and phages displaying scFvs with a specific
binding activity for the antigen are retained. These phages are then eluted and
used to infect E.coli cells resulting in the generation of a new phage population
(Fig.14 [3], [4].) This new pool of phages is usually used for another round of
selection. Usually, three to four successive rounds of selection are performed to
remove all unspecific binders and to ensure the enrichment with phages exhibiting
a high specific affinity for the antigen of interest.
Fig 14: Biopanning or selection step. From (Azzazy and Highsmith, 2002).
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I-8-6. Human viruses neutralized by recombinant antibody fragments.
The phage display system has been successfully used to isolate and characterize
human neutralizing antibody fragments (scFv or Fab format) against several viruses
which are listed in the Table 2.
Virus Target protein Format Reference
Ebola virus Glycoprotein GP Fab
(Maruyama et al., 1999;
Maruyama et al., 1999)
Hantaan virus Glycoprotein G1 Fab (Liang et al., 2003)
Hantaan virus Glycoprotein G2 Fab (Koch et al., 2003)
Hepatitis A Capsid protein Fab (Schofield et al., 2002)
Hepatitis E Capsid protein ORF2 Fab (Schofield et al., 2000)
HIV-1
Gp140-CD4
complexes Fab (Zhang et al., 2003)
HIV-1
Gp120-CD4-CCR5
complexes Fab (Moulard et al., 2002)
HIV-2 Glycoprotein gp125 Fab (Bjorling et al., 1999)
Human
cytomegalovirus
(HCMV)
B&H glycoproteins scFv (Nejatollahi et al., 2002)
Human Rotavirus VP7 protein Fab
(Higo-Moriguchi et al.,
2004)
Measles virus
Hemagglutinin H
glycoproteins Fab
(de-Carvalho-Nicacio et al.,
2002)
Puumala virus Glycoprotein G2 Fab
(de-Carvalho-Nicacio et al.,
2000)
Rabies virus Glycoprotein gp scFv (Kramer et al., 2005)
Rabies virus Glycoprotein gp scFv (Ray et al., 2001)
Resiratory Syncytial
Virus Glycoprotein F scFV (Nguyen et al., 2000)
Resiratory Syncytial
Virus Glycoprotein F Fab (Barbas et al., 1992)
SARS-CoV Glycoprotein spike Fab (ter-Meulen et al., 2004)
Simian
Immunodeficiency
virus
Glycoprotein gp120 Fab (Glamann et al., 1998)
Vaccinia virus unknown Fab (Schmaljohn et al., 1999)
Varicella—zoster
Virus
VZV antigen scFv (Kausmally et al., 2004)
Table 2. Human neutralizing recombinant antibody fragments isolated against various viruses
by phage display.
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I-9. Aim of the work
Yellow fever is an “old” disease which can be prevented by vaccination. Despite the
presence of a highly effective YF vaccine called 17D vaccine, this disease is
currently re-emerging on a large scale. The 17D vaccine is known to be a non
clonal vaccine which is constituted of heterogeneous virion sub-populations due to
the uncontrolled passage of the virus during the early years. The report of several
cases of viscerotropic and neurotropic diseases associated with YFV 17D vaccination
raised the obvious question of vaccine safety. Moreover, this vaccine is still
produced by inoculation into viable embryonated eggs and this method of
production, which limits the vaccine production capacity, strongly impairs attempts
to control the disease. Furthermore, vaccine supply shortage has already been
experienced during YF outbreaks. Thus, it appears essential to develop new
methods for manufacturing the 17D vaccine. One of the easiest way is the use of a
clonal vaccine derived from a full length cDNA transfected into a cell culture
substrate. This method allows the production of a vaccine composed of a
genetically homogeneous virion population at high efficiency and low cost. Because
YFV immunity is mainly antibody-mediated, the knowledge of YFV neutralizing
epitopes is, therefore, essential. To study this problem, the phage display
technology provides a convenient tool to isolate neutralizing recombinant antibody
fragments against YFV which could be used to identify and characterize neutralizing
epitopes. To this aim, phage antibody libraries composed of phages displaying on
their surface recombinant single chain antibody fragments (scFv) from lymphocytes
of patients who recovered from YF disease will be generated. Such libraries will be,
then, screened against YFV particles to isolate scFv with a specific affinity for the
YFV. Those scFvs will be tested for their capacity to block YF infection. The
molecular determinants of neutralization, i.e. neutralizing epitopes, will be identified
and characterized. These data would be useful for the standardization and the
design of novel YF vaccines based on infectious clones.
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II-MATERIAL
II-1. Plasticware.
Maxisorp Immunotubes Nunc, Wiesbaden
Maxisorp Microtiter plates Nunc, Wiesbaden
Large plates (243 mm x 243 mm) Nunc, Wiesbaden
II-2. Chemicals.
Acetone Riedel-de Haen, Seelze
Acrylamid/Bisacrylamid (29 :1) Roth, Karlsruhe
Agarose Invitrogen, Karlsruhe
Agarose (Low Melting Point) Invitrogen, Karlsruhe
Ammoniumpersulfat (APS) Biorad, Muenchen
Ampicillin Sigma, Deisenhofen
Bactoagar Difco, USA
Bromophenolblue Serva, Heidelberg
Complete (Protease Inhibitor) Roche, Mannheim
DNA Ladder mix (DNA marker) MBI Fermentas, St.Leon-Roth
ECL (Enhanced Chemoluminescence) Pierce, USA
EDTA (Ethylene-Dinitrilo-Tetra-Acetate) Sigma, Deisenhofen
Ethanol Roth, Karlsruhe
Ethidiumbromid Roth, Karlsruhe
Ficoll Amersham, Braunschweig
Glucose Sigma, Deisenhofen
Glycerol Roth, Karlsruhe
Glycin Merck, Darmstadt
Isopropanol Roth, Karlsruhe
Iso-Propyl-Thio-Galactoside (IPTG) MBI Fermentas, St.Leon-Roth
Kanamycin Sigma, Deisenhofen
Mercaptoethanol Roth, Karlsruhe
Neutral red Roth, Karlsruhe
N-hydroxysuccimid (NHS)-L Biotin Pierce, Rockford, USA
Ni-NTA Qiagen, Hilden
Nitrocellulose Schleicher&Schuell, Dassel
n-octyl-β-D-glucopyranoside Sigma, Deisenhofen
NP40 Sigma, Deisenhofen
Pepton Merck, Darmstadt
Polyethylenglycol (8000MW) Sigma, Deisenhofen
Protein G-Agarose beads Santa Cruz, CA, USA
Rainbow marker (RPN 756) Amersham, Braunschweig
Rotiphorese Gel 30 (30% Acrylamid) Roth, Karlsrhue
Sodium-dodecyl-sulfate (SDS) Roth, Karlsruhe
TEMED (N,N,N,N-Tetramethyl-ethylendiamine) Biorad, Muenchen
Triethylamine Sigma, Deisenhofen
Tris (Trishydroxymethylaminomethan) Roth, Karlsruhe
Triton X-100 Sigma, Deisenhofen
Trypsin-EDTA Gibco BRL, Eggenstein
Tween-20 Sigma, Deisenhofen
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II-3. Enzymes.
ApaLI New England Biolabs, Schwalbach
MMLV reverse transcriptase (H-) Promega, USA
NotI New England Biolabs, Schwalbach
RNase Inhibitor MBI Fermentas, St.Leon-Roth
SfiI New England Biolabs, Schwalbach
Shrimp Alcaline Phosphatase (SAP) MBI Fermentas, St.Leon-Roth
T4 DNA Ligase MBI Fermentas, St.Leon-Roth
Xho1 New England Biolabs, Schwalbach
II-4. Antibodies
Anti-17D polyclonal sera (immunized travellers) Provided by Dr M.Niedrig, Robert
Koch Institute, Berlin, Germany
Anti-Myc-Tag mouse antibody Oncogene, CA, USA
Anti-YFV polyclonal serum (monkey) Provided by Dr M.Niedrig, Robert
Koch Institute, Berlin, Germany
Polyclonal serum from a human acute confirmed
YF case (S-993)
Provided by Dr L. Koivogui,
PFHG, Conakry, Guinea.
HRP-conjugated streptavidin Pierce, USA
HRP-conjugated mouse anti-M13 Pharmacia, Freiburg
HRP-conjugated rabbit anti mouse IgG Dako, Denmark
HRP-conjugated rabbit anti human IgM Dako, Denmark
HRP-conjugated rabbit anti human IgG Dako, Denmark
Anti YFV-E protein mouse monoclonal antibody
(6330)
Provided by Dr M.Niedrig, Robert
Koch Institute, Berlin, Germany
Anti-His-tag mouse antibody, (H-3) Santa Cruz, CA, USA
Anti YFV-E protein mouse monoclonal antibody
(6538)
Provided by Dr M.Niedrig, Robert
Koch Institute, Berlin, Germany
II-5. Radioactive amino acids.
Redivue Pro-Mix L-[35S] in vitro
cell labelling mix:
Amino acid mixture for in vitro
labelling containing L-[35S]
Methionine and L-[35S] Cysteine,
14.3 mCi/ml, >1000 Ci/mmol.
Amersham Biosciences, Freiburg.
II-6. Commercial Kits.
Micro BCA Protein Assay Reagent kit Pierce, USA
One step RT-PCR kit Qiagen, Hilden
QIAamp viral RNA Mini kit Qiagen, Hilden
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QIAprep Maxipreps kit Qiagen, Hilden
QIAprep Minipreps kit Qiagen, Hilden
QIAquick Gel extraction kit Qiagen, Hilden
QIAquick PCR purification kit Qiagen, Hilden
RNeasy Mini kit Qiagen, Hilden
Sulfo-NHS-LC-Biotinylation kit (EZ-Link) Pierce, USA
Taq-PCR Core kit Qiagen, Hilden
II-7. Vectors.
pHEN3 phagemid vector used for the expression of scFv as a fusion protein
scFV-pIII. (Kontermann et al, xxx).
pAB1 prokaryotic expression vector allowing the expression of scFvs as
soluble molecules. (Kontermann et al, xxx).
Fig.15: Schematic representation of the pHEN3 phagemid and the pAB1 plasmid. Lac p:
promoter LacZ, pelB: pelB leader sequence.
II-8. Viruses.
YF 17D vaccine strain:
17D-204-WHO strain obtained as a commercial preparation of the 17D-204-
WHO vaccine, manufactured by the Robert Koch Institute,
Berlin, Germany.
Wild-type YFV strains:
Strain Year Origin Source Reference
HB1782 1986 CAR Human CAR86
ETH2777 1961 Ethiopia Human Ethiopia86
BA-55 1986 Nigeria Human Nigeria86
ArD76320 1990 Senegal Mosquito Senegal90
Asibi strain 1927 Ghana Human Ghana27
Ampicilline Resistance Gene
M13 ori colE1 ori
pHEN3
lac-p pel B
SfiI
XhoI
20 aa 
linker
ApaLI NotI
His-Tag Myc-Tag pIII gene
LMB3 primer fdSeq1 primer
Ampicilline Resistance Gene
colE1 ori
pAB1
lac-p pel B
SfiI
His-Tag Myc-Tag
NotI
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African wild-type yellow fever viruses obtained as lyophilized stocks made on
suckling mouse brain from National Reference Center for Arboviruses and Viral
Haemorrhagic Fevers, Lyon, France.
II-9. Bacteria and phages.
E.coli, TG1 strain Electroporation-competent cells, supE thi-1 ∆(lac-proAB)∆
(mcrB-hsdSM)5 (rk
- mk
-) [F´traD36 proAB laclqZ∆M15],
Stratagene, Heidelberg.
VCS M13 helper phage Stratagene, Heidelberg.
II-10. Eukaryotic Cells.
Vero-76 cells Cell line from African Green Monkey kidney, ATCC CRL-
1587
PS cells Cell line from porcine kidney, obtained from the National
Reference Center for Arboviruses and Viral Haemorrhagic
Fevers, Lyon, France.
II-11. PCR primers.
The primers used in this study are those described by Marks et al (Marks et al.,
1991) except that restriction sites (ApaLI, NotI, SfiI and XhoI) were added at
5´ends. These primers were provided by MWG-Biotech AG, Ebersberg, Germany.
II-11-1. Degenerated primers specific for the VH and VL genes.
W=A,T / M=A,C /R=A,G/K=G,T /Y=C,T / S=G,C / V=G,A,C / D=G,A,T / B=G,T,C / H=A,T,C
II-11-1-1. Primers for VLκ genes.
Back primers (for the 1st PCR=PCR 1a and for the 2nd PCR=PCR 1b):
huVκ1Back-Apa 5’ GCCGTTAGTGCACAGATCCAGWTGACCCAGTCTCC 3´
huVκ2Back-Apa 5’ GCCGTTAGTGCACAGGTTGTGATGACTCAGTCTCC 3´
huVκ3Back-Apa 5’ GCCGTTAGTGCACAGATTGTGWTGACRCAGTCTCC 3´
huVκ4Back-Apa 5’ GCCGTTAGTGCACAGATTGTGATGACCCACACTCC 3´
huVκ5Back-Apa 5’ GCCGTTAGTGCACAGACGACACTCACG CAGTCTCC 3´
huVκ6Back-Apa 5’ GCCGTTAGTGCACAGATTGTGCTGACTCAGTCTCC 3
ApaL1 restriction sites are underlined.
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Foward Primer (for the 1st PCR=PCR 1a):
huCκFor 5’ GAAGACAGATGGTGCAGCCACAGT 3´
Forward Primers( for the 2nd PCR=PCR 1b):
huJκ1For-Not 5’ GCCTTCTGCGGCCGCACGTTTGATYTCCASCTTGGTCCC 3´
huJκ2For-Not 5’ GCCTTCTGCGGCCGCACGTTTGATATCCACTTTGGTCCC 3´
huJκ3For-Not 5’ GCCTTCTGCGGCCGCACGTTTAATCTCCAGTCGTGTCCC 3´
Not I restriction sites are underlined.
II-11-1-2. Primers for VLλ genes.
Back primers (for the 1st PCR=PCR 1a and for the 2nd PCR=PCR 1b):
huVλBack-Apa 5’ GGCGGTAGTGCACAGTCTGTGCTGACTCAGCCACC 3´
huVλBack-Apa 5’ GGCGGTAGTGCACAGTCTGTGYTGACGCAGCCGCC 3´
huVλCBack-Apa 5’ GGCGGTAGTGCACAGTCTGTCGTGACGCAGCCGCC 3´
huVλ2Back-Apa 5’ GGCGGTAGTGCACARTCTGCCCTGACTCAGCCT 3´
huVλ3ABack-Apa 5’ GGCGGTAGTGCACTTTCCTATGWGCTGACTCAGCCACC 3´
huVλ3BBack-Apa 5’ GGCGGTAGTGCACTTTCTTCTGAGCTGACTCAGGACCC 3´
huVλ4Back-Apa 5’ GGCGGTAGTGCACACGTTATACTGACTCAACCGCC 3´
huVλ5Back-Apa 5’ GGCGGTAGTGCACAGGCTGTGCTGACTCAGCCGTC 3´
huVλ6Back-Apa 5’ GGCGGTAGTGCACTTATTTTTATGCTGACTCAGCCCCA 3´
huVλ7/8Back-Apa 5’ GGCGGTAGTGCACAGRCTGTGGTG ACYCAGGAGCC 3´
huVλ9Back-Apa 5’ GGCGGTAGTGCACWGCCTGTGCTGACTCAGCCMCC 3´
ApaL1 restriction sites are underlined.
Forward Primers (for the 1st PCR=PCR 1a):
HuCλFor1 5’ TGAACATTCTGTAGGGGCCACTG 3´
HuCλFor2 5’ AGAGCATTCTGCAGGGGCCACTG 3´
Forward Primers (for the 2nd PCR=PCR 1b):
HuCλFor1-Not 5’ GAGTCATTCTGCGGCCGCACCTAGGACGGTGACCTTGGTCCC 3´
HuCλFor2-Not 5’ GAGTCATTCTGCGGCCGCACCTAGGACGGTCACCTTGGTCCC 3´
HuCλFor3-Not 5’ GAGTCATTCTGCGGCCGCACCTAA AACGGTGAGCTGGGTCCC 3´
Not I restriction sites are underlined.
II-11-1-3. Primers for VH genes.
Back primers (for the 1st PCR=PCR 2a and for the 2nd PCR=PCR 2b):
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huVH1/7Back-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCCAGRTGCAGCTGGTGCARTCTGG 3´
huVH2Back-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCCAGRTGACCTTGAAGGAGTCTGG 3´
huVH3ABack-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCSAGGTGCAGCTGGTGGAGTCTGG 3´
huVH3BBack-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGWCYGG 3´
huVH4ABack-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTACAGCAGTGGGG 3´
huVH4BBack-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCCAGSTGCAGCTGCAGGAGTGSGG 3´
huVH5Back-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCGARGTGCAGCTGGTGCAGTCTGG 3´
huVH6Back-Sfi 5’ CTCGCGGCCCAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGG 3´
Sfi I restriction sites are underlined.
Forward Primers (for the 1st PCR=PCR 2a):
huIgGFor1 5’ GACCGATGGGCCCTTGGTGGA 3’
huIgGFor2 5’ GACGGATGGGCCCTTGGTGGA 3’
Forward Primers (for the 2nd PCR=PCR 2b):
huJH1-2,4-5For-Xho 5’ ACTGGTCCGACTCGAGACGGTGACCAGGGTKCC 3’
huJH3,6For-Xho 5’ ACTGGTCCGACTCGAGACGGTGACCRTKGTCCC 3’
Xho1 restriction sites are underlined.
II-11-2. pHEN3-specific primers.
LMB3 primer 5’ CAGGAAACAGCTATGACC 3’
fdseq1 primer 5’ GAATTTTCTGTATGAGG 3’
II-11-3. YFV E, NS1 and prM proteins-specific primers.
EnvF1 5´TGTGAAGATTAATGACAAGTGCC3´
EnvF2 5’ CAATGATAAGTGCCCGAGC 3´
EnvF3 5´CAGGTCATGGCACGGTTG 3´
EnvR1 5´GGATTGACTTCAATTAGGACTTC 3´
EnvR2 5’ CACCTCAATCAGCACTTCATC 3´
NS1R1 5’ CACTATTGATGCAAGCTTCACAG 3´
NS1R2 5’ TCTCCACATTTGAGCTCTCG3´
prM forward 5´GATGTTCTGACTGTGCAATT 3´
M reverse 5´TTCCTCCATGCACCCCCT 3´
II-12. Buffers and solutions.
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II-12-1. Virus purification.
30% Glycerol Buffer Glycerol 30 g
volume adjusted to 100 ml with PBS and autoclaved
TNE Buffer (pH 7.5): Tris 1.2 g
NaCl 8.8 g
0.5 M EDTA 10 ml
volume adjusted to 1 l with dH2O
pH 7.5 adjusted with NaOH
II-12-2. Phage purification.
PEG 6000-NaCl solution: 20% PEG 6000 200 g
2.5 M NaCl 146.1 g
volume adjusted to 1 l with dH2O
II-12-3. DNA electrophoresis.
50x TAE-Buffer: Tris 242 g
Acetic acid 57.1ml
0.5 M EDTA (pH 8) 100ml
volume adjusted to 1 l with dH2O
10x agarose gel sample
buffer:
1 M Tris-HCl pH 7.5     0.5 ml
Glycerol 6 ml
Bromophenol blue 25 mg
Xylene cyanol 25 mg
volume adjusted to 10 ml with dH2O
II-12-4. ELISA.
ABTS Microwell Peroxidase Substrate KPL, USA
ELISA coating buffer: one Carbonate/Bicarbonate capsule dissolved in 100 ml
dH2O.
II-12-5. SDS PAGE and Western Blot.
SDS PAGE.
4x SDS PAGE sample buffer: 0.5 M Tris-HCl pH 6.8 4 ml
SDS 0.4 g
Glycerol 4 ml
2% Bromophenolblue 0.1 ml
dH2O 1.2 ml
β-mercaptoethanol 0.4 ml
10x SDS PAGE Running buffer: SDS 10 g
Tris 30 g
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Glycine 144 g
volume adjusted to 1 l with dH2O
Transfer buffer for Western Blot.
Anodebuffer I: 1 M Tris 300 ml
Ethanol 200 ml
adjust volume to 1 l with dH2O
Anodebuffer II: 1 M Tris 25 ml
Ethanol 200 ml
adjust volume to 1 l with dH2O
Cathode buffer: 1 M Tris 25 ml
Aminocapron acid 5.25 g
Ethanol 200 ml
volume adjusted to 1 l with dH2O
PBS: NaCl 8 g
KCl 0.2 g
Na2HPO4 1.15 g
MgCl2 0.1 g
KH2PO4 0.2 g
CaCl2 0.13 g
volume adjusted to 1 l with dH2O
II-12-6. Dot Blot buffers.
TNE + 1%NP-40
TNE + 1% n-octyl-β-D-glucopyranoside
TNE + 1%Tween-20
Rec Blot/Immunoblot substrate Mikrogen, Freiburg
II-12-7. Protein purification
Periplasmic Preparation Buffer (PPB): 1 M Tris-HCl pH 7.5 30 ml
0.5 M EDTA 10 ml
Sucrose 200 g
volume adjusted to 1 l with dH2O
5x Na-Phosphate buffer stock: Na2HPO4 29.8g
NaCl 147g
volume adjusted to 1 l with dH2O
IMAC loading buffer: 5x Na-Phosphate stock 200
ml
20 mM imidazole 1.38
g
volume adjusted to 1 l with dH2O
IMAC wash buffer: 5x Na-Phosphate stock 200,ml
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35 mM imidazole 2.38
g
volume adjusted to 1 l with dH2O
IMAC elution buffer: 5x Na-Phosphate stock 200 ml
100 mM imidazole 6.81 g
volume adjusted to 1 l with dH2O
Coomassie Blue staining solution: Coomassie Brilliant Blue R-250 2.5 g
Methanol 450 ml
Acetic acid 400 ml
volume adjusted to 1 l with dH2O
Coomassie Blue destaining solution: Methanol 450 ml
Acetic acid 100 ml
volume adjusted to 1 l with dH2O
RIPA Buffer: 1 M Tris-HCl pH 7.5 1 ml
5 M NaCl 3 ml
0.5 M EDTA 1 ml
n-octyl-β-D-glucopyranoside 0.5 g
Protease Inhibitor cocktail 1 tablet
volume adjusted to 100 ml with dH2O
II-12-8. pH shift buffers.
Low pH Buffer (pH 5) 0.05 M MES
0.1 M NaCl
volume adjusted to 100 ml with dH2O
pH 5 adjusted with HCl
Control pH Buffer (pH 8): TNE buffer adjusted to pH 8 with NaOH.
II-13. Media for bacterial culture.
M9 medium: Na2HPO4 58 g
KH2PO4 30 g
NaCl 5g
NH4Cl 10 g
Volume adjusted to 1 l with dH2O and
autoclaved
Minimal plates: H2O 880 ml
Agar 15 g
autoclaved
20% glucose 10 ml
1 M MgSO4 1 ml
Vitamin B1 (2 mg/ml) 1 ml
M9 medium 100 ml
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LB medium: Bacto-Trypton 10 g
Yeast extract 5 g
NaCl 10 g
Volume adjusted to 1 l with dH2O and autoclaved
LB medium-1% glucose LB medium 1 l
Glucose 10 g
LB agar plates (+/- 1% glucose) LB medium (+/- 1% glucose) 250 ml
Agar 3.75 g
Volume adjusted to 1 l with dH2O and
autoclaved
II-14. Media for cell culture.
Dulbecco´s Modified Eagle´s Medium
(DMEM)
Gibco BRL, Eggenstein.
Dulbecco´s Modified Eagle´s Medium
(DMEM) without Methionine and Cysteine.
Sigma, Deisenhofen.
Fetal calf serum (FCS) Gibco BRL, Eggenstein.
L-Glutamine Gibco BRL, Eggenstein.
Penicillin-Streptomycin Gibco BRL, Eggenstein.
2x DMEM a la Frantz Brandl Sigma, Deisenhofen.
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III-METHODS
III-1. Schematic representation of the construction of the phage
libraries expressing recombinant antibody fragments (scFvs).
Fig 16a: Overview of the phage libraries construction. Cloning of VL fragments into pHEN3 to
obtain VL sub-libraries
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Fig 16b: Overview of the phage libraries construction. Cloning of VH fragments into VL-pHEN3 to
obtain scFv libraries.
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III-2. Isolation of lymphocytes from two African donors who
recovered from yellow fever.
Peripheral blood lymphocytes (PBL) were isolated from blood of two donors from
Guinea who were infected with yellow fever virus during an outbreak which
occurred in 2000. Blood samples were collected approx. 6 months after acute
infection. 20 ml anticoagulated blood were mixed 1:1 with an equal amount of PBS,
loaded onto a 10 ml Ficoll layer and centrifuged at 1500 g for 30 min at RT. This
step allows the separation of erythrocytes which are found in the ficoll solution at
the bottom of the tube from white cells (PBL, leukocytes) which are located at the
interface. The top of the tube represents the plasma fraction. PBL cells from the
interface were harvested and washed twice with PBS by centrifugation at 1500 g at
room temperature (RT). After washes, PBL were directly used for total RNA
extraction after trypan blue counting.
III-3. First strand cDNA synthesis.
Total RNA was extracted from 107 PBL isolated in III-2 using the RNeasy kit
(Qiagen) according to the manufacturer´s instructions. Quantitation of RNA was
determined by measuring OD260 with a standard spectrophotometer.
The first strand of cDNA was synthesized from total RNA by reverse transcription
using two different types of primers: oligo(dT)15 primer and random hexamers.
A) Oligo(dT)15 primer.
total RNA (isolated in III-2) 4 µg
oligo(dT)15 primer (0.5µg) 4 µl
DEPC-treated water to 10 µl
The reaction was incubated at 65°C for 5 min to melt secondary structures present
on mRNA which could interfere with the cDNA synthesis. At this time, the tube was
immediately cooled on ice for 5 min to prevent the secondary structures to form.
The following components were then added:
+5X RT buffer 5 µl
10mM dNTPs mix 3 µl
+ RNase Inhibitor 2 µl
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+ MMLV RT (H-)(200 Units) 1 µl
DEPC-treated water to 25 µl
The reverse transcription reaction was incubated at 42°C for 1 h. The enzyme was
then inactivated by incubating the tube at 70°C for 15 min.
B) Random hexamers.
total RNA (isolated in 2-1) 4 µg
random hexamers (100ng) 2 µl
DEPC-treated water to 10 µl
The reverse transcription reaction was performed as described above when using
the oligo(dT)15 primers except for different temperatures conditions. The tube was
incubated at 25°C for 10 min and then incubated at 42°C for 50 min. The enzyme
was finally inactivated by heating at 70°C for 15 min.
Both cDNA preparations were pooled and stored at –70°C until use as a template
for PCR amplification.
III-4. PCR amplification of the Variable Kappa Light chain (VLκ),
Variable Lambda Light chain (VLλ) and Variable Heavy chain (VH)
genes of antibodies.
VLκ, VLλ and VH genes were amplified using a semi-nested PCR protocol (cf. Fig
16a and 16b) using the cDNA, synthesized in section III-3
III-4-1. PCR conditions and protocol.
The first PCR step [PCR 1a for VL] and [PCR 2a for VH] was performed as follows:
10x PCR buffer 5 µl
5x Q solution 10 µl
10mM dNTPs mix 1 µl
back primer (10 pmol/µl) 3 µl
forward primer (10 pmol/µl) 3 µl
Taq polymerase (5 U/µl) 0.5 µl
H2O 26.5 µl
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First strand cDNA pool (from2-2) 1 µl
Final volume 50 µl
PCR 1a/2a was performed using the following program:
Initial denaturation 30 sec 94°C
Denaturation 30 sec 94°C
Annealing 45 sec 50°C
Elongation 1 min 72°C
Final extension 10 min 72°C
Number of cycles: 20
The semi nested PCR [PCR 1b for VL] and [PCR 2b for VH] was performed as
follows:
10x PCR buffer 5 µl
5x Q solution 10 µl
10mM dNTPs mix 1 µl
back primer (10 pmol/µl) 3 µl
forward primer (10 pmol/µl) 3 µl
Taq polymerase (5 U/µl) 0.5 µl
H2O 22.5 µl
PCR products from PCR 1a (for PCR 1b) or
PCR products from PCR 2a (for PCR 2b)
5 µl
Final volume 50 µl
PCR 2a/2b was performed using the following program:
Initial denaturation 30 sec 94°C
Denaturation 30 sec 94°C
Annealing 45 sec 50°C
Elongation 1 min 72°C
Final extension 10 min 72°C
Number of cycles: 25
III-4-2. Combination of degenerated primers used to amplify the Variable
Kappa Light chains (VLκ).
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PCR 1a: PCR 1b:
reaction Back primer For primer reaction Back primer For primer
1a huVκ1Back-Apa CκFor 1b huVκ1Back-Apa huJκXFor-Not*
2a huVκ2Back-Apa CκFor 2b huVκ2Back-Apa huJκXFor-Not*
3a huVκ3Back-Apa CκFor 3b huVκ3Back-Apa huJκXFor-Not*
4a huVκ4Back-Apa CκFor 4b huVκ4Back-Apa huJκXFor-Not*
5a huVκ5Back-Apa CκFor 5b huVκ5Back-Apa huJκXFor-Not*
6a huVκ6Back-Apa CκFor 6b huVκ6Back-Apa huJκXFor-Not*
*huJκXFor-Not: mix of huJκ1For-Not, huJκ2For-Not and huJκ3For-Not (10 pmol/µl for each
primer)
III-4-3. Combination of degenerated primers used to amplify the Variable
Lambda Light chains (VLλ).
PCR 1a: PCR 1b:
reaction Back primer For primer reaction Back primer For primer
7a huVλ1aBack-Apa huCλForX* 7b huVλ1aBack-Apa huVλXFor-Not*
8a huVλ1bBack-Apa huCλForX* 8b huVλ1bBack-Apa huVλXFor-Not*
9a huVλ1cBack-Apa huCλForX* 9b huVλ1cBack-Apa huVλXFor-Not*
10a huVλ2Back-Apa huCλForX* 10b huVλ2Back-Apa huVλXFor-Not*
11a huVλ3aBack-Apa huCλForX* 11b huVλ3aBack-Apa huVλXFor-Not*
12a huVλ3bBack-Apa huCλForX* 12b huVλ3bBack-Apa huVλXFor-Not*
13a huVλ4Back-Apa huCλForX* 13b huVλ4Back-Apa huVλXFor-Not*
14a huVλ5Back-Apa huCλForX* 14b huVλ5Back-Apa huVλXFor-Not*
15a huVλ6Back-Apa huCλForX* 15b huVλ6Back-Apa huVλXFor-Not*
16a huVλ7/8Back-Apa huCλForX* 16b huVλ7/8Back-Apa huVλXFor-Not*
17a huVλ9Back-Apa huCλForX* 17b huVλ9Back-Apa huVλXFor-Not*
*huCλForX: mix of huCλFor1 and huCλFor2 primers(10 pmol/µl for each primer)
*huVλXFor-Not: mix of huVλ1For-Not, huVλ2For-Not and huVλ3For-Not primers (10 pmol/µl
for each primer)
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III-4-4. Combination of degenerated primers used to amplify the Variable
Heavy chains (VH).
PCR 2a: PCR 2b:
reaction Back primer For primer reaction Back primer For primer
18a
huVH1/7Back-
Sfi
huIgGForX* 18b huVH1/7Back-Sfi huJHXFor-Xho*
19a huVH2Back-Sfi huIgGForX* 19b huVH2Back-Sfi huJHXFor-Xho*
20a huVH3Back-Sfi huIgGForX* 20b huVH3Back-Sfi huJHXFor-Xho*
21a huVH3bBack-Sfi huIgGForX* 21b huVH3bBack-Sfi huJHXFor-Xho*
22a huVH4Back-Sfi huIgGForX* 22b huVH4Back-Sfi huJHXFor-Xho*
23a huVH4bBack-Sfi huIgGForX* 23b huVH4bBack-Sfi huJHXFor-Xho*
24a huVH5Back-Sfi huIgGForX* 24b huVH5Back-Sfi huJHXFor-Xho*
25a huVH6Back-Sfi huIgGForX* 25b huVH6Back-Sfi huJHXFor-Xho*
*huIgGForX: mix of huIgGFor1 and huIgGFor2 primers (10 pmol/µl for each primer).
*huJHXFor-Xho: mix of huJH1-2, 4-5For-Xho and huJH3, 6For-Xho primers(10 pmol/µl for
each primer).
PCR fragments obtained after the semi-nested PCR (1b to 25b) were individually
separated on a 1% agarose gel and extracted using the Gel Extraction kit (Qiagen)
in a 43.5 µl H2O eluate and stored at -20°C until cloning.
III-5. Cloning of VLκ and VLλ PCR products into the pHEN3
phagemid to generate VLκ and VLλ bacterial sub-libraries.
III-5-1. Digestion of the VLκ and VLλ PCR products (reactions 1b to 17b
obtained from PCR 1b) and the phagemid pHEN3.
VL (κ and λ) PCR products
(reactions 1b to 17b)
43.5 µl pHEN3 phagemid
(5 µg)
2 µl
10x Buffer 4 (ApaL1). 5 µl 10x Buffer 4 (ApaL1). 3 µl
BSA (10 mg/ml). 0.5 µl BSA (10 mg/ml). 0.5 µl
ApaLI (10 U/µl) 1 µl ApaLI (10 U/µl) 1.5 µl
H2O 23 µl
Final volume 50 µl Final volume 30 µl
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The reaction was incubated overnight at 37°C. Digested DNA was purified using the
PCR Purification kit (Qiagen) and eluted in 43.5 µl H2O. To add a second restriction
site at 5´end, DNA was subjected to the second digestion reaction as following:
ApaL1-digested VL (κ and λ)
 PCR products
43.5 µl ApaL1-digested pHEN3 43.5 µl
10x Buffer 3 (Not1) 5 µl 10x Buffer 3 (Not1) 5 µl
BSA (10 mg/ml). 0.5 µl BSA (10 mg/ml). 0.5 µl
NotI (10 U/µl) 1 µl NotI (10 units) 1 µl
Final volume 50 µl Final volume 50 µl
The reaction tube was incubated for 6 h at 37°C and the double-digested DNA was
purified using the PCR Purification kit (Qiagen) and eluted in 43.5 µl H2O
III-5-2. Dephosphorylation of the pHEN3 vector.
The SAP (Shrimp Alkaline phosphatase) exonuclease enzyme removes the
5´phosphate groups of DNA. The treatment is performed to avoid the
recircularization of the vector during the ligation reaction and, thus, to optimize the
number of fragment-inserted vectors clones.
ApaL1-Not1-digested pHEN3 50 µl
10x SAP buffer 6 µl
SAP 2 µl
H2O 2 µl
Final volume 60 µl
The tube was incubated for 1 h at 37°C and the dephosphorylated double digested
pHEN3 vector was purified using the PCR purification kit.
ApaLI/NotI-digested inserts (VLκ and VLλ PCR products) and vector (pHEN3) were
run on a 1% agarose gel for quantitation.
III-5-3. Ligation.
Ligation was performed as follows:
ApaLI-NotI-digested and dephosphorylated pHEN3 (10 µg) X µl
ApaLI-NotI-digested inserts (2-4 µg) X µl
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10x T4 Ligase buffer 6 µl
T4 ligase (2 U/ µl) 2 µl
H2O
Final volume 60 µl
The reaction was incubated overnight at 16°C. Ligated products were concentrated
through ethanol-precipitation: 1/10 vol., 3 M NaOAc pH 5 and 2.5 vol. 100%
ethanol were added to the ligation reaction and the mixture was stored at –20°C for
4 h. At this time, the DNA was precipitated by centrifugation at 20 000 g for 30
min. The pellet was washed two times with 70% ethanol, air-dried and resuspended
in 10 µl dH2O.
III-5-4. Transformation of electrocompetent TG1 E.coli cells by
electroporation and plating of VLκ and VLλ sub-libraries.
To generate the VLκ and VLλ sub-libraries, TG1 E.coli cells were transformed with
the ligation products obtained above. Since the diversity of the sub-libraries is
dependent on the efficient introduction of DNA into bacteria, the electroporation
method, which is one of the most efficient transformation method, was used. This
technique is based on subjecting a mixture of bacteria and DNA to an intense
electric field which creates pores in the cell membrane promoting the entry of the
DNA into the bacteria. 2 µl of the concentrated ligation reaction were mixed with 40
µl electro-competent TG1 cells (Stratagene) into a chilled electroporation cuvette.
The mixture was electroporated using a Bio-Rad electroporator using the following
settings: 1700 V, 200 Ohms and 25 µF. The mixture was then transferred into 1 ml
LB medium and incubated for 1 h at 37°C while shaking. Next, 990 µl of this culture
was plated onto large plates (243 mm x 243 mm) containing LB agar/1%
glucose/100 µg/ml ampicillin and incubated o.n at 30°C. Large plates were used to
maximize the number of recovered clones, thus, increasing the diversity of the
library. Transformed bacteria were incubated at 30°C to ensure an homogeneous
growth of all clones and to avoid the overgrowth of some clones compared to
others. The presence of glucose ensures the repression of the Lac promoter which
drives the expression of the fusion protein from the phagemid, thus, preventing
growth dysregulation due to the expression of the fusion protein.
III-5-5. Estimation of the library size.
The size of each library was determined by serial dilutions. 10 µl of the
electroporated cells were mixed with 990 µl LB medium and serially diluted (10-1 to
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10-6). 100 µl of each dilution was plated onto LB agar plates/1% glucose/100 µg/ml
ampicillin and incubated o.n. at 30°C. The day after, clones were counted and the
size of each sub-library was estimated.
III-5-6. DNA preparation of VLκ and VLλ sub-libraries.
Colonies obtained on large plates were scraped in 5 ml LB medium and used to
inoculate 100ml LB medium/1% glucose/100 µg/ml ampicillin. Large scale DNA
(VLκ and VLλ phagemids) of each sub-library was prepared by using the Maxipreps
kit (Qiagen) according to the manufacture´s instructions and used for further steps.
III-6 Cloning of VH PCR products into VLκ-pHEN3 and VLλ-pHEN3
phagemids to generate the VLκ-VH and VLλ-VH final bacterial
libraries.
VH-PCR products (reactions 18b to 25b) and VL-phagemids (from III-5-6) were
digested with SfiI restriction enzyme, as described:
VLκ-pHEN3 phagemid
(from Maxipreps III-5-6)
5 µg VLλ-pHEN3 phagemid
(from Maxipreps III-5-6)
5 µg
10x Buffer 2 (SfiI) 5 µl 10x Buffer 2 (SfiI) 5 µl
BSA (10 mg/ml). 0.5 µl BSA (10 mg/ml). 0.5 µl
SfiI (20 U/µl) 1 µl SfiI (20 U/µl) 1 µl
Final volume 50 µl Final volume 50 µl
VH-PCR products
(reactions 18b to 25b)
43.5 µl
10x Buffer 2 (Sfi1) 5 µl
BSA (10 mg/ml). 0.5 µl
SfiI (20 U/µl) 1 µl
Final volume 50 µl
All reactions were incubated overnight at 50°C and digested DNA was purified using
the PCR Purification kit (Qiagen) and eluted in 43.5 µl H2O. The second digestion
reaction using the restriction enzyme XhoI was performed as below:
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SfiI-digested VH-PCR products 43.5 µl SfiI-digested VLκ-pHEN3 and
VLλ-pHEN3 phagemids
43.5 µl
10x Buffer 4 (XhoI) 5 µl 10x Buffer 4 (XhoI) 5 µl
BSA (10 mg/ml). 0.5 µl BSA (10 mg/ml). 0.5 µl
XhoI (10 U/µl) 1 µl XhoI (10 U/µl) 1 µl
Final volume 50 µl Final volume 50 µl
The reaction was incubated for 6 h at 37°C and double-digested DNA was purified
using the PCR Purification kit (Qiagen) and eluted in 43.5 µl H2O. The SfiI/XhoI-
digested VLκ-pHEN3 and VLλ-pHEN3 phagemids were dephosphorylated as
described in III-5-2. Both digested inserts and phagemids were run on a 1%
agarose gel electrophoresis for quantitation. Ligation was performed as follows:
SfiI/XhoI-digested VLκ-pHEN3 and VLλ-pHEN3 phagemids (10 µg) X µl
SfiI/XhoI-digested VH inserts (2-4 µg) X µl
10 x T4 Ligase buffer 6 µl
T4 ligase (2U/µl) 2 µl
H2O
Final volume 60 µl
The reaction was incubated overnight at 16°C. Ligation products were precipitated
and resuspended in 10 µl dH2O. The VLκ-VH and VLλ-VH final libraries were
constructed by transforming TG1 cells as described for the VLκ and VLλ sub-
libraries in section III-5-4.
III-7. Colony PCR.
The proportion of colonies (from the sub-libraries and the final libraries) having an
insert of the correct size was evaluated by PCR of single colonies using primers
specific (LMB3 and fdseq1) for the pHEN3 backbone (see Fig 15). Single clones
were picked up from agar plates and transferred directly into a the PCR reaction
mix. An initial denaturation step of 5 min at 94°C allows the burst of bacterial cells
and the release of the phagemid which can be then amplified by PCR.
colony PCR reaction mix:
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10x PCR buffer 2 µl
5x Q-solution 4 µl
10mM dNTPs mix 0.5 µl
LMB3 primer (10 pmol/µl) 2 µl
fdseq1 primer (10 pmol/µl) 2 µl
Taq polymerase (5 U/µl) 0.3 µl
H2O 9.2 µl
Final volume 20 µl
colony PCR program:
Initial denaturation 5 min 94°C
Denaturation 30 sec 94°C
Annealing 45 sec 50°C
Elongation 1 min 72°C
Final extension 10 min 72°C
Number of cycles: 35
The presence of the insert was checked by running the PCR products on a 1%
agarose electrophoresis gel.
III-8. Rescue of recombinant phages displaying scFV fragments
from the final bacterial libraries.
III-8-1. Preparation of a helper phage working stock.
Helper phage stock, used to promote the rescue of recombinant phages from
bacterial libraries, was prepared by propagation of an aliquot of the commercial
VCSM13 helper phage (Pharmacia). VCSM13 is a helper phage which contains a
slightly defective origin of replication. When the VCSM13 helper phage infects cells
carrying the phagemid pHEN3, its genome is normally processed to provide in trans
all proteins required to generate recombinant phages. However, due the mutation
in the helper phage genome ori, this genome is less efficiently encapsidated than
the phagemid into virion progeny, resulting in the production of recombinant
phages which contain preferentially the phagemid. Nevertheless, this helper phage
can be amplified to generate a working stock. In the absence of the phagemid, the
helper phage genome ori is well enough encapsidated to produce sufficient new
helper phages.
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VCSM13 helper phages (Pharmacia) were serially diluted in LB medium and each
dilution (100 µl) was mixed with 100 µl log-phase TG1 and 3 ml of top agar. The
mixture was plated onto LB-agar plates and incubated overnight at 37°C. A log-
phase culture is used to ensure the presence of F-pili on the surface of the bacteria
and thus, to ensure the ability of those bacteria to be infected by helper phages.
The semi-solid top agar overlay prevents the diffusion of bacteriophages to the
whole bacteria lawn, resulting in the generation of plaques. As the M13 phage is a
non lytic phage, real lysis plaques cannot be observed. Nevertheless, phage-
infected cells exhibit a reduced growth rate and therefore, single “plaques” can be
visualized. A single “plaque” from the lawn corresponding to an identical helper
phage population was picked from the agar plate and transferred into 3 ml LB
medium containing 100 µl log-phase E. coli TG1 cells. The mixture was shaken for 3
h allowing the infection process to take place. The grown plaque was then large-
scale amplified by inoculating 500 ml LB medium containing 25 µg/ml kanamycin.
The addition of antibiotics ensures the selection of bacteria carrying the VCSM13
genome which contains a kanamycin resistance gene. After overnight incubation,
the culture was centrifuged and the supernatant which contains helper phages was
filtered through a 0.45 µm filter, aliquoted and stored at -20°C. Those working
stocks aliquots were titered as follows: 10 µl of working stock was 10 fold-serially
diluted in 990 µl LB medium and 100 µl of each dilution was mixed with 100 µl log-
phase TG1 and 3 ml of top agar. The mixture was plated onto LB-agar plates and
incubated overnight at 37°C. Plaques were counted on each plate and used to
determine the helper phage working stock titer. Stocks were stored at –70°C until
subsequent use.
III-8-2. Rescue of recombinant phages from constructed scFv libraries.
100 ml LB medium/1% Glucose/ 100 µg/ml ampicillin was inoculated with TG1 cells
from each library to get an initial OD600 = 0.1. The culture was incubated at 37°C
while shaking until OD600=0.5 was reached (log-phase of TG1). At this time, around
1012 VCSM13 helper phages (from stock produced in section III-8-1) were added to
the culture and incubated for 1 h standing at 37°C and for 1 h shaking at 37°C to
allow the infection process to take place. Bacteria were then pelleted by
centrifugation for 10 min at 4000 g and the pellet was resuspended with 400 ml LB
medium with 100 µg/ml ampicillin (to ensure the presence of the phagemid pHEN3
which encodes for the scFv-g3p fusion protein), 25 µg/ml kanamycin (to ensure the
presence of the VCSM13 helper phage genome) and without glucose (to avoid the
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repression of the Lac promoter and, thus, to promote the expression of the scFv-
g3p fusion proteins). The culture was then incubated overnight at 30°C to allow the
production of recombinant phages and their release into the supernatant. After
overnight incubation, the culture was spun at 4000 g for 10 min and the
supernatant was transferred into a new vessel. 1/8 volume (50ml) of a PEG6000-2.5
M NaCl solution was added to precipitate phages from the supernatant. The mixture
was incubated 2 h at 4°C and centrifuged at 4000 g to pellet phages. The phage
pellet was resuspended with 1 ml PBS and centrifuged to pellet down all remaining
bacterial debris. The supernatant was harvested, dispatched into 100µl aliquots and
stored at -20°C. Phages obtained from each library were titered as following: 10 µl
of the phage preparation was 10 fold serially-diluted into 990 µl LB medium and
100 µl of each dilution was incubated with 100 µl log-phase TG1 cells for 1 h
standing and 1 h shaking at 37°C (to promote the infection process as described
previously). 100 µl of each dilution was then spread onto LB/1% glucose/100 µg/ml
ampicillin plates and incubated overnight at 37°C. The number of colonies from
each plate was counted and the phage titre was calculated for each library.
III-9. Preparation and purification of YFV 17D-204-WHO particles.
III-9-1. Preparation of a YFV 17D-204-WHO master stock.
A YFV 17D-204-WHO master stock which was used for all subsequent experiments
was obtained by infecting subconfluent Vero cells in a T75 flask with a commercial
seed lot of the YFV 17D-204-WHO vaccine from the Robert Koch Institut, Berlin,
Germany. The vaccine preparation was diluted in 5 ml DMEM without FCS and
spread on Vero cells for 1 h at 37°C to allow virus adsorption. At this time, the
inoculum was removed and replaced with 20 ml DMEM supplemented with 4% FCS,
L-Glutamine and Penicillin-Streptomycin. 4 days post infection, the supernatant was
harvested and centrifuged at 5000 g for 20 min at 4°C. This master stock was
titered by plaque assay and 500 µl aliquots of the YFV 17D-204-WHO were stored
at –70°C until subsequent use.
III-9-2. Titer determination by plaque assay.
The titer of the YFV 17D-204-WHO stock was determined by plaque assay. 100 µl
of the stock was mixed with 900 µl DMEM without FCS. The mixture was then 10
fold serially-diluted in DMEM without FCS (10-1 to 10-7) and each dilution was used
to infect Vero cells as described above in a 6 well plate format. After 1 h at 37°C,
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the mixture was removed, cells were washed once with PBS and overlaid with a
mix[1:1] of 2% [v/v] low melting point (LMP) agarose and 2X DMEM supplemented
with 4% FCS, 2 mM glutamine and antibiotics. Plates were kept at RT for 10 min
until the agarose contained in the overlay had solidified. Plates were then incubated
at 37°C for 4 days. This method using a semi-solid overlay prevents virus diffusion
from one infected cell to the whole culture. As a result, small round plaques form in
the cell monolayer as the virus replicates and spreads from cell to cell. For the
detection of these plaques, cells were overlaid 4 days post infection with 0.005% of
neutral red which is vital dye diluted in 2% LMP agarose. One day after staining,
plaques were counted and the titer of the virus stock determined.
III-9-3. Purification of YFV 17D-204-WHO particles.
A T75 flask of 90% confluent Vero cells was infected with YF 17D-204 WHO viruses
from the working stock at a multiplicity of infection (moi) =0.1 for 5 days at 37°C.
The moi corresponds to the ratio [virus PFU / number of cells]. The supernatant
was then harvested, purified by centrifugation for 10 min at 500 g and re-used to
infect six T225 flasks of 90% confluent Vero cells (dilution 1:1000) for 5 days. YFV
17D-204-WHO particles contained in supernatants were purified by centrifugation
at 70 000 g in a Beckmann SW28 rotor for 2 h at 4°C through a 30% glycerol
cushion diluted in PBS (v/v). Pelleted glycerol-purified virions were resuspended in
TNE buffer, aliquoted and stored at-70°C. Proteins were quantified using the BCA
assay kit (Pierce) according to the manufacture’s instructions.
III-9-4. Determination of purified YFV 17D-204-WHO particles antigenicity
in ELISA.
The antigenicity of purified YFV 17D-204-WHO virions (from III-9-3) was tested in
ELISA using various sera specific for the YFV. Microtiter plates were coated o.n. at
4°C with 2.5 µg per well (in a final volume of 100 µl) either with YFV 17D-204 WHO
virions or with BSA. After washing with PBS and blocking with 200 µl 2% MPBS per
well, polyclonal sera, from YFV 17D-204-WHO-infected monkeys diluted 1:300 or
from a human acute confirmed YF case (S-993) diluted 1:100, were added to each
well for 2 h at RT. Anti YFV-E protein monoclonal antibodies 6538 and 6330 diluted
1:500 were also used. ELISA plates were then washed 3 times with PBS/ 0.1%
Tween-20 and 3 times with PBS. Detection of antibody binding to YFV 17D-204-
WHO particles was performed by adding for 1 h at RT either HRP-conjugated rabbit
anti human IgG, HRP-conjugated rabbit anti human IgM or HRP-conjugated rabbit
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anti mouse IgG, all diluted 1:1000. After 3 washes with PBS/ 0.1% Tween-20 and 3
washes with PBS, the assay was developed by adding 100µl of ABTS substrate in
each well. The colorimetric reaction was stopped by adding 100µl of 0.1% SDS and
the absorbance was read at 405 nm on a standard ELISA microtitre plate reader.
III-10. Biopanning.
The biopanning procedure was mainly performed as described in the laboratory
manual “Antibody engineering” (Kontermann and Duebel, 2001)
.
III-10-1. Selection step.
The two phage libraries were panned against glycerol-purified YFV 17D-204-WHO
particles. Maxisorp immunotubes were coated o.n. at 4°C with purified YFV 17D-
204-WHO virions at a concentration of 25 µg/ml in 5 ml 0.05 M carbonate buffer pH
9.6. The use of this buffer promotes the binding of virions on the plastic surface
through adsorption. After washing with PBS and blocking with 2% skimmed milk in
PBS (2% MPBS) for 2 h at RT, 1015 phage transforming units (t.u) from each library
(from III-8-2) were diluted in 5 ml (2% MPBS) and incubated for 1 h at RT. The
phage solution was then removed and the immunotube was washed 5 times with
PBS/ 0.1% Tween-20 and 5 times with PBS (by pouring in and out). Finally, bound
phages were eluted by incubating with 1 ml of a 100 mM triethylamine solution for
8 min (the acidic pH 2.2 of this buffer promotes the release of phage particles from
the antigen without affecting their infectivity) and immediately neutralized with 500
µl of 1 M Tris-HCl pH 7.5. One ml of those eluted phages was incubated with 10 ml
of log-phase TG1 for 1 h standing at 37°C and 1 h shaking at 37°C. Bacteria were
pelleted and resuspended with 1 ml LB medium. To determine the titer of eluted
phages, 10 µl of this preparation was 10 fold serially-diluted in LB medium and 100
µl of each dilution was spread onto LB agar/ 1% glucose/100 µg/ml ampicillin
plates and incubated overnight at 30°C. The rest of the bacteria infected with
eluted phages (990 µl) was spread on LB-agar 1% glucose/ 100 µg/ml ampicillin
large plates. Those infected bacteria represented the phage population which have
been “positively selected” against the YF 17D-204-WHO antigen.
III-10-2. Rescue of phages isolated from the first round of selection.
To amplify the phage population obtained after the first round of selection, bacteria
which have grown on large plates were scraped in 10 ml LB medium and added to
50 ml LB medium/ 1% glucose/ 100 µg/ml ampicillin to get a starting OD600 = 0.1.
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The culture was then incubated at 37°C until OD600 = 0.4-0.5. 10
12 t.u of helper
phages were added and recombinant phages were rescued, purified and titered as
described in section III-8-2. The new phage population was used to perform the
next round of selection against the YF 17D-204-WHO antigen as described in III-
10-1. In total, four successive rounds of selection were performed using different
stringency of washes (5x for the first round and 10x for the second, the third and
the fourth round).
III-10-3. Polyclonal phage ELISA.
Microtiter plates were coated o.n. at 4°C with 2.5 µg per well (in a final volume of
100 µl) either with YFV 17D-204 WHO virions or with BSA. After washing with PBS
and blocking with 200 µl 2% MPBS per well, 1013 t.u. phages of the polyclonal
phage solution rescued from each round of selection were added for 2 h at RT.
ELISA plates were then washed 3 times with PBS/0.1% Tween-20 and 3 times with
PBS. Polyclonal phages which bound to YFV 17D-204-WHO were detected by adding
100 µl per well of horseradish peroxidase-conjugated mouse anti-M13 antibody
diluted 1:2000. The assay was developed by adding 100µl of ABTS substrate. The
colorimetric reaction was stopped by adding 100µl of 0.1% SDS and the
absorbance was read at 405 nm on a standard ELISA microtitre plate reader.
III-10-4. Monoclonal phage ELISA.
Single clones from the third and the fourth round were picked up from the agar
plates, transferred into 500 µl LB/ 1% glucose/ 100µg/ml ampicillin amd grown
overnight. 5 µl of the overnight culture was used to inoculate 300µl LB/ 1% glucose
/100 µg/ml ampicillin and incubated for 2 h at 37°C until OD600 was approx. = 0.5.
At this time, 20 µl helper phages (1013 tu) were added in each culture and the
infection process was done as described above in section III-10-1. Bacteria were
pelleted, resuspended into 500 µl LB/ 100 µg/ml ampicillin/ 25µg/ml kanamycin/
without glucose and incubated overnight at 30°C. The protocol used to perform
monoclonal phage ELISA was identical to the one used for polyclonal phage ELISA
except that 100 µl of cleared bacterial supernatant-containing monoclonal phages
were used instead of 100 µl of polyclonal phages.
III-10-5. BstNI fingerprintings.
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To check scFv diversity, BstNI fingerprintings were performed. scFV fragments from
monoclonal phages which were found to be positive in ELISA were PCR-amplified as
described in section III-7. 10 µl of the PCR reaction was digested by BstN1
endonuclease as follows:
PCR-amplified scFv 10 µl
10X Buffer 3 3 µl
BSA (10 mg/ml). 0.3 µl
BstNI (20 U/µl) 1 µl
H2O 15.7 µl
Final volume 30 µl
The reaction was incubated at 60°C for 4 h. BstN1 patterns from each clone were
visualized on a 2 % agarose gel.
III-11. Expression and purification of scFvs in E.coli TG1 cells.
III-11-1. Cloning in the prokaryotic expression plasmid pAB1.
For soluble expression, scFv fragments were sub-cloned into the pAB1 plasmid. This
vector introduces a His-tag at the C-terminus of the scFv and allows inducible scFv
expression in the periplasmic space of E.coli cells. Phagemids of interest
(representing each BstNI fingerprintings pattern observed above) were extracted
from E.coli cells by the alkaline lysis procedure using the Minipreps kit (Qiagen).
Each purified phagemid was digested by SfiI and NotI endonucleases as previously
described to release the whole scFv fragment (VH chain-linker-VL chain). The
digestion reaction was run on a 1% agarose gel and the band corresponding to scFv
nucleotide sequence (approx. 700bp) was excised. DNA was extracted from
agarose using the Gel Extraction kit (Qiagen) and ligated into SfiI/NotI-digested
pAB1 plasmid. Ligation products were used to transform bacteria and positive
clones (i.e. containing a pAB1-scFv recombinant plasmid) were identified by
Miniprep screening.
III-11-2. Expression of scFvs in E.coli cells.
Two liters of LB medium containing 0.1% glucose and 100 µg/ml ampicillin were
inoculated with 15 ml of an o.n. culture of the positive clones previously identified
and grown at 37°C until OD=0.9. At this time, 0.27 g IPTG was added to the
culture to a final concentration of 1mM IPTG. The culture was grown at 25°C for 4
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hours to allow the induction of the Lac Z promoter by IPTG, the expression of scFvs
and their accumulation in the periplasmic space of the bacteria. The culture was
then centrifuged at 5000 g for 10 min at 4°C. The supernatant was removed and
the bacterial pellet was resuspended in 120 ml of hypertonic solution (20%
sucrose) to allow the disruption of the outer bacterial membrane, resulting in the
release of scFvs from the periplasmic space. To ensure the complete cell membrane
disruption, 5 mg/ml of lyzozyme was also added and the mixture was left on ice for
30 min. At this time, 1 M MgSO4 was added to stabilize the spheroplasts (bacteria
without their outer membrane) and the mixture was centrifuged at 15 000 g for 10
min at 4°C. The supernatant containing soluble scFvs was harvested and dialyzed
overnight against 2 liters of PBS/ 20 mM imidazole. This step allows the reduction
of sucrose concentration and the enrichment with imidazole, which is used for
further purification of scFv.
III-11-3. ScFv purification by Immobilized  Metal ion Affinity
Chromatography (IMAC).
The dialyzed scFv solution was centrifuged at 20 000 g for 10 min at 4°C and the
supernatant was incubated with 3 ml Ni-NTA solution for 1 h rotating at 4°C. During
this step, scFvs with a fused Histidine tag at the C terminus will bind to the Ni2+-
ions. The mixture was then loaded onto a filter column. Contaminants and other
proteins pass through the column, whereas Ni-NTA-scFvs complexes are retained.
The column was then washed with 60 ml washing buffer (containing 35 mM
imidazole) to further remove all contaminants which did not interact specifically
with the Ni-NTA matrix. Finally, scFvs were eluted by adding 7 ml of elution buffer
(containing 150 mM imidazole). Fractions of 1 ml each were collected in different
tubes.
III-11-4. Determination of scFvs by Coomassie staining and Western Blot
analysis.
To determine the fractions containing the highest amounts of scFvs and to check
the purity, 15 µl of each fraction were run on a 12 % SDS PAGE. The scFvs were
detected by Western Blot and their purity was evaluated by Coomassie staining.
III-11-4-1. SDS-Polyacrylamid gel electrophoresis (SDS-PAGE).
Protein samples were separated on a 12% denaturing polyacrylamid gel. 10µl of
protein sample were mixed with 2.5µl of 4x SDS PAGE sample buffer and denatured
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for 5 min at 95°C. The polyacrylamid gel was cast using a 6% stacking gel and a
12% resolving gel. The sample was loaded on this polyacrylamid gel and run until
separation was sufficient. 5µl of a protein marker was run in parallel.
III-11-4-2. Coomassie staining.
After running, the SDS-PAGE gel was soaked in a G250 Coomassie solution,
incubated for 30 min and washed extensively with the Coomassie destaining
solution.
III-11-4-3. Western blot (WB) analysis.
ScFv proteins were selectively detected by Western Blot using an antibody specific
for the his-tag located a the C-terminus. To this aim, proteins were run on a 12%
SDS-PAGE and transferred onto a nitrocellulose membrane by electroblotting as
follows:
Anode
3 Whatman paper soaked in Anode buffer I
3 Whatman paper soaked in Anode buffer II
Nitrocellulose membrane soaked in dH2O
Gel
6 Whatman paper soaked in Cathode buffer
Cathode
Transfer conditions: 43 mA per membrane (9 cm x 6 cm) for 1h
After the transfer, the membrane was blocked with 5% MPBS for 1 h at RT. The
first antibody (anti His-tag mouse antibody) diluted 1:100 in 5% MPBS was added
to the membrane for 1h at RT. Unbound antibodies were removed by washing 3
times (10 min each wash) the membrane with PBS/ 0.1% Tween. HRP-conjugated
goat anti mouse antibody was diluted 1:2000 in 5% MPBS and incubated with the
membrane for 1h at RT. At this time, the membrane was washed again 3 times (10
min each wash) with PBS/ 0.1% Tween. The Super Signal Kit (Pierce) was used as
a substrate for the peroxidase. After a 5 min incubation time with the substrate, the
membrane was exposed to a film (Amersham Pharmacia) allowing the detection of
the scFvs.
III-11-5. scFv ELISA.
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The protocol used to perform scFv ELISA was identical to that used for polyclonal
phage ELISA except that 2 µg of scFv were used instead of 100 µl of polyclonal
phage solution. Detection of scFv binding to YFV 17D-204-WHO particles was
performed using anti His-tag mouse antibody diluted 1:100 for 1 h at RT. After 3
washes with PBS/0.1% Tween-20 and and 3 washes with PBS, HRP-conjugated
goat anti mouse antibody diluted 1:2000 was added. 100 µl/well of ABTS was
added as a substrate for the peroxidase and the absorbance was measured at 405
nm using a ELISA spectrophotometer.
III-12. Dot Blot analysis.
10 µl of 17D-204-WHO antigen (from section III-9-3) were mixed with 10 µl of
each detergent-containing solution and incubated for 20 min at RT. At this time, a
drop of this preparation was allowed to adsorb on a nitrocellulose membrane by air-
drying. The membrane was blocked by adding a 5% MPBS for 1 h at RT. 100 µl of
scFv were then incubated with the blotted membrane for 2 h at RT. After washes
with PBS/0.1 % Tween, the anti-His-tag mouse antibody diluted 1:100 was added
and incubated at RT for 1h, followed by HRP-conjugated anti-mouse goat antibody
diluted 1:2000. Binding of scFv to YFV was visualized by incubation with
RecBlot/Immunoblot substrate.
III-13. Radioimmunoprecipitation assay (RIPA).
III-13-1. Production of radiolabeled soluble viral proteins from radiolabeled
YF 17D-204-WHO virions.
A 90% confluent T75 flask with Vero cells was infected with YFV 17D-204-WHO at
moi=1. 24 h post infection, the culture medium was removed and replaced with
cysteine and methionine-free DMEM supplemented with 2% FCS, 2 mM glutamine
and antibiotics for 1 h at 37°C. At that time, 1 mCi of [35S] methionine and [35S]
cysteine was added. After 48 h, the culture supernatant was harvested and
radiolabeled virions were purified through a 30 % glycerol cushion as described
above (III-9-3). Pelleted virions were resuspended in TNE buffer containing 0,5 %
n-octyl-β-D-glucopyranoside with a protease inhibitor cocktail and sonicated 3 times
for 10 sec at 4°C. The lysed radiolabeled virion preparation was centrifuged at 20
000 g for 1 h at 4°C and the supernatant was used for immunoprecipitation.
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III-13-2. RIPA.
150 µl of supernatant containing soluble radiolabeled YF viral proteins (from III-13-
1) were incubated with 1.5 µg of scFv for 4 h at 4°C. Antigen-scFv complexes were
immunoprecipitated by addition of 1 µg anti His-tag mouse antibody and 20 µl
protein G-coupled agarose beads overnight, rotating at 4°C. As positive control, the
radiolabeled viral protein mixture was incubated with 1 µg of YFV-E specific mAbs
6538 or 6330 and 20 µl protein G-coupled agarose beads. As negative controls,
soluble radiolabeled YF viral proteins were incubated either with 1.5 µg of irrelevant
scFv, 1 µg of anti His-tag mouse antibody and 20 µl protein G-coupled agarose
beads, or with 1 µg anti His-tag mouse antibody and 20 µl protein G-coupled
agarose beads only. The agarose beads were pelleted and washed 3 times with TNE
buffer containing 0.5 % n-octyl-β-D-glucopyranoside with the protease inhibitor
cocktail and once with Tris-HCl buffer pH 7.5. Samples were resuspended in 15 µl
of Laemmli buffer, boiled 5 min, centrifuged 5 min and separated on a 12% SDS-
PAGE gel as described above. The gel was fixed in 20 % methanol-10% acetic acid
solution, dried and exposed to X-ray film for the detection of YFV radiolabeled
proteins which were immunoprecipitated by scFvs.
III-14. pH sensitivity experiments.
The ability of scFvs to bind their epitopes upon low pH treatment was performed as
follows. 2.5 µg (10µl) of purified  YFV 17D-204-WHO virions were coated o.n. at
4°C in an ELISA plate as described previously. pH treatment of the YFV particles
was performed by adding either 100µl of a pH 5 buffer (0.05 M MES, 0.1 M NaCl) or
100 µl of a pH 8 buffer (TNE buffer) for 1 h at 37°C. At this time, the preparation
was back-neutralized by adding 10 µl of pH 8 buffer (1 M Tris-HCl, pH 8). Ability of
mAbs or scFvs to bind YFV antigen was performed by ELISA as described in section
III-11-5.
III-15. Competition ELISA using biotinylated antibodies.
III-15-1. Biotinylation.
ScFv-7A were biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation Kit
(Pierce). 10 µg of purified scFv-7A were mixed with Sulfo-NHS-LC-Biotin and
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incubated for 2 h on ice to allow the coupling of N-terminal group of scFvs with
NHS-biotin to obtain biotinylated scFvs. Removal of excess of biotin and the
purification of biotinylated scFvs were performed by dialyzing the samples o.n.
against PBS.
III-15-2. Competition ELISA.
2 µg of biotinylated scFv-7A were mixed with increasing amounts of non-
biotinylated competitor, either scFvs-5A, R3(27), 1A, 2A, R3(9) or mAbs 6538,
6330. The mixture was then added to a microtiter plate coated with YFV-17D-204
WHO virions as described in section III-9-4 and incubated for 1 h at RT. The plate
was washed 3 times with PBS/ 0,1 %Tween and 3 times with PBS. Bound
biotinylated scFv-7A were detected by using HRP-conjugated streptavidin diluted
1:10 000. Competition was expressed as the percentage of binding after incubation
with competitors compared to biotinylated scFv-7A alone.
III-16. Plaque reduction neutralization test (PRNT).
The ability of each scFv to block YFV infection was tested by a plaque reduction
neutralization assay (PRNT) using PS cells (porcine kidney) or Vero cells (African
Green Monkey kidney). 100 PFU of YFV 17D-204-WHO from the virus stock diluted
in DMEM without FCS, supplemented with 2 mM glutamine and antibiotics were
incubated for 1 h at 37°C with various amounts of each scFv to obtain final
concentrations ranging from 0.07 µg/ml to 10 µg/ml scFv. As a control, 100 PFU
were diluted and incubated for 1h at 37°C without scFv. The virus-scFv mixture was
spread on 90 % confluent PS cells or Vero cells in a 6 well plate format to allow
adsorption. After 1 h at 37°C, the mixture was removed, cells were washed once
with PBS and overlaid with 2% LMP Agarose-2X DMEM [1:1] supplemented with 4%
FCS, 2 mM glutamine and antibiotics. Plates were incubated at 37°C for 4 days. For
plaque detection, cells were overlaid with 0.005% neutral red dye. Plaques were
counted and the percentage of neutralization was expressed as: 100 – [(number of
plaques virus + scFv / number of plaques virus alone) x 100].
III-17. Generation of escape mutants.
To map the neutralizing epitopes on the envelope E protein, scFv-7A neutralization-
resistant virus variants were generated. For this purpose, the YFV-17D-204-WHO
strain was passaged three times in Vero cells in the presence of sub-neutralizing
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concentrations of scFv-7A. After the third passage, escape mutants were plaque-
purified and tested in PRNT. Practically, 100 PFU of YFV 17D-204-WHO were
incubated for 1 h at 37°C with 95% of the scFv-7A concentration which had been
shown to completely neutralize the inoculum (7µg/ml, see results). The mixture
was inoculated on Vero cells for 1 h at 37°C in a 6 well plate format. The inoculum
was removed and replaced with fresh medium supplemented with scFv-7A
(7µg/ml). Three days post-infection, 50 µl of the supernatant were incubated with
1ml DMEM /scFv-7A (7 µg/ml) for 1 h at 37°C and inoculated on cells for 1 h at
37°C. After removing the inoculum, fresh medium containing scFv-7A (7 µg/ml)
was added. This selection procedure was repeated twice. After the third round of
selection, twenty single clones were picked up from the plate, propagated, plaque-
titered and tested in PRNT with various concentrations of scFv-7A as described in
section III-16.
III-18. Microneutralization assay.
To test the ability of sera from wild-type YFV-infected patients or from YFV 17D-
204-WHO-vaccinated donors to neutralize escape variants, microneutralization
assays were performed.
III-18-1. Determination of the 50% Tissue Culture Infectious Dose (TCID50).
Each virus was 10-fold serially diluted in DMEM without FCS and 100 µl of each
dilution was added to 2.5 x 104 Vero cells in a 96 well plate format and incubated at
37°C for 1 h. Each dilution was tested in five replicates. The inoculum was then
removed and cells were washed 3 times with PBS. 100 µl of DMEM supplemented
with 4% FCS was added to each well and the plates were incubated at 37°C. Six
days post infection, the cytopathic effect (CPE) was observed in each well and the
TCID50 for each virus was calculated according to the Reed-Muench formula:
TCID50 = 10 
log total dilution above 50% - (I x log h).
I (interpolated value of the 50% endpoint) = (% of wells infected at dilution above
50% - 50%)/(% of wells infected at dilution above 50% - % of wells infected at
dilution below 50%).
h = dilution factor.
III-18-2. Microneutralization assay.
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Sera were inactivated for 30 min at 56°C and serially diluted in DMEM without FCS
on a log2 scale. 25 µl of each dilution were mixed with 25 µl of virus corresponding
to 100 TCID50 and the mixture was incubated at 37° C for 1h. The mixture was
then spread on 2.5x104 Vero cells and incubated for 1h at 37°C. Cells were then
washed 3 times with PBS, 100 µl of fresh medium was added and the CPE was
observed in each well six days post infection. Each dilution was tested in five
replicates. The 50% end-point dilution of each serum, corresponding to the dilution
at which 50% of wells were completely protected from infection, was determined
according to the Reed-Muench formula as described above.
III-19. Sequencing analysis.
100 ng of the DNA (PCR products) to be sequenced were mixed together with 10
pmol of the primer and 6 µl of dH2O. The sequencing analysis was performed
through technical assistance using a MegaBACE sequencer (Amersham Pharmacia).
III-19-1. Sequencing analysis of scFvs displayed by YFV-17D-204-WHO
specific monoclonal phages
Phagemids from bacterial clones, from which YF-17D-204-WHO specific monoclonal
phages were rescued, were PCR amplified using LMB3 and fdseq1 primers. Those
primers are specific for the pHEN3 backbone and are located upstream and
downstream of the cloned scFv as shown in Fig 15. PCR products were directly
sequenced in both directions using either the LMB3 or fdseq1 primers.
The closest germline gene for VL and VH chains were identified by a Blast search of
the antibody-database IgBlast (http://www.ncbi.nlm.nih.gov/igblast/).
III-19-2. Sequencing analysis of prM and E proteins of all YFV strains (17D-
204 WHO, wild-type strains and escape mutants).
Viral RNA of the different viruses was isolated from cell culture supernatants using
the QIAamp viral RNA mini kit (QIAGEN). The E protein of the neutralization escape
mutants was amplified by RT/PCR and sequenced as described above. RT-PCR and
sequencing of the M protein were performed using a prM forward primer and an M
reverse primer. Wildtype YFV strains were first genotyped by amplifying a 670
nucleotide fragment within the prM-E region. The rest of the E protein was
sequenced using two sets of primers that generate two overlapping fragments (see
section II-11-3 in Material). Primers were designed by aligning wild-type YFV
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sequences accessible in the GenBank and designated EnvF1, EnvF2, EnvF3, EnvR1,
EnvR2, NS1R1 and NS1R2. Due to the sequence variability of the envelope protein
gene, the East/Central African strains were amplified using primer combinations
EnvF2/EnvR1 and EnvF3/NS1R2, and the West African strains using EnvF1/EnvR2
and EnvF3/NS1R1.
III-20. Molecular Modelling.
The sequence of the YFV-E protein and the molecular location of substitutions were
modeled on the 3D structure of the Dengue virus type 2 envelope glycoprotein
(SWIS-prot PDB code:1K4R) using the RasMol software
(www.umass.edu/microbio/rasmol).
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IV-1. Generation of two phage libraries displaying recombinant
antibody fragments (scFvs) from two recovered yellow fever
patients.
IV-1-1. Amplification of the Variable Kappa light chains (VLκ), the Variable
Lambda light chains (VLλ) and the Variable Heavy chains (VH) genes by
PCR.
The light chain variable domains (kappa locus and lambda locus) of the whole
antibody repertoire of each patient (YF2 and YF3) were PCR-amplified from total
RNA extracted from circulating lymphocytes using combinations of degenerated
primers (see Materiel and Methods) by a semi-nested PCR. As seen in Fig. 17, all
primer combinations were able to amplify VLλ and VLκ domains (350 bp). The
amplification of heavy chain variable domains (VH) was performed with the same
method using VH-specific primers. All combinations amplified a 400 bp fragment
corresponding to VH-segments. Some differences in amplification efficiency are
observed due to the varying of some degenerated primers to anneal to the
template. This underlines the great variability especially of the VH genes.(Fig 17,
PCR reactions 11b, 13b, 18b, 19b, 24b).
Fig 17. PCR amplification of genes encoding for variable domains of light chains (Kappa and
Lambda) and heavy chains.
400bp
400bp
300bp
300bp
VL Kappa genes 
amplification
VL Lambda genes 
amplification
VH genes 
amplification
1b 2b 3b 4b 5b 6b 7b 8b 9b 10b 11b 12b 13b 14b 15b 16b 17b
18b 19b 20b 21b 22b 23b 24b 25b
PCR reaction:
PCR reaction:
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IV-1-2. Construction of bacterial scFv libraries and rescue of recombinant
phages displaying scFvs on their surface.
IV-1-2-1. Construction of bacterial VLκ-pHEN3 and VLλ-pHEN3 sub-libraries.
The size of each sub-library was determined by serial dilutions and found to range
between 4.106 and 3.107 individual clones. The presence of the insert was found in
more than 85% of tested clones.
VLκ sublibrary-
YF2
VLλ sublibrary-
YF2
VLκ sublibrary-YF3
VLλ sublibrary-
YF3
Size 3.107 4.106 4.106 4.106
% insert 90% 90% 85% 92%
IV-1-2-2. Construction of bacterial VLκ-VH-pHEN3 and VLλ-VH-pHEN3 final
libraries.
The size of each final library was found to range between 2.106 and 107 individual
clones. PCR screening identified the presence of an entire scFv (VH-VL) in more
than 80 % of total clones.
VLκ-VH-pHEN3
library-YF2
VLλ-VH-pHEN3
library-YF2
VLκ-VH-pHEN3
library-YF3
VLλ-VH-pHEN3
library-YF3
Size 5.106  6.106 2.106 107
% insert 80% 85% 90% 80%
IV-1-2-3. Rescue of recombinant phages from YF2 and YF3 libraries.
Each final bacterial library (VLκ-VH-pHEN3 and VLλ-VH-pHEN3 libraries from YF2
and YF3 donors) was infected with helper phages to produce recombinant phages
displaying scFvs on their surface. The phage titer was determined for each final
library:
VLκ-VH-pHEN3
library-YF2
VLλ-VH-pHEN3
library-YF2
VLκ-VH-pHEN3
library-YF3
VLλ-VH-
pHEN3 library-
YF3
Phage Titer 1016 t.u/ml  1015 t.u./ml 1013 t.u./ml 1013 t.u./ml
All four libraries were then used for biopanning against purified YFV 17D-204-WHO
virions.
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IV-2. Isolation of monoclonal phages with a specific affinity for YFV
17D-204-WHO particles.
IV-2-1. Purification of YFV 17D-204-WHO particles.
To isolate recombinant phages displaying scFvs specific for YFV, large scale-
produced YFV-17D-204-WHO virions were purified through a 30% glycerol cushion.
To test the quality of the antigen to be used in further selection steps, purified YFV
virions were coated on a 96 well ELISA plate at different concentrations. For
detection, a polyclonal serum from YFV 17D-infected monkeys, two mouse
monoclonal antibodies specific of the YFV-E protein and one human serum isolated
from an acute confirmed YF case were employed. As a negative control, a
polyclonal from a normal donor (i.e. whithout YFV antibodies) was used. As seen in
Fig. 18, all sera specific for YFV react with the purified YFV-17D-204-WHO virions,
whereas the irrelevant serum does not. Thus, this result showed that the purified
YFV 17D-204-WHO particle preparation was a suitable antigen which could be
further used for the biopanning.
Fig 18. Antigenicity of purified YFV-17D-204-WHO particles in ELISA. Anti YF (monkey):
polyclonal serum obtained from YFV 17D-204-WHO-infected monkeys. mAb 6358 & 6330: anti YFV E
protein mouse monoclonal antibodies. S-993: serum isolated from a human acute YF case. irr serum:
naïve human serum. IgG:immunoglobulines G, IgM: immunoglobulines G.
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IV-2-2. Enrichment of specific phage binders to the YFV antigen through
biopanning.
In order to isolate recombinant phages displaying scFv with a specific affinity for
YFV, selection steps were performed as follows. Recombinant phages rescued from
all constructed libraries were pooled and panned against purified YFV 17D-204-
WHO particles. This antigen was used because it can be handled under biosafety
level 2 conditions without any chemical or physical inactivation. Thus, sensitive
conformational epitopes are protected from denaturation. Four rounds of selection
were performed successively, in order to enrich phages specific for the YFV antigen.
Expanded phages from each round (polyclonal phages) were then tested in ELISA
for their ability to bind the YFV antigen.
Fig 19. Biopanning of YF-patient-derived antibody phage libraries against the YFV-17D-204-
WHO antigen. A)Titer of eluted phages isolated from each round of selection after panning against the
antigen. B)Polyclonal phage ELISA using rescued phages isolated after each round of selection. BSA was
used as a negative control antigen.
As shown in Fig 19A, the number of bound phages strongly decreased between the
first and the second round and strongly increased during the second and the third
round which shows a characteristic enrichment of specific binders for the antigen.
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This enrichment process was confirmed by the polyclonal phage ELISA (see Fig
19B), which showed an increase of the signal representing a increase of the binding
activity of the polyclonal phages for the YFV antigen. The plateau after the third
round suggests that the maximal binding activity was obtained after three rounds
of selection. Taken together these data show that the selection step succeeded and
that three successive rounds of selection were sufficient enough to allow an optimal
enrichment of phages with a specific affinity for the YFV 17D-204-WHO antigen.
IV-2-3. Screening of monoclonal phages from round 3 and round 4 of the
selection step.
Monoclonal phages were rescued from 58 single bacterial clones which were
obtained during rounds 3 (30 clones) and 4 (28 clones) of the selection step. Their
binding activity to YFV 17D-204-WHO particles was tested in ELISA. As shown in
Figure 20, 47 monoclonal phages (81%) were found to bind specifically the YFV
antigen in ELISA (21/30 (70%) from round 3 and 26/28 (93%) from round 4).
These results show that several monoclonal phages specific for the YF 17D-204
antigen were isolated.
Fig 20. Reactivity of 58 monoclonal phages isolated from round 3 and round 4 during the
biopanning against purified 17D-204-WHO virions. As negative control antigen, BSA was used.
IV-2-4. Genetic diversity of scFvs displayed by YFV 17D-204-WHO-specific
binders.
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To check the diversity of scFvs displayed by these 47 YFV-specific monoclonal
phages, BstN1 fingerprinting was performed. BstNI is an endonuclease which
recognizes and cleaves a frequent site on DNA. Thus, this enzyme is useful to
evaluate simultaneously the diversity of several DNA sequences, by comparing their
restriction pattern after digestion. Phagemids of all YFV-specific monoclonal phages
were isolated, digested with BstNI, and restriction fragments were run on agarose
gel for comparison. Results are summarized in Table 3. From 47 clones, six
different BstNI patterns were observed. All of them except pattern 4 were present
in round 3 and in round 4.
BstN1 pattern round frequency clone
1 3 & 4 12/47 (25.5%) 7A
2 3 & 4 8/47 (17%) R3(27)
3 3 & 4 7/47 (14.9%) 5A
4 3 1/47 (2.1%) 1A
5 3 & 4 6/47 (12.8) 2A
6 3 & 4 13/47 (27.7%) R3(9)
Table 3: Diversity of monoclonal phages specific for YFV tested by BstN1 fingerprintings.
One clone representing each BstN1 pattern (7A, R3(27), 5A, 1A, 2A and R3(9)) was
chosen and used for further characterization.
IV-3. Expression and purification of six different scFvs (7A, 5A,
R3(27), 1A, 2A and R3(9)) with a specific affinity for YFV 17D-204-
WHO virions.
IV-3-1. Expression and purification of scFv-7A, 5A, R3(27), 1A, 2A and
R3(9) as soluble molecules.
scFvs sequences from each of these six YFV-specific monoclonal phages were
isolated and cloned into the prokaryotic expression plasmid pAB1. This plasmid
contains a lac Z promoter to allow IPTG induction, a pelB leader sequence to allow
the release of expressed scFv into the periplasmic space of the bacteria and a Myc-
tag and a His-tag for detection. ScFvs were expressed in E.coli TG1 cells upon IPTG
induction and purified from periplasmic fractions by IMAC chromatography as
described in Methods. Purity of each elution fraction was tested by Coomassie
staining and Western Blot using an anti-His tag monoclonal antibody. As seen in Fig
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21, each eluted fraction contains only 32 kDa molecules which correspond to  pure
scFvs. Fractions 2, 3, 4 and 5 were pooled for each scFv, dialyzed and used for
further experiments. scFvs were quantified using the micro BCA kit (Pierce) and the
quantity of purified scFvs were found to range between 50 µg to 270 µg of proteins
per liter of bacterial culture, the efficiency varying between each clone.
Fig 21. Expression and purification of scFvs in E. coli cells. 10 µl of each eluted fractions (1 to 7)
were separated by SDS-PAGE (12% polyacrylamide) and scFvs were detected by A) Coomassie staining
and by B) Western Blot using an anti His-tag mouse antibody.
IV-3-2. Reactivity of soluble scFv-7A, 5A, R3(27), 1A, 2A and R3(9) with
the YFV 17D-204-WHO antigen.
To test whether these scFvs, when expressed as soluble molecules, were able to
bind the YFV antigen, an ELISA was performed. As shown in Figure 22, all scFvs
have an intrinsic capacity to bind YF 17D-204 WHO virions and this binding was
specific, no binding being observed with BSA.
Fig 22: scFv ELISA. Purified soluble scFvs from YFV-specific monoclonal phages were tested for their
reactivity against the YFV 17D-204-WHO antigen in ELISA. As negative control antigen, BSA was used.
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IV-3-3. Sequencing analysis of scFvs-7A, 5A, R3(27), 1A, 2A and R3(9).
To identify the nucleotide sequences of each scFv, a sequencing analysis was
performed. As mentioned previously, the scFv molecule is composed of a variable
domain of the heavy chain (VH) and a variable domain of the light chain (VL) of
antibodies. Sequencing analysis of YFV-specific scFvs revealed usage of only two
different VH and three different VL germline genes published in the database.
According to their nucleotide sequence relationships, the scFvs could be divided into
2 groups (Fig. 23). The first group includes scFvs-7A, 5A and R3 (27). Their CDR
regions of the VH domains were identical and closely related to the germline gene
VH4-59. Some differences were observed in the FR1 and FR4 regions, probably due
to the usage of degenerated primers for PCR amplification. The VL domains of these
three scFvs differ from each other by up to 12 substitutions and are closely related
to germline gene VKL-12. The substitutions are mainly located in CDR2 and CDR3.
The second group is composed of scFv-1A, 2A and R3(9). The VH chains of these
three scFvs were almost identical and closest to the germline gene VH3-11. The VL
chains of scFv-1A and scFv-2A are related to the same germline gene VL1-19.
Substitutions were located in CDR2, CDR3 and FR4 regions. The VL chain of R3(9)
was different from those of scFv-1A and 2A and closely related to the germline
gene VL2-14.
7A     QIQMTQSPSTLSASVGDRVTITC RASQSISSWLA WYQQKPGKAPNLLIY KASNLET GVPSRFSGSGSGTEFTLTITSLQPDDFATYYC QQYNSFPIT FGQGTRLEIKRAAA   VκL-12
R3(27) ----------------------- ----------- --------------- ---S—-S ------------------------D------- ----SYPFT –-P—-K-------- VκL-12
5A     --V-------------------- ------G---- --------------- ---S—-S ------------------------E------- ----NYSYT –-P--K-------- VκL-12
VH
7A     EVQLVESGPGLVKPSETLSLTCTVSGGSTY NHHWS WIRQPPGRGLEWIG YISYSGKSNYNPSLKS RVTISLEPSTTQFSLKLNSLTAADTAVYYCAR EYRDDTNYYYYSLDV WGPGTLVTVSS    VH4-59
R3(27) ----------------A------------- ----- -------------- ---------------- -------------------------------- --------------- -----T----- VH4-59
5A     ---------R-------------------- ----- -------------- ---------------- -------------------------------- --------------- -----M----- VH4-59
1A    QVQLVESGGGLVKPGGSLRLSCAASGFTFS DYYMS WIRQAPGKGLEWVS YVTSSGRTKYYADSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR PQEASEAFDI WGQGTLVTVSS         VH3-11
2A    ------------------------------ ----- -------------- ----------------- -------------------------------- ---------- ----------- VH3-11
R3(9) E----------------------------- ----- -------------- ----------------- -------------------------------- ---------- -----M----- VH3-11
VL
1A     QSVLTQPPSVSAAPGQKVTISC SGSSSNIGNNYVS WYQQLPGTAPKLLIY DNDKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYC GTWDTSLSAPYV  FGTGTKVTVLGAAA           VL1-19
2A     ---------------------- ------------- --------------- ------- -------------------------------- ----SSLSAGSYV ------L------- VL1-19
R3(9)  QSVLTQPPSVSVAPGQTARITC GGNNIGSKSVH YQQKPGQAPVLVV YDDSDRPS GIPERFSGSNSGNTATLTISRVEAGDEADYYC QVWDSSSDHSYV FGTGTQLTVLGAAA       VL2-14
Closest 
germline
V-geneCDR1FR1 FR2 CDR2 FR3 CDR3 FR4
CDR1FR1 FR2 CDR2 FR3 CDR3 FR4
CDR1FR1 FR2 CDR2 FR3 CDR3 FR4
CDR1FR1 FR2 CDR2 FR3 CDR3 FR4
CDR1FR1 FR2 CDR2 FR3 CDR3 FR4
Fig 23: Alignment of the variable heavy (VH) and the variable light chains (VL) of the YFV-
specific scFv-7A, 5A, R3(27), 1A, 2A and R3(9). Framework regions (FR) and complementarity-
determining regions (CDR) are indicated in bold. The closest germline V-gene for each chain was
identified using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/).
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IV-4. Identification of the YFV proteins recognized by the scFvs-7A,
5A, R3(27), 1A, 2A and R3(9)
IV-4-1. Western Blot analysis.
To identify the viral proteins which are recognized by these scFvs, Western blot
analysis using YFV 17D-204-WHO particles was performed. Proteins from purified
YFV 17D-204-WHO particles were separated on SDS-PAGE and transferred onto a
nitrocellulose membrane. YFV proteins were probed in Western Blot using each of
the soluble scFv. As a positive control, two monoclonal antibodies specific for the
YFV E protein (MAb 6538 and MAb 6330) were used. As seen in Fig. 24, none of the
six scFvs was able to recognize any YFV protein. Only one of the two mAbs (mAb
6330) was able to detect a 55 kDa protein which corresponds in site to the YFV
envelope glycoprotein (E protein). This result strongly suggests that all six scFvs
recognize YFV proteins in their native conformation and not under denaturing
conditions which are obtained after SDS and beta-mercaptoethanol treatment.
Fig 24: Reactivity of scFvs with YFV proteins in Western Blot. YFV proteins from purified virions
were separated on a 12% SDS-PAGE, transferred onto a nitrocellulose membrane and blotted using
scFvs or two E-specific mAbs (mAb 6538 and mAb 6330).
IV-4-2. Dot Blot analysis.
To circumvent the problem of protein/epitope denaturation following SDS-PAGE
analysis, an immunoprecipitation assay using scFvs and soluble viral proteins was
performed. The critical step of this experiment was to find a balance between
solubilizing the proteins in their native conformation and not disrupting the antigen-
antibody interaction. Therefore, the choice of the detergent used to solubilize
virions was important. Preliminary Dot Blot experiments were performed in order to
identify a detergent which preserves the integrity of viral proteins after
+ - + - + -
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solubilization. For this purpose, YFV 17D-204-WHO virions were solubilized in the
presence of several ionic and non-ionic detergents and directly blotted onto a
nitrocellulose membrane. scFvs were then added to check their ability to recognize
their epitopes after treatment. As shown in Table 4, a treatment with non-ionic
detergents like Tween-20 or β-octyl-n-D-glucopyranoside did not interfere with the
scFv-YFV binding and could be used to perform immunoprecipitation. Thus, β-octyl-
n-D-glucopyranoside was used for further experiments.
scFv
7A
scFv
5A
scFv
R3(27)
scFv
1A
scFv
2A
scFv
R3(9)
mAb
6538
mAb
6330
Western Blot: - - - - - - - +
Dot Blot:
TNE + + + + + + + +
“RIPA buffer”:
TNE +10% Triton-X100
       +10% DOC
       +10% SDS
- - - - - - - +
TNE + 1% NP40 - - - - - - + +
TNE + 1% Triton X-100 +/- +/- +/- +/- +/- +/- + +
TNE + 1% Tween-20 + + + + + + + +
TNE + 1% β-octyl-n-D-
         glucopyrannoside
+ + + + + + + +
Table 4: Reactivity of scFvs with YFV proteins solubilized under different reaction conditions.
Purified 17D-204-WHO virions were treated with buffers containing various detergents (ionic and non-
ionic) and blotted onto a nitrocellulose membrane. Each scFv was incubated with the blot and bound
scFv were detected with an anti His-tag antibody.
IV-4-3. Radioimmunoprecipitation assay (RIPA).
Since the epitopes recognized by the scFvs are dependent on the native
conformation of the viral proteins, we performed a radioimmunoprecipitation assay.
For this purpose, [35S] radiolabeled YFV 17D-204-WHO virions were produced and
radiolabeled viral proteins were solubilized using the detergent β-octyl-n-D-
glucopyranoside, which has been shown to preserve the integrity of epitopes
recognized by scFvs. Solubilized radiolabeled YFV proteins were then mixed with
each scFv and the scFv/viral protein complexes were immunoprecipitated with an
anti His-tag mouse antibody/agarose beads mixture. As positive control, two mAbs
(6538 and 6330) specific for the YFV E protein were used. Both precipitated a 55
kDa protein corresponding to the YFV E protein. As shown in Fig. 25, scFvs were
able to immunoprecipitate a protein of the same size. As negative control, a scFv
from the same library without any YFV binding activity was used as well as the anti
His-tag antibody alone. Both negative controls were not able to immunoprecipitate
this 55 kDa protein corresponding to the YFV E protein. Taken together these data
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show that scFvs are able to bind specifically the YFV-E protein and that scFvs
recognized epitopes which are conformation-dependent.
Fig 25: Immunoprecipitation of radiolabeled soluble YFV proteins. Radiolabeled soluble YFV
proteins were immunoprecipitated with each scFv. YFV-E specific mAbs 6538 and 6330 were used as
positive controls. As negative controls, an irrelevant scFV from the same library and an anti His-tag
antibody were used.
IV-5. Competition ELISA.
To determine whether the six scFvs were directed against the same or overlapping
epitopes, a competition ELISA assay using biotinylated scFv was performed.
Biotinylated scFv-7A was mixed with increasing amounts of non-biotinylated scFvs
as well as mAbs and then incubated with YFV 17D-204-WHO virions coated onto an
ELISA plate to test whether the scFvs could compete with each other for the
binding to YFV virions. The amount of bound biotinylated scFv was detected using
HRP-conjugated streptavidin. As expected, a competition between unlabeled and
biotinylated scFv-7A was observed, the amount of biotinylated scFv-7A dropping
from 100% in the absence of unlabeled scFv-7A to 30% binding in the presence of
5µg of the same scFv as competitor. As a negative control, an irrelevant scFv not
competing with biotinylated scFv-7A was used. The two closely-related scFvs-5A
and R3(27) competed with biotinylated scFv-7A, reducing the binding from 100% to
approx. 40% by using 5 µg each. ScFv-1A, 2A and mAbs (6330 and 6538) did not
displace biotinylated scFv-7A suggesting that they recognize different epitopes on
the E protein. Interestingly, scFv-R3(9), which differs from scFv-7A, 5A or R3(27),
can partially compete with scFv-7A (40% reduction of binding). Taken together
+ - + - + - + - + - + - + -
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these data show that scFv-7A, 5A and R3(27) are specific for the same or an
overlapping epitope on the E protein.
Fig 26: Competition of scFv or E-specific mAbs with biotinylated scFv-7A for binding to YFV
17D-204-WHO virions. Biotinylated scFv-7A and  various amounts of unlabeled scFvs or mAbs were
incubated with coated YFV virions. The detection of bound biotinylated scFv-7A was performed using
HRP-conjugated streptavidin.
IV-6. pH sensitivity of the epitopes.
Since the scFvs are specific for the E protein and since the E protein undergoes
irreversible conformational changes upon pH shift during the fusion process, we
investigated whether those epitopes and their recognition by scFvs are affected by
a low pH treatment. It has been previously shown that the treatment of TBE or DV
particles with a mildly acidic pH (pH 6 or below) induces identical irreversible
conformational changes on the E protein which are known to take place during the
fusion process, whereas a pH 8 treatment does not affect the E protein
conformation (Allison et al., 1995; Modis et al., 2004; Stiasny et al., 1996). To this
aim, purified YFV 17D-204-WHO virions were coated in an ELISA plate and treated
either with low pH (pH 5) or with slightly alkaline pH (pH 8) and back-neutralized to
pH 8. An ELISA test was then performed using the scFvs as well as the mAbs in
order to check whether those epitopes are still recognized after pH shift. As shown
in Fig 27, all six scFvs as well as the two E-specific monoclonal antibodies are able
to bind their epitope when YFV particles are pretreated at pH 8. In contrast, when
YFV virions are pre-treated at an acidic pH (pH 5) which leads to the reorganization
of the E proteins on the viral surface, the six scFvs and the monoclonal antibody
mAb 6538 cannot bind the YFV virions anymore, suggesting that their epitopes
were lost during the pH-induced conformational changes. In contrast, low pH
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treatment of YFV particles does not alter or only slightly reduces the capacity of the
second monoclonal antibody mAb 6330 to bind its epitope. These results correlate
with those obtained in IV-4-1 (Western Blot analysis) in which we have shown that
only the mAb 6330 was able to recognize the YFV under reduced conditions. All
these data show that the scFvs recognize conformational epitopes which are
sensitive to low pH on the E protein of YFV, located in regions which undergo pH-
induced rearrangements.
Fig 27: pH sensitivity of the epitopes recognized by the scFvs. Coated-YFV virions were treated
either at pH 5 or at pH 8. The ELISA procedure was then performed using scFvs and mAbs as described
in methods.
IV-7. Neutralization assays.
IV-7-1. Plaque Reduction Neutralization Test (PRNT) using the YFV 17D
204-WHO (vaccine strain) and YFV wild-type strain Asibi.
To investigate the ability of scFvs to block infection of cells by YFV in vitro, PRNT
was performed. YFV 17D-204-WHO were incubated with various concentrations of
each scFv, spread on Vero cells and plaque formation was observed. As shown in
Fig. 22, the three closely related scFvs-5A, 7A and R3(27) showed 50% and 100%
neutralizing activity against the YFV vaccine strain at concentrations of approx. 1
µg/ml and 10 µg/ml, respectively, whereas the three other scFv did not neutralize
at any tested concentrations. Two YFV type-specific mAbs directed against the E
protein were used as controls (mAb 6538 and 6330). MAb 6538 showed 100%
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neutralizing activity at a concentration of 1 µg/ml, whereas the potency of mAb
6330 was lower (50% neutralization at 10 µg/ml). An irrelevant scFv included as
negative control did not neutralize YFV 17D-204-WHO. To test whether scFv have a
neutralizing activity against a wild-type YFV strain, PRNT was also performed using
the Asibi strain.
Fig 28: Neutralization of the 17D-204-WHO (A) and the Asibi (B) strains of YFV by scFvs in
plaque reduction neutralization test (PRNT) on Vero cells. YFV-specific mAbs 6538 and 6330 were
used as positive controls. As negative control, an irrelevant scFv from the same library was used. Each
assay was run in triplicate.
IV-7-2. Plaque Reduction Neutralization Test (PRNT) using 5 wild-type YFV
strains representing three of the five known African genotypes.
To test whether these scFvs could neutralize other YFV wild-type strains, PRNT
experiments were performed using five strains representing three of the five known
African genotypes: CAR86 (East Africa/Central Africa), Ethiopia61 (East
Africa/Central Africa), Senegal90 (West Africa II), Nigeria87 (West Africa I) and
Ghana 1927–Asibi-(West Africa II). As shown in Fig. 23, the three closely related
scFv-5A, 7A and R3(27) are able to neutralize the CAR86, Nigeria87, Ethiopia61
and Asibi strains with a comparable efficiency; 90% neutralization being observed
at concentrations ranging from 0.3 to 1 µg/ml of scFv, scFv 5A showing the most
potent neutralizing activity. Interestingly, the Senegal 90 strain was neutralized by
those three scFvs four to ten fold less efficiently than the four other wild-type
strains. Of the second group of closely related scFvs, only scFv R3 (9) showed some
activity, neutralizing the Nigeria87 strain to maximally 60%. Cross reactivity of
those scFvs was also tested by doing PRNT using another flavivirus, a West Nile
virus strain isolated in 2000 but none of them exhibit any neutralizing activity
against this virus, showing that these neutralizing scFvs are YFV-type specific.
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Fig 29: Neutralization of several wild-type strains of YFV by scFvs in PRNT in PS cells. As
negative control, an irrelevant scFv (not reactive with YFV) from the same library was used.
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IV-8. Generation of YFV 17D-204 WHO variants exhibiting
resistance to scFv-7A neutralization.
To identify viral determinants associated with scFv neutralization, YFV mutants
which were able to escape neutralization were generated. To this aim, the YFV 17D-
204-WHO vaccine strain was passaged three times in the presence of a sub-
neutralizing concentration of scFv-7A (representing a 95% neutralization
concentration) to promote the growth of YFV 17D-204-WHO variants which could
escape the neutralization by scFv-7A. After the third passage, 20 YFV variants were
plaque purified, propagated, titered and tested in PRNT. As shown in Fig. 30, four
mutants found to be resistant to scFv-7A neutralization were isolated.
Fig 30. Neutralization sensitivity of YFV-17D escape mutants to scFv-7A. The scFv-7A
neutralization resistance of four escape mutants (7A-10, 7A-12, 7A-14 and 7A-18) which were selected
in the presence of subneutralizing concentrations of scFv-7A was tested in PRNT using various
concentrations of scFv-7A. As a positive control, the parental YFV-17D-204-WHO was used. Each assay
was performed in triplicate.
Mutants 7A-14 and 7A-18 exhibited a low neutralization resistance (75%
neutralization at 10 µg/ml scFv-7A). 50% neutralization was seen with the 7A-10
variant at the highest antibody concentration. The fourth mutant, 7A-12, was
almost completely resistant to neutralization by scFv-7A (5% neutralization at 10
µg/ml scFv-7A).
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IV-9. Identification of amino acid residues on the E protein
associated with resistance to scFv-7A neutralization.
To determine mutations in the E protein associated with neutralization resistance,
its gene was sequenced for all four escape variants as well as for the parental YFV
17D-204-WHO strain. Because changes could also have occurred in the other YFV
envelope protein, the gene encoding the M protein was also sequenced for all
viruses (escapes and parental viruses). Mutations were detected only in the E
protein gene. As shown in Table 5, a total of four amino acid changes associated
with resistance to neutralization by scFv-7A were identified, one each at positions
E-71 (domain II), E-153, E-154, and E-155 (all in domain I). The mutation at E-71
conferred the highest neutralization resistance.
Table 5: Nucleotide and amino acid changes of the E protein for 17D-204-WHO variants which
are associated with scFv-7A neutralization resistance.
IV-10. Location of amino acid substitutions associated with
resistance to scFv-7A neutralization in the E protein homodimeric
crystal structure of YFV.
The YFV E protein has not been crystallized yet. However, the crystal structure of
two others closely-related flaviviruses (Dengue virus and TBE virus) has been
resolved and published. Therefore, we used the crystal structure of the Dengue
virus E protein to locate the four substitutions that we found to be associated with
scFv-7A neutralization resistance.
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As shown in Fig. 31, aa E-153, E-154 and E-155 are located in domain I and aa E-
71 in domain II of the E protein. As expected, all substitutions were found to be
located on the outer surface of the E dimer (Fig 31, right side) and, thus, accessible
to antibodies. Another interesting point is that aa E-71 and aa E-153, E-154 and E-
155 are spatially separated by 65-70 Å in the monomeric protein. This distance is
far beyond the surface area which the VH and VL chain of an antibody fragment can
cover, ranging typically from 15 Å x 20 Å to 20 Å x 30 Å. (Davies and Cohen, 1996;
Davies et al., 1990). Therefore, aa residues E-71, E-153, E-154 and E-155 are
unlikely to participate in forming an epitope on the monomeric E protein. In
contrast, in the homodimeric, anti-parallel orientation which the molecules are
predicted to adopt on the surface of the virion, domains I and II are in close
vicinity, with a separating distance of 15-20 Å between aa E-71 and E-155 (Fig.
32). It is thus likely that the scFv-7A neutralizing epitope is formed by two E
proteins, which each contribute a different domain. We therefore postulate that the
epitope of the antibody fragment 7A is not located on the protein E monomer, but
spans adjacent domains I and II of the homodimeric form of the molecule.
Fig 31. Location of amino acid residues E-71, E-153, E-154 and E-155 associated with scFv-7A
neutralization escape in the YFV E protein modeled on the 3D structure of the dengue virus
type 2  E protein. (left side): top view of the E protein. Domains I, II and III indicated in red, yellow
and blue, respectively. (right side): side view.
E-153, E-154, E-155
E-71
E-153, E-154, E-155
E-71
inner surface
outer surface
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Fig 32: The scFv-7A epitope. E-71 is indicated in purple and E-153, E-154 and E-155 are colored in
green. The fusion peptide is depicted in pink.
IV-11. Mutations in the E protein of the YFV Senegal 90 strain.
As shown in Fig. 29, the YFV Senegal 90 strain is four to ten fold less efficiently
neutralized by scFv-7A, 5A and R3 (27) when compared to all other YFV wild-type
strains tested (Asibi, CAR86, Ethiopia61 and Nigeria87). The gene encoding for the
E protein of those five wild-type YFV strains were sequenced. Comparison of their E
protein sequences showed that four aa substitutions were observed between the
Senegal 90 strain and all other wild-type strains at position E-7, E-54, E-153 and E-
249. These substitutions were modeled on the crystal structure of the Dengue virus
E protein (Fig. 33). Interestingly, three of these four substitutions (E-7, E-153 and
E-249) were found to be located in close vicinity of the scFv-7A epitope or even
directly within (E-153). These modelling data, taken together with the
neutralization data, strongly suggest that the Senegal 90 strain could represent a
naturally-occurring scFv-7A escape variant, equivalent to the escape variants (7A-
14, 7A-18, 7A-10 and 7A-12) that we found to be present in the YFV 17D-204-WHO
vaccine preparation.
  
15-20Å
65-70Å
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Fig 33: Location of residues of the YFV Senegal 90 strain which differ from other YFV wild-
type strains. Residues E-7, E-54, E-153, E-249 are colored in black. Residues of the scFv-7A epitope
are also indicated (green and purple). A) Top view. B) Side view.
IV-11. Importance of the mutations E-71 and E-155 in terms of
neutralization escape using human polyclonal sera from YF patients
and 17D vaccinees.
To evaluate the impact of the escape mutants in a human context and to determine
the importance of the neutralizing epitope E-71,-E-153,-E-154,-E-155, we tested
their ability to escape neutralization of sera from YF-patients and from travelers
who were routinely immunized with the YFV 17D-204-WHO vaccine strain. To this
aim, microneutralization assays were performed with the two most interesting
mutants 7A-10 and 7A-12 using polyclonal sera obtained from recovered YF-
patients and from travelers immunized with the YFV 17D-204-WHO vaccine. Fig. 34
represents the inverse of the 50% end point dilution of each serum for each virus
(escape mutants vs parental 17D-204-WHO) expressed in a log10 scale. Both sera
from YF-patients (YF2 and YF3) neutralized the variant 7A-12 up to ten fold less
effectively when compared to the parental YFV 17D-204-WHO strain. In contrast,
the sera of the immunized travelers (sera 3, 5, 7, 14, 20, 37, 85 and 86) showed
full or only slightly reduced neutralizing activity against this variant. Paradoxically,
the neutralizing titers of most sera against the variant 7A-10 were significantly
higher (up to 10 fold) compared with titers against the parental YFV 17D-204-WHO
strain.
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Fig 34: Sensitivity of escape mutants 7A-10 and 7A-12 to neutralization by sera from YF
patients and from 17D vaccinees. As a positive control, the parental YFV-17D-204-WHO virus was
used. 50% endpoint dilution represents the dilution of each serum at which 50% of the wells were
protected from infection and are indicated as reciprocal dilution in a log10 scale. Each serum was tested
in five replicates.
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V-DISCUSSION
V-1 Quality of antibody libraries and results of selection.
V-1-1. Construction of two human immune antibody phage display libraries
and their panning against purified YFV 17D-204-WHO virions.
The successful isolation of potent neutralizing antibody fragments by the phage
display system is dependent on two critical parameters: the quality of the library
and the quality of the antigen used for the screening. We used, as a source of RNA,
peripheral blood lymphocytes (PBL) because they are easy to obtain. The PBL cells
were harvested from patients who recovered of YFV infection six months after acute
infection. At this time point, the majority of B-memory cells and long-lived plasma
cells generated following YFV infection are believed to reside mainly in lymphoid
tissues. Consequently, we may have have only a partial access to the antibody
repertoire which was developed against the YFV. Dut to logistic problems in West
Africa, it was not possible to obtain lymphocytes at the optimal time point, which is
approx. four weeks after acute infection. The obtention of lymphocytes from bone
marrow or spleen would circumvent this limitation but such a method is hardly
feasible when biological materiel has to be harvested from humans, particularly in
Africa. However, due to the affinity maturation process, only antibodies with high
affinity (i.e. with high potency) were most likely isolated. Libraries are, therefore,
not representative of the total antibody response against YFV, but of the long-
lasting response which prevents reinfection.
Concerning the antigen, we used purified YFV particles from the YFV 17D-204-WHO
vaccine strain. This antigen was used, as opposed to the wild-type YFV, to isolate
antibody fragments which may be useful to identify yellow fever-type specific
epitopes. Furthermore, YFV from the vaccine strain, in contrast to the wild-type
strain, can be handled under biosafety level 2 without prior chemical or physical
inactivation. Thus, sensitive conformational epitopes are preserved. We also
preferentially used whole virions instead of recombinant YFV E proteins to ensure
that antibodies will be selected against the E protein folded in its native
conformation found on the viral surface. Sanchez et al. showed for WNV, by using
three different immunization strategies in mice (inactivated whole virus,
recombinant E protein and naked DNA), that the most potent neutralizing
antibodies were generated following immunization with inactivated whole viruses
whereas no neutralizing antibodies were isolated using a soluble form of the E
protein (Sanchez et al., 2005).
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V-1-2. Isolation of closely-related scFvs specific for the YFV E protein.
As expected, the scFvs we isolated in this study were all directed against the
envelope E protein of the YFV. Interestingly, the three scFv (5A, 7A and R3(27)),
exhibiting a potent neutralizing activity, were found to be genetically closely-related
and to recognize the same or an overlapping epitope, suggesting that only one
epitope specificity has been isolated from two different libraries. However, this
result may be due to a technical bias inherent to phage display technology,
particularly during the selection process. Washes are performed to remove
unspecific phages but this step is critical since phages displaying scFv with a low
affinity for the antigen may be lost and the enrichment will be done with phages
bearing scFvs with the highest affinity. It cannot be excluded that others scFvs with
a lower affinity or which recognize other epitopes could be isolated by modifying
the selection conditions like the stringency of washes. To circumvent this problem,
new methodologies have been developed. Recently, Kramer et al. isolated 147
unique antibody fragments specific for rabies virus (RV) from four libraries by
performing selection procedures alternating on whole virions, on cells expressing
RV glycoproteins and on recombinant RV glycoproteins (Kramer et al., 2005). An
other alternative would be the use of the “substractive selection”. To suppress the
repetitive isolation of the same specificity of scFvs, the biopanning is performed as
previously described except that one of this “frequent” scFv is incorporated during
the biopanning. This process leads to the masking of the dominant epitope,
resulting in the isolation of scFvs which are low abundant or have lower affinity
(Ditzel et al., 1995; Tsui et al., 1996).
Another interesting point is that all three neutralizing scFvs have an identical VH-
CDR3, and even an identical VH chain, and they differ from each other mainly by
their VL-CDR3 region and by their relative neutralizing capacity (scFv-5A being the
most potent one). Since these three neutralizing scFvs recognize the same or an
overlapping epitope, this result strongly supports the fact that the VH-CDR3 region
is probably the most important determinant of antigen specificity of antibodies as
previously described (Kabat and Wu, 1991). These three scFvs could reflect the
affinity maturation process which occurs during the development of the adaptive
immune response. During affinity maturation, B-cells are clonally to the affinity of
their expressed antibodies; the antibodies with the lowest Kd are selected and
amplified. Thus, the three scFvs may represent three mutated versions of one
original clone, each having a different affinity for the antigen. This is also supported
by the fact that lymphocytes were harvested 6 months after acute infection, at
which time, affinity maturation has already taken place. For the reasons outlined
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before, this epitope specificity may represent the main type-specific antibody
response induced by wild-type YFV, possibly also determining the major
neutralizing epitope on the YFV vaccine.
V-2.Nature of the epitopes.
V-2-1. The epitopes are conformation-dependent and pH-sensitive.
The nature of the major neutralizing epitope has been found to be denaturation-
dependent and related to the native structure of the E protein found on the viral
surface, as shown by Dot blots, Western blots and RIPA experiments. This is further
supported by the fact that the epitopes recognized by all scFvs are sensitive to low
pH treatment. Since the treatment of flavivirus virions with low pH buffer has been
shown to mimic the irreversible conformational changes of the E protein which take
place during the fusion process, it is reasonable to assume that the epitopes of the
scFvs are located in regions of the E protein which undergo pH-induced
rearrangements during the fusion process.
V-2-2. The scFv-7A epitope is formed by amino acid residues from domain I
(E-153, E-154 and E-155) and from domain II (E-71) in the E protein.
Using YFV 17D-204-WHO neutralization escape variants, we found that the aa
residues located at position E-71, E-153, E-154 and E-155 of the E protein are
associated with scFv-7A neutralization escape. This result suggests that those aa
residues are essential parts of the epitope recognized by scFv-7A. The
measurement of the distance between E-71 and E-153, E-154 and E-155 on one E
monomer strongly suggests that the scFv-7A epitope could be a conformational
epitope formed by two E proteins, each one contributing a different domain (E-71 of
domain II from one monomer and E-153, E-154 and E-155 of domain I from the
second monomer). The substitutions in a wild-type strain (Senegal 90) which is less
sensitive to neutralization by scFv-7A were found to be in close vicinity or within
the scFv-7A epitope, suggesting the great importance of this region for YFV
neutralization. Interestingly, a study conducted on Dengue virus type 2 using Fab
fragments has recently shown that the epitope recognized by one neutralizing Fab
displays similar features than our epitope, being composed of aa residues at
position E-317 in domain III of one monomer and E-106 at the tip of domain II of
the other monomer (Goncalvez et al., 2004).
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V-3. The scFv-7A epitope.
V-3-1. E-71 is extremely conserved among all sequenced YF strains and
critical for neutralization.
We have identified one escape variant which is almost completely resistant to
neutralization by scFv-7A. This virus differs from the parental 17D-204-WHO virus
by one substitution at position E-71 in the E protein. This asparagine residue at
position E-71 is 100% conserved among all wild-type and vaccine strains of YFV
published to date, with the exception of one YFV strain isolated from mosquitos in
1979 in Trinidad, which has a N-D exchange at position E-71 (Fig 35). The high
degree of conservation of the aa residue E-71 could lie in the fact that it is close to
the postulated internal fusion peptide within domain II, which is predicted to span
E-98 to E-110. Any mutation in this region is likely to alter fusion capacity and
infectivity of the virus. The escape variant 7A-12 mutated at position E-71 showed
much higher resistance to neutralization with scFV-7A than the escape variants
mutated at E-153, E-154 and E-155 (95% vs. 25-50% in PRNT) showing that E-71
is the most critical amino acid residue in this complex YFV type-specific neutralizing
epitope. Furthermore, in microneutralization experiments, the neutralizing titers of
the sera from YF patients were up to 10 fold reduced with the variant 7A-12
supporting the fact that E-71 is an important determinant for YFV neutralization.
V-3-2. Aa residues E-153, E-154 and E-155 contribute to a lesser extent in
the scFv-7A epitope.
The escape variants 7A-14, 7A-18 and 7A-10 which are mutated at positions E-153,
E-154 and E-155 exhibit a lower neutralization resistance than the variant 7A-12,
suggesting that those aa residues contribute to lesser extend to the scFv-7A
epitope.
V-3-2-1. Role of E-155 in the scFv-7A epitope.
The variant 7A-10 mutated at position E-155 has an intermediate resistance to
neutralization (50% in PRNT). The aspartic acid residue E-155 is, like E-71, highly
conserved among YFV strains except the 17DD vaccine strain, which displays a
serine residue at this position. Interestingly, the 17DD vaccine strains showed a
slightly increased neurovirulence in animal models (Barrett and Gould, 1986).
Moreover, a D155G mutation together with a G303K mutation in a 17D virus
variant was isolated from a human case of vaccine-associated encephalitis
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(Jennings et al., 1994). This case of YEL-AND might, therefore, be the consequence
of the selective growth of one escape variant from the vaccine preparation. In this
work, we found that the escape mutant 7A-10 substituted at position E-155 was
efficiently neutralized by polyclonal sera from 17D immunized travelers. This result,
therefore, underlines the fact that E-155 mutants are normally well controlled by
immune responses induced by the YFV-17D vaccines and suggests a major role of
the mutation G303K in the 17D-associated encephalitis case. The role of single
mutations in the E protein of YFV-17D variants has to be interpreted carefully since
YEL-AND and YEL-AVD are probably the result of a pluri-causative process. Thus,
animal pathogenicity studies must be performed to evaluate the importance of
these mutations. Interestingly, E-155 has been also reported together with other
substitutions as a potential determinant for YFV viscerotropism and virulence
attenuation. A D155A substitution was detected together with nine other aa
substitutions in an attenuated YFV wild-type Asibi strain which was passaged six
times in HeLa cells. This Asibi variant was found to be attenuated in newborn mice
and had lost its mosquito competence (Dunster et al., 1999). A D155A mutation
was also described in a hamster-adapted YFV Asibi strain. This variant was found to
be viscerotropic for hamsters, a feature which is usually not observed in these
animals following YFV Asibi infection (McArthur et al., 2003). These data strongly
support an important role of E-155 in YFY tropism, virulence and neutralization.
Nevertheless, due to the multiplicity of the phenotypic properties of the variants
isolated in those studies and the multiplicity of substitutions occurring in the same
time, the exact role of E-155 is difficult to interpret.
V-3-2-2. Role of E-154 in the scFv-7A epitope.
The T154A substitution in the virus variant 7A-14 has previously not been reported
in a neutralization escape mutant but was found in human wild-type YFV isolates
from Ecuador and Peru (Fig.35). Regarding the neutralization resistance activity of
the variant 7A-14, the substitution at position E-154 does not play a very important
role in neutralization and, therefore, contibutes only moderately to the scFv-7A
epitope.
V-3-2-3. Role of E-153 in the scFv-7A epitope: potential N-linked glycosylation site
at position E-151.
Like the variant 7A-14 which is mutated at position E-154, the variant 7A-18, which
is substituted at position E-153, exhibits a low resistance to neutralization,
suggesting a minor role of this aa residue in the scFv-7A epitope. However, a
potential N-linked glycosylation site in the E protein is located at positions E-151
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(N), E-152 (W) and E-153 (T) in several YFV strains. Post et al. have demonstrated
that this N-linked glycosylation is only utilized by the 17DD and 17D-213 vaccine
strains (exhibiting the NWT sequence) (Post et al., 1992). All African wild-type
strains used in this study exhibit a NWN/K sequence at this position and are
therefore not glycosylated at this position (Fig.35). Because the 17D-204 WHO
strain used in this work displays a glycosylation sequence (NWT) and because this
strain is derived from the 17D-213 strain, we assume that the YFV-204-WHO strain
we used in this work is glycosylated at position E-151. However, because the YFV
17D-204 WHO strain and all African wild-type strains are all efficiently neutralized,
it seems that the glycosylation site does not play a critical role for neutralization.
Nevertheless, the escape mutants 7A-14 and 7A-18 display mutations at position E-
153 or E-153/154. Those mutations modify the aa sequence from NWT to NWA and
thus disrupt the predicted glycosylation site. Because variants 7A-14 and 7A-18 are
weakly resistant to scFv-7A neutralization, it is reasonable to think that this
glycosylation site may play a minor role in neutralization. The presence of sugars at
this position may define the scFv-7A neutralizing epitope to some extent. The
relationship between neutralization, antibody binding and glycosylation is not well
understood. Although the glycosylation site at position E-153 is found only in few
number of YFV strains, it is well conserved among several other flaviviruses. The
presence of N-linked carbohydrates at position E-153 together with N-linked
carbohydrates at position 67 which is unique to DV, has been shown for this virus
to be required for recognition by DC-SIGN, a putative cellular receptor for DV
(Navarro-Sanchez et al., 2003). Studies performed with other flaviviruses have
shown that glycosylation of the E protein plays an important role in virus tropism
(neuroinvasiness) and virus neutralization. It has been described for WNV that the
loss of the glycosylation site at position E-153 of some isolates is correlated with
the loss of neuroinvasiveness in mice (Beasley et al., 2004; Shirato et al., 2004).
Studies of deglycosylated epitopes of JEV have shown a loss of interaction with
well-characterized JEV-specific monoclonal antibodies (Lad et al., 2000).
Interestingly, the adaptation of Dengue virus in mosquito cells result in the loss of
the glycosylation site at position E-153 (Lee et al., 1997). A similar result was
obtained with the Louping Ill virus for which the loss of neuroinvasiveness was
correlated with the loss of glycosylation site at position 308 (Jiang et al., 1993).
However, for YFV and for the mutants obtained in this study, the role of the N-
linked carbohydrates at position E-153 is still obscure. On other hand, according to
the weak neutralization resistance observed for the variants 7A-14 and 7A-18, it
cannot be excluded that substitutions E-153 and E-154 may be responsible for
minor conformational changes leading to the rearrangement of the scFv-7A epitope
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which in turn promotes the destabilization of the interaction epitope-scFV.
Interestingly, the YFV Senegal 90 strain, which is less efficiently neutralized by
scFv-7A, displays a lysine residue at position E-153 which is not found in vaccine
strains or in all other wild-type strains (see Fig.35).
V-4. Three isolated scFvs exhibit a broad and potent neutralizing
activity in vitro.
Three scFvs (7A, 5A and R3(27)), which are genetically closely related, were able to
neutralize six different YFV strains in vitro (one vaccine strain: the 17D-204-WHO
and five African YFV wild-type strains representing three of the five known African
genotypes: the East Africa/Central Africa (EA/CA), the West Africa I (WAI) and the
West Africa II (WAII)). Interestingly, we observed that all scFvs exhibited a higher
potency when PRNT experiments were performed using PS cells instead of Vero
cells (Fig. 28 and 29). For example, 100 % neutralization was observed against the
YFV Asibi strain using 0.07 µg/ml of scFv-5A in PS cells whereas the same
neutralizating activity was obtained at a concentration of 5 µg/ml scFv in Vero cells.
These differences may reflect virus tropism and its ability and its efficiency to infect
different types of cells. Unfortunately, we were unable to test their neutralizing
activity against the other vaccine strain 17DD or against the wild-type strains from
South America. This experiment would be extremely interesting to see whether
such antibody fragments could block all known YFV genotypes. To test whether the
scFvs exhibit a cross-reactivity towards others flaviviruses, we conducted a PRNT
experiment using WNV strain isolated in France in 2000. None of the neutralizing
scFvs display any neutralizing activity against this virus, suggesting that the scFvs
are YFV-specific. As WNV is not the most closely related virus to YFV, it could be
interesting to test cross-reactivity of scFvs towards viruses which belong to the YFV
sero-complex.
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Fig 35: Alignment of the partial sequence of the E protein for several YFV.
 
17D-204-WHO              51 DRPAEVRKVCYNAVLTHVKINDKCPSTGEAHLAEENEGDNACKRTYSDRGWGNGCGLFGKG 110
17D-213                  51 ------------------------------------------------------------- 110
RKI-17D-112/95           51 ------------------------------------------------------------- 110
17D-204-ATCC             51 ------------------------------------------------------------- 110
17D-204-Pasteur          51 ------------------------------------------------------------- 110
17DD                     51 -----A------------------------------------------------------- 110
Asibi                    51 -G---A------------------------------------------------------- 110 
85-82H                   51 -G---A------------------------------------------------------- 110
Nigeria87                51 -G---A------------------------------------------------------- 110
56205/Nigeria/1991       51 -G---A------------------------------------------------------- 110
Guinea/2000/             51 -G---A------------------------------------------------------- 110
Dar1279/Senegal/1965     51 -G---A------------------------------------------------------- 110
1914-81/Ecuador/1981     51 -G---A-----S---------------------------H--------------------- 110
Strain                   51 -G---A-----S---------------------------H--------------------- 110
1362/Peru/1977           51 -G---A-----S---------------------------H--------------------- 110
V-528A/Colombia/1979     51 -G---A-----S----N---------------E---------------------------- 110
AR350397/Brazil/1979     51 -G---A-----S----N---------------E---------------------------- 110
CAR86                    51 -G---A-----S------------------------D------------------------ 110
112/Sudan/1940           51 -G---A-----S------------------------D------------------------ 110
ArB8883/C.               51 -G---A-----S------------------------D------------------------ 110
Ethopia61                51 -G---A-----S------------------------D------------------------ 110
7914/Kenya/1993          51 -G---A-----S------------------------D------------------------ 110
SE7445/Uganda/1964       51 -G---A-----S------------------------D------------------------ 110
DaHB1504                 51 -G---A-----S------------------------D------------------------ 110
788379/Trinidad/1979     51 --------------------D---------------------------------------- 110
Senegal90                51 ------------------------------------------------------------- 110
FNV                      51 ------------------------------------------------------------- 110
FVV                      51 –G---A------------------------------------------------------- 110
7A-10 escape mutant      51 ------------------------------------------------------------- 110
7A-12 escape mutant      51 --------------------K---------------------------------------- 110
Fusion peptideE71
 
17D-204-WHO              111 SIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAKQENWTTDIKTLKFDALSGSQ 168
17D-213                  111 --------------------------------------------------------- 168
RKI-17D-112/95           111 --------------------------------------------------------- 168
17D-204-ATCC             111 -----------------------------------------N--------------- 168
17D-204-Pasteur          111 -----------------------------------------N--------------- 168
17DD                     111 -----------------------------------------N-S------------- 168
Asibi                    111 -----------------------------------------N--------------- 168 
85-82H                   111 -----------------------------------------N--------------- 168
Nigeria87                111 -----------------------------------------N--------------- 168
56205/Nigeria/1991       111 -----------------------------------------N--------------- 168
Guinea/2000/             111 -----------------------------------------N--------------- 168
Dar1279/Senegal/1965     111 -----------------------------------------N--------------- 168
1914-81/Ecuador/1981     111 -----------------------------------------NA-------------- 168
Strain                   111 --------------------------------------------------------- 168
1362/Peru/1977           111 -----------------------------------------NA-------------- 168
V-528A/Colombia/1979     111 -----------------------------------------N--------------- 168
AR350397/Brazil/1979     111 -----------------------------------------N--------------- 168
CAR86                    111 -----------------------------------------N--------------- 168
112/Sudan/1940           111 -----------------------------------------N--------------- 168
ArB8883/C.               111 -----------------------------------------N--------------- 168
Ethopia61                111 -----------------------------------------N--------------- 168
7914/Kenya/1993          111 -----------------------------------------N--------------- 168
SE7445/Uganda/1964       111 -----------------------------------------N--------------- 168
DaHB1504                 111 -----------------------------------------N--------------- 168
788379/Trinidad/1979     111 ---------------------------------------D-K---------V----- 168
Senegal90                111 -----------------------------------------K--------------- 168
FNV                      111 -----------------------------------------K--------------- 168
FVV 111 -----------------------------------------N--------------- 168
7A-10                    111 -------------------------------------------G------------- 168
7A-12                    111 --------------------------------------------------------- 168
E153,154,155
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V-5. Homology of the scFv-7A with previously described YFV
neutralizing epitopes of monoclonal mouse antibodies.
Three previous studies have identified neutralizing epitopes for YFV using murine
monoclonal antibodies. These epitopes of YFV type-specific, neutralizing mouse
monoclonal antibodies were mapped in domain I (E-155 and E-158), domain II (E-
71 and E-72) and domain III (E-305/ E-325) of the E protein. Strikingly, a high
correlation is observed between those murine neutralizing epitopes and results we
obtained in this report since substitutions associated with neutralization escape in
both works were found to be at position E-71 and E-155. Aa E-72, E-153, E-154
and E-158 are found to be adjacent to those aa. Interestingly, the data presented
here might possibly reconcile all previous published data by assuming that E-71, E-
72. E-153, E-154, E-155 and E-158 form together a major YFV neutralizing epitope.
Fig 36: The putative major epitope of YFV. Aa residues E-71, E-72, E-153, E-154, E-155 and E-158
are coloured in cyan.
V-6. Neutralization of scFv-7A escape mutants generated from a
17D 204-WHO vaccine lot with sera from 17D-immunized travelers.
This work described the isolation of neutralization escape mutants which were
grown under selection pressure using a recombinant antibody fragment and, thus,
were originally present in the vaccine preparation. This result directly underlines
the quasispecies nature of the 17D vaccine demonstrating that each vaccine lot is a
heterogeneous mixture of viral subpopulations and may contain pre-formed
neutralization escape variants. Consequently, it cannot be ruled out that naturally
occurring neutralization escape mutants present in the vaccine preparation could
carry a risk of neutralization escape in persons immunized with 17D vaccine
(particularly travelers). This possibility has been previously raised by reports of
 
Inner surface
Outer surface
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several YFV vaccination-associated disease cases. We have demonstrated here that
17D-escape variants were still sensitive to neutralization by polyclonal sera from
travelers with minor drops in neutralizing titers. These data suggest that mutations
at position E-71/E-153/E-154/E-155 do not carry a risk of neutralization escape in
persons immunized with the 17D vaccine. Although the antibody response defined
by scFvs-7A, 5A and R3(27) seems to be a major humoral response developed
against YFV, this result reinforces the fact that multiple neutralizing epitopes exist
for the YFV. Interestingly, the neutralizing titers of polyclonal sera from yellow fever
cases were up to 10 fold lower for the 7A-12 variant (N71K mutation) whereas such
differences were not observed when sera from 17D vaccines were used, suggesting
that antibody responses raised against the wild-type YFV and the 17D YFV vaccine
strain differ. Suprinsingly, the variant 7A-10 showed approx. 10 fold increased
sensitivity to neutralization with half of the human sera. This result might be the
consequence of conformational changes in the E protein induced by the mutation
D155G, and, thus, resulting in the exposure of other neutralizing epitopes.
V-7. Neutralization of the YFV Senegal 90 strain.
We found that the wild type strain Senegal 90, isolated from mosquitos was four to
ten times less sensitive to neutralization than all other wild types viruses tested.
Because, in the E protein of this virus, mutations are found in close vicinity of E-71,
E-153, E-154 and E-155, it is justified to consider the YFV Senegal 90 strain as a
naturally occurring neutralization escape variant. The origin of the YFV strain
Senegal 90 is quiet surprising. This virus has been isolated from mosquitos in 1990
in Senegal. The observed substitutions have never been described in other YFV so
far. Interestingly, it has been previously shown that the expression of neutralizing
epitopes differ between YFV propagated in mosquito and mammalian cells. (Barrett
et al., 1990). A possible explanation is that such differential expression process
may represent a evolutionary mechanism to avoid neutralization which could occur
during the blood meal. This could explain why this variant is less efficiently
neutralized by antibody fragments (7A, 5A and R3(27)) from human anti-YFV
repertoire. Furthermore, these data reinforce the fact that the region formed by the
scFv-7A epitope may represent the major human neutralizing YFV epitope.
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V-8. Potential mechanism of the scFv neutralization.
Neutralization of viruses by antibodies is a complex process and the mechanisms
involved remain controversial (Klasse and Sattentau, 2001). Generally speaking,
the mechanism by which antibodies block virus infectivity is called neutralization.
Specifically, antibody-mediated neutralization is usually referred to a process by
which an antibody is able to bind to the viral surface, promoting a reduction of viral
entry functions. There is still some debate on whether virus neutralization is due to
the binding of a single antibody to one critical viral epitope (“single-hit
neutralization”) or due to the binding of a threshold number of viral epitopes
(“multiple-hit neutralization or occupancy model”). The latter seems to be the
mechanism which takes place in most of the viral neutralization processes reported
so far (Burton et al., 2001).
However, because the virus replication cycle is a multi-step event, antibody
neutralization may occur at each step of this process. Antibody binding to the
surface of the virion may prevent virus attachment to target cells. This attachment
blocking mechanism may be due to an antibody which binds viral epitopes needed
to interact with the cellular receptor. Aggregation of virions could also be a critical
process. All further steps inhibited by antibodies are classified as post attachment
neutralization (PAN). Antibodies may neutralize viruses after they have attached to
the target cells. As the replication cycle of most of viruses including flaviviruses
require an endocytosis-mediated internalization step, neutralizing antibodies may
also prevent the internalization process. Because endocytosed viruses require a
fusion step between the viral and the cell membranes to promote the release of the
viral genome into the cytoplasm, antibodies may act by preventing the fusion
event, leading to the degradation of the internalized virus in the endosome.
Theoretically, antibodies may also interfere after the capsid release by
compromising later replicative steps. For flaviviruses, most of antibodies which
exhibit a neutralizing activity are specific for the E protein and in some instances for
the NS-1 protein. Antibodies binding to the E protein could prevent infection by
blocking attachment of the virus to the cellular receptor and by interfering in later
steps during fusion with cell membrane. Studies on the neutralization mechanism
have revealed that antibodies against the domain III mainly act by preventing
attachment of the virus to the target cells (Crill and Roehrig, 2001; He et al., 1995;
Roehrig et al., 1998). This has been reinforced by a study (Thullier et al., 2001)
which described that a monoclonal antibody specific for the domain III of dengue
virus (E-306 to E-314) acts by preventing the association of this domain III epitope
with the putative cellular receptor heparan-sulfate. Interestingly, the analysis of
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sera from dengue-infected people suggest that dengue virus neutralization may
occur primarily by preventing cellular attachment (He et al., 1995) On the other
hand, monoclonal antibodies specific for the domain II have been shown to block
virus-mediated cell membrane fusion probably by interacting with the fusion
peptide (Roehrig et al., 1998) This potential role of antibodies interfering with the
fusion process had been previously proposed for WNV (Gollins and Porterfield,
1986), and has been demonstrated for JEV (Butrapet et al., 1998). However, in the
study performed by Crill et al., neutralizing antibodies specific for domains I and II
were also found to block adsorption to Vero cells but to a lesser extend than those
specific for domain III (Crill and Roehrig, 2001). The authors proposed that, by
binding to domain I or domain II, such antibodies may block domain III-mediated
virus-cell interaction through steric hindrance or by inducing some conformational
changes in domain III, resulting in a loss of virus attachment capacity. Taken
together, these studies strongly suggest that antibodies against domain III block
viral attachment whereas those against domain II blocks the fusion process. The
role of antibodies against domain I remains uncertain. Recently, Nybakken et al.
described that a neutralizing Fab fragment specific for domain III was able to
neutralize the WNV not by blocking virus attachment to its target cell as expected,
but at a step after viral attachment (Nybakken et al., 2005). In this paper, analysis
of the epitope recognized by this Fab in domain III showed that it is located in a
region which is sensitive to conformational changes during pH shift at the junction
between domain I and domain III. This strongly suggests that this Fab may play its
role by interfering with the fusion process. Since the junction between domain I and
domain III undergoes rearrangements following pH shift, the authors proposed a
neutralization mechanism in which such antibodies may bind pH-sensitive regions
of the E protein, resulting in the blocking of conformational changes of the E protein
which are essential for the fusion process to take place. According to the structure
of the pre and post-fusion states of the E protein, these regions are localized mainly
on domain II, at the junction of domain I with domain II and at the junction of
domain I with domain III. This is also supported by the published neutralizing
mAbs, listed in Table 1. In this work, we found that the neutralizing scFv-7A
epitope is formed by aa from domains I and II of the E protein, is conformation-
dependent and is also pH-sensitive. Furthermore, the molecular localization of this
epitope showed a close proximity with the fusion peptide. Thus, we can hypothesize
that scFv-7A plays its neutralizing role by blocking the fusion process. However, it
cannot be excluded that due the close vicinity of the scFv-7A epitope with domain
III, recombinant antibody fragments may neutralize YFV by blocking attachment
through induction of conformational changes as hypothesized previously.
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Nevertheless, due to their small size, scFvs are unlikely to prevent virus attachment
through steric hindrance. Furthermore, according to the proposed fusion
mechanism for flaviviruses and the molecular location of these residues, it is
tempting to speculate that scFv-7A may act by “clamping” the E protein homodimer
and, thus, preventing its dissociation upon pH shift. As the dissociation of the E
homodimer is a pre-requisite for trimerization and subsequently for the fusion
process to take place, this binding might be sufficient enough to prevent fusion and
therefore replication of the virus. A similar mechanism has been recently proposed
for DV (Goncalvez et al., 2004). In their study, E-106 of the fusion peptide in
domain I and E-317 in domain III have been described as forming an epitope for a
DV E protein-specific Fab. A previous study of the E protein of TBEV showed the E-
317 residue to be critical for the homodimer stabilization and the authors suggested
that the region which includes E-317 may regulate the dissociation of the E
homodimer upon pH shift during the fusion process, (Bressanelli et al., 2004;
Goncalvez et al., 2004). Thus, the neutralization mechanism by which this Fab
plays its role may take place through the prevention of the fusion process by
blocking the transition of E dimers to E trimers. Thus, it is reasonable to suggest a
similar neutralization mechanism for the scFv we isolated in this work.
V-9. Potentiel use of these scFvs as a therapeutical tool to treat YF.
Since the scFvs isolated here are able to neutralize six different strains of YFV in
vitro and since YFV clearance is mainly antibody-mediated, our results raise the
question whether those molecules could be a useful therapeutical tool to treat YF in
humans. As scFvs can be easily expressed in bacteria, this system represents a
cheap, easy and effective way to produce high amounts of human neutralizing
antibodies.
However, it has been observed that in vitro neutralization potency may not be
predictive of in vivo neutralization potency, and even in vitro non-neutralizing
antibodies may confer in vivo protection (Brandriss et al., 1986; Iacono-Connors et
al., 1996; Mozdzanowska et al., 1999). Thus, animal protection studies must be
performed to evaluate the potency of our antibodies. Several studies have shown
that antibody fragments (scFv or Fab) specific for Influenza virus, RSV, HSV-2 and
VSV could protect mice upon challenge (Crowe et al., 1994; Kalinke et al., 1996;
Mozdzanowska et al., 2003; Zeitlin et al., 1996). The major drawback of scFvs or
Fab fragments as a therapeutical tool to treat viral diseases is their extremely short
biological half-life in blood. It has been shown that the half-life of monomeric scFv
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in the plasma does not exceed 10 min in mice and the molecules are rapidly cleared
via the kidneys (Pavlinkova et al., 1999). As their plasma half-life directly correlates
with their molecular weight, several studies have been performed to engineer those
molecules into diverse formats like scFv dimers, trimers or tetramers resulting in an
increase of their half-life (for review see Holliger and Hudson, 2005; Kontermann
and Duebel, 2001). In contrast, recombinant antibody fragments in the IgG format
have been described in a number of publications to protect animal models from
challenge (for review, see ter Meulen and Goudsmit, In Press). These molecules are
bivalent and, thus can bind two antigens conferring a higher avidity when compared
to scFv. Intact antibodies contain the Fc domain which recruits cytotoxic effectors.
Furthermore, the half-life of such molecules is enhanced through the interaction
between the Fc domain and the FcRn/FcRp receptor by sequestrating from the
degradative pathway (Kim et al., 1999). The absence of the Fc receptor in scFv
molecule is one of the major drawback of the use of these molecules in the in vivo
context. The preponderant role of the Fc domain to provide a protection against
YFV in vivo has been emphasized by Schlesinger et al., who showed that Fab
fragments derived from a protective E-specific monoclonal antibody failed to protect
mice against YFV-induced encephalitis (Schlesinger and Chapman, 1995). Taken
together, these data show that scFv molecules are very unlikely to confer in vivo
protection. However, recent advances in antibody engineering may circumvent such
limitations by generating scFv-Fc fused proteins which can be produced in
mammalian cells. These molecules retain the antigen specificity and display higher
stability, half-life and functionality and may provide a valuable tool to protect and
treat against diseases (Ray et al., 2001).
V-10. Implications for the design of a cDNA-based YF vaccine.
As mentioned previously, the present live attenuated 17D-vaccine strains, even if
they are considered as extremely safe, have several drawbacks which prevent the
efficient control of yellow fever disease. The inherent problem of their quasispecies
nature, which may be responsible for severe adverse effects, as well as its old
method of production on embryonated eggs are obstacles to a modern method of
vaccine mass-production. Therefore, the concept of a rational design of a new
generation of YFV vaccines has been put foward. In 1989, Rice et al described the
construction of an infectious cDNA clone for the YFV 17D-204 vaccine strain (Rice et
al., 1989). Due to genetic instability of the cDNA, a two-step in vitro ligation
approach allowed the creation of a full length YF cDNA that could be used for the in
vitro transcription of infectious YF RNA. This was a milestone in flavivirus research
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and in cDNA-based vaccine development. Recently, Bredenbeek et al reported the
successful generation of a one step-cloning stable full length infectious YFV cDNA.
The plasmid carrying the YFV cDNA was bacterially amplified, linearized and
transcripts were produced through an SP6 RNA polymerase-dependent in vitro RNA
transcription. Transcripts were transfected into mammalian cells, and YF viruses
were obtained with titers and infectiousity comparable to the classically propagated
YFV (Bredenbeek et al., 2003). Thus, this infectious cDNA clone-based technology
may provide a valuable tool to produce high amounts of homogeneous YF virions
which could be used as vaccine. One of the major advantages of this system is the
diversity of molecular strategies which can be used to engineer a safer and more
efficient live vaccine. This technology provides a platform to identify molecular
determinants which govern virulence, attenuation and tropism for YFV. To this end,
our data may serve for the engineering and the standardization of a new YFV
vaccine based on an infectious cDNA clone, which could be used as a successor of
the present live attenuated 17D vaccine.
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VII-2. Abbreviations.
Aa Amino acid
ADCC Antibody-dependent cell-mediated cytotoxicity
Amp ampicillin
APS Ammoniumpersulfate
BSA Bovine serum albumine
BSL Biosafety level
C celsius
cDNA complementary Desoxyribonucleic acid
CDR Complementary determining region
CPE Cytopathic effect
DEPC dethylaminepolycarbonate
DMEM Dulbecco modified eagle medium
DNA Desoxyribonucleic acid
DOC Deoxycholate
DV Dengue virus
E.coli Escherichia coli
EDTA Etylendiaminetetraacetic acid
ELISA Enzyme linked immunosorbent assay
FCS Fetal calf serum
FNV French neurotropic virus
FR Framework region
Fv Fragment variable
FVV French viscerotropic virus
HRP Horseradish peroxidase
IMAC Immobilized ion affinity chromotography
IPTG Iso-propyl-thio-galactoside
JEV Japanese encephalitis virus
kDa kiloDalton
mAb Monoclonal antibody
MES 2-N-Morpholinoethansulfonic acid
min minute
MMLV Murine moloney leukemia virus
moi Multiplicity of infection
MW Molecular weight
NCR Non coding region
NK cells Natural killer cells
NP-40 Nonidet 40
o.n. overnight
dNTP desoxynucleosidtriphosphat
ssDNA Single stranded desoxyribonucleic acid
OD Optical density
ORF Open reading frame
PBL Peripheric blood lymphocytes
PBS Phosphate buffer saline
PEG polyethylenglycol
PCR Polymerase chain reaction
PFU Plaque forming unit
Taq Thermophilus aquaticus
pH Potentiel hydrogenii
PRNT Plaque Reduction Neutralization Test
RF Replicative form
RIPA Radioimmunoprecipitation assay
RNA Ribonucleic acid
RT-PCR Reverse transcription polymerase chain reaction
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scFv Single chain Fragment variable
SDS Sodium dodecyl sulfate
sec second
TBEV Tick borne encephalitis virus
TCID50 50% tissue culture infectious dose
TEMED N,N,N,N Tetramethyl-ethylendiamine
TNE Tris-NaCl-EDTA
VL Variable light chain
VH Variable heavy chain
WHO World Health Organization
WNV West Nile virus
YEL-AND Yellow fever-associated neurotropic disease
YEL-AVD Yellow fever-associated viscerotropic disease
YF Yellow fever
YFV Yellow fever virus
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